Exploitation of the Ligand-Binding Properties of the Mannose 6-Phosphate/Insulin-Like Growth Factor II (IGF-II) Receptor to Inhibit IGF-II-Dependent Growth of Cancer Cells by Zavorka Thomas, Megan
University of Nebraska Medical Center 
DigitalCommons@UNMC 
Theses & Dissertations Graduate Studies 
Spring 5-7-2016 
Exploitation of the Ligand-Binding Properties of the Mannose 
6-Phosphate/Insulin-Like Growth Factor II (IGF-II) Receptor to 
Inhibit IGF-II-Dependent Growth of Cancer Cells 
Megan Zavorka Thomas 
University of Nebraska Medical Center 
Follow this and additional works at: https://digitalcommons.unmc.edu/etd 
 Part of the Biochemistry Commons, Cancer Biology Commons, and the Molecular Biology Commons 
Recommended Citation 
Zavorka Thomas, Megan, "Exploitation of the Ligand-Binding Properties of the Mannose 6-Phosphate/
Insulin-Like Growth Factor II (IGF-II) Receptor to Inhibit IGF-II-Dependent Growth of Cancer Cells" (2016). 
Theses & Dissertations. 106. 
https://digitalcommons.unmc.edu/etd/106 
This Dissertation is brought to you for free and open access by the Graduate Studies at DigitalCommons@UNMC. It 
has been accepted for inclusion in Theses & Dissertations by an authorized administrator of 
DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu. 
EXPLOITATION OF THE LIGAND-BINDING PROPERTIES OF THE MANNOSE 6-
PHOSPHATE/INSULIN-LIKE GROWTH FACTOR II (IGF-II) RECEPTOR TO INHIBIT 
IGF-II-DEPENDENT GROWTH OF CANCER CELLS 
By 
Megan E. Zavorka Thomas 
A Dissertation 
Presented to the Faculty of 
The Graduate College in the University of Nebraska 
In Partial Fullfilment of the Requirements 
For the Degree of Doctor of Philosophy 
Department of Biochemistry and Molecular Biology 
Under the Supervision of Professor Richard G. MacDonald 




EXPLOITATION OF THE LIGAND-BINDING PROPERTIES OF THE MANNOSE 6-
PHOSPHATE/INSULIN-LIKE GROWTH FACTOR II (IGF-II) RECEPTOR TO INHIBIT 
IGF-II-DEPENDENT GROWTH OF CANCER CELLS 
Megan E. Zavorka Thomas, Ph.D. 
University of Nebraska, 2016 
Advisor: Richard G. MacDonald, Ph.D. 
The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) is a 
multifunctional, type I transmembrane receptor that is a member of the P-type lectin 
family.  A large, extracytoplasmic (EC) region of the M6P/IGF2R binds various ligands, 
allowing the receptor to regulate multiple biological functions, including the role as a 
tumor suppressor.  Two major classes of ligands, M6P-glycosylated (i.e. any proteins 
that bear M6P due to post-translational modification in the trans-Golgi network (TGN)) 
and non-glycosylated (i.e., the mitogen insulin-like growth factor II (IGF-II)), bind within 
distinct regions of the EC of the receptor and are trafficked to the lysosome.  The 
M6P/IGF2R as well as the cation-dependent mannose 6-phosphate receptor (CD-MPR) 
are mostly involved in lysosomal biogenesis, trafficking newly synthesized lysosomal 
enzymes from the TGN to the early endosomes, where the vesicles mature into 
lysosomes.  The receptors undergo recycling during the late endosomal phase where 
they are retrograde transported back to the TGN for another round of trafficking. 
However, a fraction of the receptors is found on the cell surface, where the M6P/IGF2R, 
but not the CD-MPR, is able to bind extracellular ligands.  Through this action, IGF-II can 
bind to the M6P/IGF2R and will be degraded in the lysosome, reducing the bioavailability 
of the growth factor for the mitogenic insulin-like growth factor I receptor (IGF1R); thus, 
the M6P/IGF2R is considered a clearance receptor and tumor suppressor.  Due to its 
growth suppressive function, the M6P/IGF2R is believed to play a role in cancer biology. 
 
 
High-affinity, bivalent M6P-based ligands, such as lysosomal enzymes, bind and 
stabilize the dimeric M6P/IGF2R at the cell surface, leading to its internalization at a 
faster rate than when there is no M6P-based ligand bound.  Therefore, the major goal of 
our work is to produce a panel of M6P-based ligands capable of bi- or multivalent 
binding to the M6P/IGF2R that could suppress IGF-II-dependent growth of cancer cells.  
Additionally, the M6P receptors (MPR) are well conserved through evolution, with the 
earliest form of “true” MPR known to date in the invertebrates such as mollusk.  
However, the social amoeba, D. discoideum, produces lysosomal enzymes that bind to 
the M6P/IGF2R, a discovery that predated identification of a receptor capable of 
transporting these acid hydrolases within this organism.  We provide evidence of a 
putative MPR protein that retains all the necessary components of a M6P receptor 
homology domain that also binds M6P.  The studies presented herein further our 
understanding of the origin of the M6P/IGFR as well as exploiting this receptor as a 
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A.  Overview 
The mannose 6-phosphate/insulin-like growth factor II receptor (M6P/IGF2R) is a 
multifunctional, type I transmembrane receptor that is a member of the P-type lectin 
family.  A large, extracytoplasmic (EC) region of the M6P/IGF2R binds various ligands, 
allowing the receptor to regulate multiple biological functions, including the role as a 
tumor suppressor.  Two major classes of ligands, M6P-glycosylated (i.e. any proteins 
that bear M6P due to post-translational modification in the trans-Golgi network (TGN)) 
and non-glycosylated (i.e., the mitogen insulin-like growth factor II (IGF-II)), bind within 
distinct regions of the EC of the receptor and are trafficked to the lysosome.  The 
M6P/IGF2R as well as the cation-dependent mannose 6-phosphate receptor (CD-MPR) 
are mostly involved in lysosomal biogenesis, binding newly synthesized lysosomal 
enzyme from the TGN to the early endosomes, where the vesicles mature into 
lysosomes.  The receptors undergo recycling during the late endosomal phase where 
they are retrograde transported back to the TGN for another round of trafficking.  
However, a fraction of the receptors is found on the cell surface, where the M6P/IGF2R, 
but not the CD-MPR, is able to bind extracellular ligands.  Through this action, IGF-II can 
bind to the M6P/IGF2R and be degraded in the lysosome, reducing the bioavailability of 
the growth factor for the mitogenic insulin-like growth factor I receptor (IGF1R); thus, the 
M6P/IGF2R is considered a clearance receptor and tumor suppressor.  Due to its growth 
suppressive function, the M6P/IGF2R is believed to play a role in cancer biology.  With 
the recent knowledge on the M6P/IGF2R’s structure and function on cellular biology, 
there is still much to be learned that may have significant impacts on health and disease.  
Our goal is to exploit the M6P/IGF2R as a novel therapeutic target in limiting IGF-II from 




B.  M6P Receptors 
The lysosomes are acidic intracellular organelles containing hydrolytic enzymes 
that function in degradation of proteins and other macromolecules.  The lysosomes 
contain over 60 acid hydrolases that degrade endogenous and exogenous materials.  
Newly synthesized lysosomal enzymes are delivered from the trans-Golgi network to the 
lysosome by the mannose 6-phosphate receptors (MPRs).  The MPRs have M6P-
binding sites that recognize the M6P recognition marker on the glycoprotein’s N-linked 
oligosaccharides.  Lysosomes void of the proper complement of acid hydrolases can 
result in over 50 different lysosomal storage diseases (1-5). 
There are two MPRs that transport glycosylated proteins: the cation-dependent 
MPR (46 kDa) and the cation-independent MPR (CI-MPR; 300 kDa) (6) which the latter 
is also called CD222 or M6P/IGF2R.  The CD-MPR and CI-MPR belong to the P-type 
lectin family of type-1 integral membrane glycoproteins and are found mostly within the 
TGN and endosome trafficking network, but a small portion is trafficked to the plasma 
membrane.  The MPRs have some redundant functions, yet they differ in their binding 
affinities and specificities for their ligands.  Also, the M6P/IGF2R is distinct in that it has 
evolved into a multifunctional protein that binds many types of ligands.  
 
B.1.  Discovery of M6P/IGF2R 
Studies in the 1970s by Neufeld and colleagues on lysosomal storage diseases 
observed that there was a deficit of acid hydrolases in cultured fibroblast cells from I-cell 
patients yet these enzymes were present in the culture medium.  When “corrective 
factors” (lysosomal enzymes from normal fibroblasts) were added to the culture medium 
of the I-cell fibroblasts, the cells took up the enzymes; the normal fibroblasts were 
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unable to endocytose the enzymes secreted by the I-cell fibroblasts (7).  This similar 
phenomenon was seen in Mucoliidosis-II (8).  It was noticed that “high uptake” form of 
the acid hydrolases were internalized at a faster rate than the “low uptake” forms.  The 
“high uptake” forms were endocytosed while the “low uptake” forms were not, yet the 
“low uptake” forms were still enzymatically active.  It was thought that a recognition 
marker must be allowing uptake of the enzyme through a receptor-mediated pathway (9) 
but the recognition marker was not necessary for enzyme activity.  It was later 
determined that the phosphate on the M6P moiety on these “high uptake” forms of 
lysosomal enzymes is critical for recognition and internalization of the enzymes as 
incubation with alkaline phosphatase transformed the higher endocytosed ligand to a 
lower uptake, and that M6P competitively inhibited endocytosis (10).  Kinetic studies 
validated these results using iduronidase as the enzyme added to cells deficient in this 
enzyme, which was inhibited by addition of M6P and the stereoisomer fructose 1-
phosphate (F1P) (11).  Together, it was proposed that a M6P recognition receptor on the 
cell surface was responsible for uptake of the enzymes possessing M6P residues.  This 
receptor was soon named the CI-MPR, which was purified and characterized in the early 
1980’s, and was found to have a molecular weight of 215 kDa (12-17). 
Around the same time that the M6P receptor was discovered, a human 
somatomedin (otherwise known as IGF-II) was used to partially purify a receptor greater 
than 240 kDa in molecular weight that was distinct from the insulin receptor (IR) (18).  
Work from three laboratories was able to determine that the sequence for the two 
receptors were identical, and that the receptor could bind both M6P ligands and IGF-II; 
thus, the receptor for somatomedin was the CI-MPR (19-21). 
The CD-MPR was discovered in CI-MPR-deficient cells, yet lysosomal enzymes 
were still properly sorted (14, 22).  Further analysis revealed that the CD-MPR differed 
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from the larger MPR in that it required divalent cations to bind to its ligands, and that the 
CD-MPR is coded from a different location within the genome than its larger counterpart 
(14, 23, 24). 
 
B.2.  M6P/IGF2R Evolution 
The MPRs have been well conserved in evolution.  The CD-MPR has a similar 
sequence and protein structure as one of the 15 EC domains of the M6P/IGF2R, 
suggesting that the M6P/IGF2R may have evolved from duplications of the CD-MPR 
(25).  The M6P/IGF2R has been sequenced or characterized in many species with the 
greatest characterization in human and mouse.  To date, the complete cDNA sequences 
of the M6P/IGF2R have been obtained from multiple mammals, including bovine (20), 
human (21, 26), mouse (27), rat (19), pig, and many others (28).  There are also 
incomplete sequences for sheep, kangaroo (29), and goat (30).   
The M6P/IGF2R orthologs from non-mammalian vertebrates, such as chicken, 
bind to M6P but bind only very weakly to IGF-II (31).  Further analysis showed that the 
M6P/IGF2R in the chicken shared only 61% identity with the mammalian receptor, 
indicating that the receptor acquired the property of IGF-II binding some time after the 
divergence of mammals from birds (32).  Interestingly, the M6P/IGF2R isolated from the 
oriental garden lizard (Calotes versicolor) can bind human IGF-II (25), which may be 
attributed to convergent evolution.  The MPR is conserved in fish; however, there is less 
sequence identity with the mammalian receptor (48-50% identity) and has amino acid 
substitutions in key ligand binding sites (33).  The M6P/IGF2R was characterized from 
zebrafish and found to be 51% identical to the human receptor, making this the most 
primitive vertebrate species with the MPR (34).   
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Invertebrates also have conserved a version of the M6P/IGF2R.  This has been 
seen in the starfish (35) and mollusk (36, 37), and there is a MPR-like binding protein in 
Drosophila melanogaster (38).  The mollusk does have an interesting domain that 
interacts with the alpha-fucosidase enzyme that has not been seen with the other 
species, suggesting a different potential role of the receptor (25, 30).  Since Drosophila 
has only 23-29% homology to the human M6P/IGF2R, it is considered to be only a MPR-
like protein called lysosomal enzyme receptor protein (LERP) (25, 38). 
Although it was thought that yeast did not have an MPR and that they sorted their 
lysosomal enzymes via the VPS10 gene product through a specific amino acid 
sequence unrelated to M6P binding, Whyte and Munro discovered that yeast do in fact 
have a yeast homolog of MPR, which they termed Mrl1p (39).  Unlike the mammalian 
MPRs, Mrl1p does not seem to be as important in lysosome biogenesis in yeast as the 
mammalian counterparts, since knockout of the MRL1 gene did not substantially affect 
lysosome maturation (39).  Still, the Mrl1p protein may be an evolutionary precursor to 
the MRPs in the subsequent domain. 
Dictyostelium discoideum, a social amoeba, possesses M6P-methylesters on its 
lysosomal enzymes that can recognize and bind the mammalian M6P/IGF2R (40-42).  
However, D. discoideum has unique characteristics about its lysosomal enzymes that 
differ from the higher-order species.  D. discoideum’s acid hydrolases have 
phosphodiesters and these methylphosphomannosyl groups resist acid hydrolysis (41, 
43).  In addition, D. discoideum has many sulfate residues in lysosomal enzymes, mainly 
existing as mannose 6-sulfate (M6S).  In fact, only about 2% of the oligosaccharide 
residues within the lysosomal enzymes exist as phosphomonoesters (41, 44).  Thus, 
even though D. discoideum acid hydrolases can bind to the mammalian M6P/IGF2R, it 
may have its own version of MPR that favors the phosphodiester- or M6S-binding, but to 
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date, no MPR-like receptor has been found.  Work from the MacDonald and Berkowitz 
laboratories has found a putative mannose 6-phosphate receptor in D. discoideum.  This 
D. discoideum mannose 6-phosphate receptor (DDMPR) has five mannose 6-phosphate 
receptor homology (MRH) domains and is predicted to have a similar sequence and fold 
as the mammalian domain 3.  If this receptor is in fact an MPR, the DDMPR would be a 
very interesting protein to characterize, because it would be the first such MPR-like 
protein discovered in a species in the slime mold branch after divergence from the 
lineage leading to animals, fungi, ciliates and plants within Eukaryota. 
 
B.3.  Genomic structure of M6P/IGF2R 
The genes encoding the M6P/IGF2R in both mouse and human map to different 
loci than both the genes encoding IGF-II (chromosome 11 in human) (45) and CD-MPR 
(chromosome 12 with 7 exons and total length of 12 kb in human) (46, 47).  The 
M6p/Igf2r gene locus is mapped to chromosome 17 in mouse, and is maternally 
imprinted.  The murine M6p/Igf2r gene is about 93 kilobases (kb) long and has 48 exons 
and is predicted to code for 2482 amino acids (48).  Exons 1-46 code for the 15 EC 
domains that are similar to the bovine and human M6P/IGF2R EC domains.  Each 
domain is encoded by 3-5 exons, and the fibronectin-like domain within repeat 11 is 
encoded by exon 39.  Part of exon 46 codes for the transmembrane domain while exons 
46-48 code for the cytoplasmic tail (48).  In human, the M6P/IGF2R gene  maps to 
chromosome 6q26 and has 48 exons comparable to the mouse, with a total size of 136 
kb (49).  There is no correspondence of the exon boundaries of the M6P/IGF2R with the 
EC domain structure, with each EC domain encoded by three to five exons, similar to the 
CD-MPR.  The 226-bp promoter region has a 54-bp enhancer with two E-box motifs, and 
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putative binding sites for the transcription factors Sp1 and nerve growth factor-1A (46).  
The human and mouse genes encoding the M6P/IGF2R are differentially imprinted.  In 
the mouse, the M6p/Igf2r gene is maternally imprinted and expressed in all tissues, but 
the IGF2R gene in human is biallelically expressed (49-51), as is the Igf2 and M6p/Igf2r 
in chicken (52).  Contrary, the IGF2 in human is maternally imprinted, and with loss of 
imprinting there is increased risk of cancer (53).  Furthermore, when M6P/IGF2R is 
monoallelically imprinted, it increases the risk of cancers, such as Wilms’ tumors (49). 
Expression of M6P/IGF2R is developmentally regulated and tissue-specific (54-
58), with the highest expression of M6P/IGF2R and IGF2 around prenatal 16-20 days of 
development, dropping postnatally in rat and mouse tissues (59).  In human, the 
M6P/IGF2R level is non-significantly higher in prenatal tissues compared to postnatal 
tissues, with high expression in all tissues studied (57).  The MP6/IGF2R plays a crucial 
role in development, as knockout of this gene leads to fetal overgrowth and neonatal 
lethality (60).  According to Matzner et al., there was differential expression of the two 
MPRs in specific tissues during early and late-stage embryogenesis, suggesting that 
these two receptors have non-redundant roles in lysosome biogenesis that are cell- and 
stage-dependent, despite their overlapping functions (54). 
 
B.4.  M6P/IGF2R protein structure 
The M6P/IGF2R is a 300-kDa type-1 integral membrane glycoprotein consisting 
of a 44-residue amino-terminal signal sequence, 2269-residue EC region, 23-residue 
transmembrane region, and a163- residue carboxyl-terminal cytoplasmic tail (Figure 1.1) 
(20). There are 15 contiguous MRH repeat domains, each consisting of ~147 amino acid 
residues, that share 14-38% sequence identity and cysteine distribution (20, 46).  Each 
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EC repeat of the M6P/IGF2R, as well as the single EC domain of the CD-MPR, has nine 
β-strands forming a flattened β-barrel structure, stabilized by 3-4 disulfide bonds and 
held together by a flexible linker.  Sequence alignment and homology mapping predict 
that all of the domains have the overall similar structure with the exception of domain 13 
having a fibronectin-like extra loop that protrudes out and supports the binding of IGF-II 
to domain 11  (61, 62).   
To date, only domains 1-3 of the bovine M6P/IGF2R and 11-14 of the human 
M6P/IGF2R have been structurally solved using x-ray crystallography techniques (61, 
63, 64), which have revealed great detail about the receptor’s structure and function.   
The tertiary structures of the other EC domains have been predicted through sequence 
alignment and molecular modeling using the solved domains as a reference (Figure 1.2).   
The crystal structure of domains 1-3 indicates that repeat 3 sits above repeats 1 
and 2, suggesting that the M6P/IGF2R forms distinct structural units in groups of three 
repeats of the EC, producing five tri-repeats, oriented back-to-front (63).  The IGF-II 
binding site in this proposed model would be on the opposite side of the receptor from 
the M6P-binding sites.  However, the crystal structure of domains 11-14 showed the 
structure was a more open or linear configuration, resembling beads on a string where 
each repeat was a bead (64).  Collectively, the two crystal structures suggest a structure 
that is more tightly packed with the tri-repeats retaining a compact architecture at the 






Figure 1.1: Schematic diagram of the M6P/IGF2R, indicating its dimeric nature and 
major structural domains having known functions.  Abbreviations: uPAR, urokinase-
type plasminogen activator receptor; M6P, mannose 6-phosphate monoester binding 
preference; M6P-GlcNAc, mannose 6-phosphate diester binding preference; IGF-II, 











Figure 1.2: Sequences and tertiary structures of the MRH domains of the 
M6P/IGF2R. A) Sequence alignment of domains 1, 2, 3, 9, and 11 of the bovine 
M6P/IGF2R with the extracellular domain of the bovine CD-MPR.  Arrows represent the 
extent of the β-sheets.  There are 6-8 conserved cysteine residues in these domains, 
indicated in gray highlighting. B) A ribbon diagram of the tertiary structure of the bovine 
M6P/IGF2R domains 1 (blue), 2 (pink), and 3 (green).  The disulfide bonds that 
interconnect the overall β -barrel sandwich structure are indicated in yellow.  This figure 
was originially published in The Journal of Biological Chemistry and has been reprinted 
with permission of the publisher.  Olson, L. J., Dahms, N. M., and Kim, J.-J. P. (2004) 
The N-terminal carbohydrate recognition site of the cation-independent mannose 6-
phosphate receptor, J. Biol. Chem. 279, 34000-34009.  The American Society for 
Biochemistry and Molecular Biology, Inc. 
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Several motifs important for protein-protein interactions, phosphorylation, and 
trafficking are located within the cytoplasmic tail of the M6P/IGF2R (Figure 1.3).  The 
adaptor protein (AP) complexes interact with the single tyrosine-based motif, YSKV, 
which promotes clathrin-mediated endocytosis of the receptor at the plasma membrane 
(1).  The acidic-cluster dileucine motif (SFHDDSDEDLL for human M6P/IGF2R) in the 
cytoplasmic tail interacts with the Golgi-localized γ-ear-containing ADP-ribosylation 
factor-binding (GGA) proteins and AP-1, allowing for trafficking of the receptor from the 
TGN to the endosome (65).  Also, there have been reports of tyrosine phosphorylation at 
one of the four consensus motifs that are potential substrates for protein kinase C 
(PKC), cyclic adenosine 5’-monophosphate (cAMP)-dependent protein kinase and 
casein kinases (CK) 1 and 2 (66-69), which may play a role in internalization and 
trafficking. 
 
B.5.  Biosynthesis and processing of the M6P/IGF2R (co- and post-translational 
modifications) 
There are nineteen potential N-linked glycosylation sites within the EC domain of 
the M6P/IGF2R (20, 46).  However, the molecular mass differences of unglycosylated 
and glycosylated receptor forms in H-35 hepatoma cells suggest that there are 4-6 high-
mannose oligosaccharide side chains (70).  Studies show that most of these high-
mannose oligosaccharide modifications converted to complex-type oligosaccharide 
forms when the receptor is mature (46, 68, 71).   Even though the M6P/IGF2R has N-
linked glycosylation, glycosylation is not necessary for M6P or IGF-II to bind to the 
receptor (46, 68, 72); however, it has not yet been determined if glycosylation affects the 






Figure 1.3: The cytoplasmic tail of the MPRs contains the trafficking signals.  The 
CI-MPR (M6P/IGF2R) and CD-MPR have multiple motifs within the cytoplasmic tail that 
mediate interactions with binding partners, which influences trafficking and recycling of 
the receptors.  This figure was originially published in Nature Reviews Molecular Cell 
Biology and has been reprinted with permission of the publisher.  Ghosh, P., Dahms, N. 
M., and Kornfeld, S. (2003) Mannose 6-phosphate receptors: new twists in the tale, Nat. 









Using the CD-MPR as a reference of the disulfide-bond pattern, the 15 EC 
domains of the M6P/IGF2R have similarities in the locations of the cysteine residues 
(46).  Studies using reducing agents indirectly confirmed that the MP6/IGF2R has 
intramolecular disulfide bonds (46, 68, 72-75).  It is thought that the disulfide bond 
formation is an essential early step in the proper folding of the M6P/IGF2R.  Additional 
post-translational modifications include phosphorylation of threonine, serine and tyrosine 
residues in the cytoplasmic domain of the M6P/IGF2R (67, 68, 76, 77), but only the 
phosphorylation at serine residues has been thoroughly studied at this time.  Ser19, 
Ser85, and Ser156 are potential phosphorylation sites within the cytoplasmic domain of 
the receptor.  When Ser86 and Ser156, which lie within the casein kinase-like motifs, are 
phosphorylated, there is an association with TGN and clathrin-coated vesicle localization 
in Chinese hamster ovary cells, indicating that its phosphorylation status may regulate 
M6P/IGF2R trafficking (46, 78).  The amount of M6P/IGF2R present on the cell surface 
may be regulated by serine phosphorylation by PKC or the inhibition of sensitive 
phosphatases via okadaic acid (46, 69, 79, 80).  Plasma membrane M6P/IGF2R can be 
phosphorylated on serine by type V transforming growth factor (TGF)-β, which has 
serine/threonine kinase activity (80), and can have a two-fold increase in internalization 
of a lysosomal enzyme; this suggests that the internalization rate of M6P/IGF2R can be 
modulated via the phosphorylation of its cytoplasmic tail (46, 81).  If these serine 
residues are mutated, abolishing phosphorylation, the steady-state sorting of the acid 
hydrolases is unaffected in bovine (46, 82) or mouse (46, 83) cells.  The acidic-cluster 
dileucine motif in the carboxyl-terminal tail provides the critical sorting signals that are 
recognized by GGA proteins in the TGN (46, 65, 83-85), suggesting that phosphorylation 
may be more important for modulating kinetics.  One last modulation of the M6P/IGF2R 
is palmitoylation in the cytoplasmic domain, but the attachment sites and functional 
significance are unknown, unlike the CD-MPR (46, 86). Palmitoylation at Cys30 and 
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Cys34 of the cytosolic tail of CD-MPR is important for anchoring the receptor in the lipid 
bilayer and normal trafficking of the receptor (87). 
 
C.  Ligand binding properties of the M6P/IGF2R 
The M6P/IGF2R binds a diverse array of ligands, conferring multiple functions on 
this receptor.  Not long after the receptor was discovered, it was predicted that each of 
the 15 EC repeats may bind its own specific ligand (22).  Today, we now know that 
nearly half of the EC repeats play functional roles by binding certain ligands; 
interestingly, all of these functions reside in the odd-numbered repeats.  The polypeptide 
growth factor IGF-II or glycoproteins with M6P modifications on their N-linked 
oligosaccharides are the best-characterized ligands for the M6P/IGF2R. 
 
C.1.  Carbohydrate recognition by the MPRs: Binding of M6P-based ligands 
The M6P/IGF2R and CD-MPR have an overlapping yet distinct distribution of 
ligands.  There are over 60 acid hydrolases that need to be transported to the lysosome 
following their synthesis in the endoplasmic reticulum and post-translational processing 
and folding in the trans Golgi where they acquire M6P moities.  Each of these ligands 
varies in size, positioning and number of N-linked oligosaccharides, phosphomannosyl 
modifications, and glycosidic linkage between mannose residues on high-mannose 
structures.  This makes a complex network of lysosomal enzymes to be trafficked.  The 
MPRs are expressed in most cell types and have been studied extensively to determine 
the role that each receptor plays in lysosomal enzyme targeting.  The MPRs have 
different affinities for the different lysosomal enzymes, with some ligands showing 
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preferential binding to one MPR over the other.  Mouse fibroblast cell lines with knockout 
of one of the MPRs or both were used for multiple studies on the lysosomal enzyme 
trafficking.  When both MPRs were absent, there was severe mis-sorting of lysosomal 
enzymes, but when either receptor on its own was absent, there was only partial mis-
sorting of enzymes, where the lysosomes remained normal or near-normal.  The 
secretions from these single-knockout studies showed that the same species of 
enzymes were mis-sorted but in different ratios depending on which receptor was 
missing (88).  Additionally, an excess of one receptor could not fully compensate for the 
absence of the other receptor, suggesting that the receptors preferentially recognize 
different features on the acid hydrolases (89).  However, the excess amounts of 
M6P/IGF2R can compensate for loss of the CD-MPR using a secretion-recapture 
mechanism, where the receptor is able to take up secreted lysosomal enzymes from the 
medium rather than binding them in the Golgi and sorting internally to the lysosome 
directly (68, 90).  The differences in binding affinities of the lysosomal enzymes to the 
MPRs confirmed that the receptors have overlapping binding repertoires, yet each 
preferentially binds to a unique subset of the lysosomal enzymes (91).  Furthermore, a 
M6P proteomic analysis of serum from MPR-deficient mice indicated that some of the 
acid hydrolases (i.e., heparanase and α-mannosidase B1) have distinct preferences, 
respectively, for either the CD-MPR or the M6P/IGF2R (92).  The M6P/IGF2R appears 
to be more efficient at lysosomal targeting than the CD-MPR, as there is an increase in 
M6P-capped glycoproteins in the medium when the M6P/IGF2R is absent relative to the 
absence of the CD-MPR (91).  It is still not known how and for what reason two MPRs 
have evolved that display overlapping yet distinct specificities for lysosomal targeting, 




C.1.a.  Structural characteristics of M6P-glycans for M6P/IGF2R binding 
M6P monoesters bind to the M6P/IGF2R with micromolar affinity (KD = 5-8 x 10
-6 
M) (93) and utilize hydrogen bond interactions for productive binding.  The phosphate on 
the sixth carbon hydrogen-bonds with a Ser residue and water molecules while the 2-
hydroxyl group of the mannosyl ring forms a hydrogen bond with Gln and Arg residues, 
and this hydroxyl must be in the axial position as opposed to the equatorial position to do 
so (i.e., compared with the geometry of glucose 6-phosphate (G6P) at carbon 2) (63).  If 
the mannose does not have a phosphate or the sugar has the hydroxyl in the wrong 
configuration, there is a 10,000-fold reduction in M6P-binding affinity for the M6P/IGF2R 
(94).  The phosphate positioning and glycosidic linkage within the oligosaccharide is also 
important for optimal binding.  Chemically synthesized oligomannosides or 
pseudoglycoproteins have been used as inhibitors to determine whether the phosphate 
group on the ultimate mannose is required for productive binding as well as varying the 
glycosidic linkages between mannose groups, α(1,2), α(1,3), and α(1,6).  Radioligand 
displacement analysis determined that the α(1,2)-linked mannose structures had 
stronger inhibition of 125I-β-galactosidase binding to the M6P/IGF2R.  The penultimate 
glycosidic linkages did not have an inhibitory effect (95, 96).  When the final glycosidic 
linkage was α(1,3)- or α(1,6)-linked, the affinity was reduced by 6-fold compared to the 
α(1,2)-linkage.  Increasing the mannose-chain length improved the inhibition for binding 
to the M6P/IGF2R, suggesting that the two mannose groups leading up to the ultimate 
M6P may make contacts with the M6P-binding pocket of the receptor (95).  
Crystallography of the CD-MPR, which has a structurally homologous M6P-binding 
domain, in complex with pentamannosyl 6-monophosphate (PMP) or a phosphorylated 
α(1,2)-linked tri-mannoside confirmed that there are hydrogen bonds formed between 
the two mannose groups leading up to the final M6P and the M6P-binding pocket of the 
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receptor (97, 98).  Two moles of M6P or one mole of a high-mannose oligosaccharide 
bearing two M6P moieties bind to one mole of M6P/IGF2R, as demonstrated by 
equilibrium dialysis experiments (46, 93, 95); however, the high-mannose 
oligosaccharide improved binding affinity by 100-1000-fold (1-10 nM) over M6P, 
indicating that these ligands have a multivalent interaction with the M6P/IGF2R (91, 93).   
 
C.1.b.  Structural requirements of the M6P/IGF2R for M6P recognition 
Several laboratories have contributed to our understanding of the specific 
requirements for the recognition of M6P-containing moieties by the M6P/IGF2R.  These 
biochemical and biophysical studies have determined the pH dependency for M6P-
based binding, the specific amino acid residues required to make functional contacts 
with the ligand, and the binding sites’ specific preferences for glycosidic modifications.  
Optimal binding of M6P-bearing ligands by the M6P/IGF2R occurs at a pH of 
approximately 6.4 while the receptor is unable to bind at a pH below 5.5, supporting the 
observations of the dissociation of lysosomal enzymes and other cargo from the 
M6P/IGF2R in the acidic environment of the endosome (46).  The M6P/IGF2R, but not 
the CD-MPR, maintains M6P-binding ability at neutral pH, permitting the receptor to 
internalize extracellular M6P-based ligands (93, 94).  Furthermore, the M6P/IGF2R 
recognizes M6P-GlcNAc phosphodiesters and hydrolase enzymes from D. discoideum 
that do not contain M6P modifications but rather mannose 6-sulfate (M6S) and methyl 
phosphodiester (M6P-OCH3) (99, 100).  The capacity to bind different glycosyl 
modifications on M6P-based ligands at various pH conditions is attributed to four 
individual M6P-binding locations within the EC domain of the receptor (93, 101, 102).   
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Site-directed mutagenesis studies have determined that Gln348, Arg391, 
Glu416, Tyr421, and Ser387 within domain 3 of the bovine M6P/IGF2R are important for 
high-affinity binding of glycosylated proteins.  The same motif of amino acid residues is 
conserved within domain 9 (Gln1292, Arg1334, Glu1354, Tyr1360) of the bovine 
M6P/IGF2R (103) as well as the bovine CD-MPR (Gln66, Arg111, Glu133, Tyr143) 
(104).  These amino acid residues are able to directly interact with M6P groups, with Glu 
and Tyr forming hydrogen bonds with the 4- and 3-hydroxyl groups and Gln and Arg 
hydrogen bonding with the 2-hydroxyl of the mannose ring (63).  This same motif in 
domain 5 is assigned as Gln644, Arg687, Glu709, and Tyr714 and for domain 15 as 
Gln2160, Arg2170, Glu2227, Tyr2233 (101, 105), indicating that these residues are 
essential for carbohydrate recognition by the bovine M6P/IGF2R in all four M6P-binding 
sites (Figure 1.4).  Moreover, crystallographic studies have determined additional 
residues within the M6P-binding pockets that hydrogen bond with the two mannose 
groups leading up to the ultimate mannose group; mutation of Arg435/1334 to Ala or Lys 
abrogates nearly all M6P-based binding by the M6P/IGF2R (106).   
M6P binds  to distinct carbohydrate recognition sites in domains 3 and 9 with 
high affinity, and domains 5 and 15 with low affinity (46, 93, 95, 101, 106, 107).  
Recombinant M6P/IGF2R mini-receptors allowed for characterization and ligand-type 
preferences of the four M6P-binding sites.  There are two high-affinity M6P sites (KD=1 
nM) located in domains 3 and 9 and two lower-affinity M6P-binding sites within domains 
5 (KD= 20 mM for M6P and 1 mM for M6P-diester) and 15 (KD=13 µM), where domain 5 
prefers phosphodiester-modified ligands (101, 104, 108).  To date, only domains 1-3 





Figure 1.4: The M6P recognition by the M6P/IGF2R.  A) Ribbon diagram of domain 3 
(green) with bound M6P (yellow).  B) M6P forms multiple hydrogen bonds within the 
binding pocket.  The phosphate group of M6P makes contact with Ser386 and is 
stabilized by the involvement of three water molecules (W1-3) depicted as red spheres. 
Glu416 and Tyr421 form hydrogen bonds with the 4- and 3-hydroxyl groups. Gln348 and 
Arg 391 hydrogen bonds with the 2-hydroxyl of the mannose ring.  C) Ribbon diagram 
indicating the contribution that Ser386 has in ligand binding.  This figure was originially 
published in The Journal of Biological Chemistry and has been reprinted with permission 
of the publisher.  Olson, L. J., Dahms, N. M., and Kim, J.-J. P. (2004) The N-terminal 
carbohydrate recognition site of the cation-independent mannose 6-phosphate receptor, 





crystallography.  The crystal structure of domains 1-3 indicates that domains 1-2 act to 
stabilize the M6P-binding site of domain 3 and are necessary to produce a high-affinity 
binding pocket (63). 
Further analysis of the binding properties of the M6P-binding domains was done 
using affinity chromatography and acid-dependent dissociation analysis (108).  Domain 
9 has a more acidic pH optimum for binding (pH of 6.4-6.5) compared to the N-terminal 
binding domain (pH of ~6.9).  Furthermore, domain 9 is able to retain more binding of 
M6P-based ligands as the pH drops below 5.5 compared with domain 3 (108).  The 
ability of the M6P/IGF2R to bind M6P-based ligands throughout a broader pH range may 
account for how the receptor binds ligands at slightly alkaline conditions (pH 7.4 at the 
cell surface) and in slightly acidic luminal compartments (pH 6.5 at the TGN and 
endosomes), allowing for an expansive repertoire of ligand binding.  Moreover, domain 
3, with the aid of domains 1 and 2, forms a broader M6P-binding pocket that may allow 
this site to be more promiscuous in the type of ligand that it binds, such as M6P, M6S, 
M6P-phosphodiester, etc.) (108).  Acid α-glucosidase (GAA) with a M6P or M6P-OCH3 
modification on its N-linked oligosaccharides was used in surface plasmon resonance 
(SPR) studies to determine whether domain 5 preferred mono- or diester M6P binding.  
Domain 5 displayed 14- to 18-fold higher affinity for M6P-phosphodiester than M6P, 
which explains the delivery of phosphodiester-containing lysosomal enzymes (such as 
those that escaped the uncovering enzyme’s action in the TGN, where the N-
acetylglucosamine linked to the M6P is enzymatically removed to reveal the M6P 
moiety) to the lysosome by this domain of the M6P/IGF2R (105).  Unlike domains 3 and 
9 of the M6P/IGF2R, domain 5 lacks two critical cysteines that form a disulfide bond, 
which may allow for M6P-phosphodiester recognition (105).  Recently, domain 15 has 
been determined to have very low affinity M6P-binding ability, as it has only three of the 
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four critical amino acid residues that are required for high-affinity M6P binding and lacks 
two cysteine residues (101).  This site binds its ligands with a KD of 13 µM; thus, the 
physiological significance of this binding functionality is not clear at this time. In 
summary, each M6P-binding site has similar yet unique structural features and binding 
specificities that allow the M6P/IGF2R to recognize a diverse repertoire of M6P-modified 
proteins 
 
C.2.  Structural requirements for IGF-II binding by the M6P/IGF2R 
IGF-II is a small, acidic polypeptide that has many biological effects, with the 
most important roles in growth and development, cell division and differentiation (109).  
IGF-II is 67 amino acid residues in length in its mature form, which has a high sequence 
and structure homology to IGF-I and insulin (110-113), yet the latter polypeptides are 
unable to bind the M6P/IGF2R. 
IGF-II binds to a hydrophobic cleft in domain 11 of the M6P/IGF2R while the 
fibronectin-like repeat in domain 13 enhances the binding affinity (114, 115).  IGF-II 
binding is mostly attributed to I1572, as mutagenesis studies have shown that binding is 
abrogated by a substitution with threonine (116-118).  Furthermore, the core 
hydrophobic cluster within domain 11 of the bovine M6P/IGF2R contains amino acid 
residues Tyr1542, Glu1544, Phen1567, Thr1570 that form an overall positively charged 
surface for the negatively charged IGF-II surface to bind (Phe19 of IGF-II) (64). 
Additionally, binding affinity for IGF-II can be increased 6-fold with an E1544L 
substitution, which may increase the binding affinity with electrostatic interaction 
between E1544 and D20 on IGF-II (119).   
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A crystal structure of IGF-II in complex with an M6P/IGF2R fragment (domains 
11-13) provided details on the mechanism of IGF-II binding to the receptor (64).  The 
IGF-II binding site in domain 11 involves the same four implicated loops that are found 
within the M6P-binding sites of domains 3 and 9.  A hydrophobic cluster consisting of 
Thr1542, Phe1567 and Leu1629 lying at the mouth of the β-barrel forms a patch that 
surrounds the IGF-II anchor residue Phe19 (Figure 1.5).  Phe19 and Leu53 of the IGF-II 
polypeptide mediate binding to the hydrophobic cluster (64).  The FnII domain within 
domain 13 does not directly interact with the IGF-II binding, but minor solvent accessible 
surface area changes in Trp1939 and Phe1941 are in proximity to IGF-II side chains and 
affect the AB-loop flexibility (64).  
The binding pocket produced by domain 11 by itself is enough for productive 
binding of IGF-II to the M6P/IGF2R (46, 120); however, binding of IGF-II to the receptor 
is improved 5-10-fold when domain 13 with the fibronectin-like domain is also present 
(114, 115, 120).  This fibronectin-like domain is a 43-residue insert in domain 13 that has 
approximately 50% sequence identity to the fibronectin type II (FnII) domain.  FnII 
domains are found in many proteins, with their most prominent role in collagen binding; 
additionally, Devi et al. suggested that FnII within domain 13 was important for the high-
affinity binding of the M6P/IGF2R for IGF-II (114), which was shown by Linnell et al. not 
to interact directly with the polypeptide but rather to act as a stabilizer for the binding 
pocket.  In support of this, the predicted IGF-II binding pocket within domain 11 is 
adjacent to domain 13 containing the FnII fragment, thus allowing repeat 13 to slow the 
rate of IGF-II dissociation from the M6P/IGF2R, which enhances binding affinity (61, 
114, 116). 
An interesting observation was made from purified M6P/IGF2R from opossum 
and kangaroo indicating that the receptors of the metatherian mammals (marsupials) 
24 
 
exhibited lower binding affinities for IGF-II than the receptors of eutherian mammals; 
other animal species such as monotremes, chicken and frog do not display significant 
affinity for IGF-II (29, 31, 46, 121-124).  These differences may have arisen from 
divergent evolution, as the IGF-II non-binding species have substantially different amino 
acid sequences in their domain 11 regions when compared with most eutherian 
mammals (46, 123, 125).  On the contrary, the receptors of non-mammalian vertebrate 
fish (trout) appear to bind IGF-II (46, 126), while the zebrafish has a conserved 
isoleucine important for IGF-II-binding, but lacks conserved flanking regions involved in 
binding (127).   
Furthermore, the dimeric M6P/IGF2R does not seem to affect IGF-II binding to 
the receptor.  M6P-based ligands can bind to the M6P/IGF2R dimeric structure 
producing bivalent, high affinity binding that requires cooperation between subunits of 
the monomers, which may or may not affect IGF-II binding.  To address this, co-
immunoprecipitation studies of differentially expressed epitope-tagged soluble mini-
receptors determined that IGF-II can bind to each monomer independently and there 
was no inhibitory effect on IGF-II binding induced by the formation of M6P/IGF2R dimers 
(128).  While M6P/IGF2R dimerization does not affect IGF-II binding, prior studies 
propose that some phosphomannosylated ligands can block IGF-II binding (129, 130), 
although others determine that the receptor can accommodate both types of ligands 
simultaneously (131).  Therefore, the binding of IGF-II and M6P-based ligands by the 




Figure 1.5:  The interface of the M6P/IGF2R interaction with IGF-II.  A) The IGF-II 
binding pocket is formed by domains 11-13 of the bovine M6P/IGF2R.  The primary 
binding site for IGF-II (magenta) is located within domain 11 (yellow) but contacts are 
made from the type II fibronectin-like domain (FnII) of domain 13 (black). B) Side chains 
within domain 11 undergo a shift, changing the surface area upon IGF-II binding.  This 
figure was originially published in Trends in Biomedical Sciences and has been reprinted 
with permission of the publisher.  Brown, J., Jones, E.Y., Forbes, B.E. (2009) Keeping 
IGF-II under control: Lessons from the IGF-II-IGF2R crystal structure, Trends in 




C.3.  Additional non-M6P-modified M6P/IGF2R ligands 
The M6P/IGF2R has been shown to bind other ligands apart from IGF-II and 
M6P-based glycoproteins, although their binding properties are far less studied than for 
IGF-II and the M6P ligands.  There are a number of other ligands that interact by M6P-
independent or unknown mechanisms, including: urokinase-type plasminogen activator 
receptor (uPAR) (132), plasminogen (133), retinoic acid (RA) (134), serglycin (135), and 
heparanase (136).  The interaction between RA and the M6P/IGF2R is not completely 
understood at this time.  Studies using full-length and soluble M6P/IGF2R have indicated 
that the receptor’s cytoplasmic domain is necessary for RA binding.  Additionally, binding 
of RA to the M6P/IGF2R enhances the internalization rate of the receptor and of 
passenger ligands (IGF-II and secreted lysosomal enzymes) that results in decreased 
cell proliferation and increased apoptosis (134).  Plasminogen and uPAR binding sites 
have both been mapped to domain 1 of the M6P/IGF2R (137); however, there is some 
controversy as to the precise interaction.  Kreiling et al. used co-immunoprecipitation 
assays to show that soluble M6P/IGF2R can bind uPAR in an M6P-dependent manner, 
but the full-length membrane-associated receptor displays weak binding to uPAR that is 
M6P-independent (138).  The M6P/IGF2R may function to regulate activation of 
plasminogen (137).  Heparanase appears to bind the M6P/IGF2R in the EC domain that 
acts as a tether for this enzyme to be stretched further out into the EC matrix for 
degradation of heparan sulfate (136), but the receptor may also function as an 
internalization route for heparanase into the cell (139).  Serglycin has varying 
glycosaminoglycan chains depending on the cell type, which can consist of heparin, 
heparan sulfate, or chondroitin sulfate chains.  Serglycin plays a role in lysosome 




C.4.  Biochemical and structural evidence for M6P/IGF2R dimerization 
It has been observed that M6P/IGF2R exists as homodimers at the cell surface 
independent of bound ligand (140, 141), but in detergent-solubilized preparations, the 
receptor mostly exists as a monomer (131, 142).   Interestingly, this is unlike the CD-
MPR that is detected as a dimeric or tetrameric complex under most conditions (46, 
143).  Even though the M6P/IGF2R is monomeric in detergent-solubilized preparations, 
there is strong evidence that M6P/IGF2R forms dimers with bound multivalent ligands, 
such as the naturally occurring lysosomal enzyme human -glucuronidase (hGUS) (131, 
141, 144).  Using soluble, epitope-tagged M6P/IGF2R constructs, it has been 
demonstrated that the EC region of the receptor is sufficient to produce oligomerization 
(141, 144).  Further analysis using forced expression of chimeric receptors (EC and TM 
regions of the M6P/IGF2R fused to the cytoplasmic tail of the EGFR) revealed the 
formation of dimers in the absence of M6P-based multivalent ligands (141).  
Furthermore, sedimentation coefficient studies demonstrated possible dimer formation 
using a truncation of the M6P/IGF2R encompassing domains 11-13, but did not see any 
dimeric formation when using a separate mini-receptor of domains 11-12 (64).  Even 
though the authors of that study saw only weak interactions between these domains, it is 
thought that additional contacts made throughout the EC domain may enhance the 
dimeric structure of the M6P/IGF2R.  Based upon the current literature, the M6P/IGF2R 
exists as a monomer but forms weak dimers in membranes that can be further stabilized 
with the binding of multivalent M6P-based ligands.  Moreover, the internalization rate 
study done by York et al. revealed an enhanced internalization of IGF-II bound to the 
M6P/IGF2R when hGUS was present, further supporting the hypothesis that multivalent 




Even though weak, dimeric structures of the M6P/IGF2R form in the plasma 
membrane, the precise domain responsible for dimerization has yet to be determined.  
Nevertheless, multiple interactions may occur along the EC domain with domain 12 
being most critical in influencing dimerization (64, 140, 141).  Crystal structures for the 
dimer of domains 11-14 of the M6P/IGF2R indicate that this region forms the bulk of the 
receptor dimer (64), while domain 5 in the bovine M6P/IGF2R has also been shown to 
contribute to dimerization (102), suggesting that additional contacts within domain 5 of 
each monomer may further support dimerization (Figure 1.6).  
 Although there is increasing evidence suggesting that M6P/IGF2R forms a 
dimeric complex in membranes, the exact mechanism and interplay between the 
domains of each monomer has yet to be defined.  Additionally, it is believed that 
multivalent M6P-based ligands can stabilize the dimeric receptor, but they are not 
necessary for initiation of the dimer complex.  This was seen when an epitope-tagged 
double mutant of the soluble form of the M6P/IGF2R encompassing domains 1-15 was 
pulled down with a different epitope-tagged wild-type mini-receptor of domains 1-15 in 
the absence of multivalent ligand (128).  Nevertheless, it remains unclear how 
multivalent M6P-based ligands, when bound to the dimeric M6P/IGF2R, can accelerate 
the internalization of the receptor and passenger ligands as seen with hGUS (131).  
Whether the increased rate of receptor internalization is mediated by the clathrin-
dependent endocytosis pathway is still up for debate.  One hypothesis is that when the 
multivalent M6P-based ligands bind to the dimeric or oligimeric M6P/IGF2R structure, it 
leads to clustering of the internalization signals that are present in the C-terminal tail 
(131, 145).  Another explanation is that a conformational change within the EC domain 
caused by ligand binding can result in an optimal presentation of the internalization 





Figure 1.6: Model of the ectodomain of the M6P/IGF2R tertiary structure.  A) The 
monomeric M6P/IGF2R ectodomain is depicted as a series of ribbons for each domain, 
folding into tri-repeats.  The crystal structure of domains 1-3 and 11-14 have been 
solved, and the remaining domains have been modeled through sequence alignment.  
B) The M6P/IGF2R forms a dimer in membranes where multiple contacts are made 
throughout the length of the ectodomain.  Domain 12 is predominantly involved in the 
dimeric structure.  This figure was originially published in Trends in Biomedical Sciences 
and has been reprinted with permission of the publisher.  Brown, J., Jones, E.Y., Forbes, 
B.E. (2009) Keeping IGF-II under control: Lessons from the IGF-II-IGF2R crystal 








mediated endocytosis machinery (131).  It is also unknown at this time if the M6P/IGF2R 
can form higher-order oligomeric states through multivalent ligand interactions and the 
potential effect they would have on the receptor’s intracellular trafficking. 
 
D.  M6P/IGF2R function 
D.1.  M6P/IGF2R localization and trafficking  
The MPRs are predominantly found in the TGN and lysosomal network, with about 10% 
of receptor found at the plasma membrane at most times, but the actual amount varies 
among cell types (46, 146-150).  The MRPs undergo constitutive trafficking that is not 
dependent on ligand binding (151, 152).  However, upon binding of different ligands 
(insulin, IGF-I, IGF-II, or M6P-based) to receptors, these ligands may cause a type-
dependent shift in the distribution of that receptor from the intracellular compartments to 
the cell surface to decrease EC ligand (151, 153).  The MPRs mainly function in 
lysosome biogenesis, but also function to recapture any M6P-capped acid hydrolases 
that escape sorting and were secreted by the cell, as well as certain extracellular ligands 
such as IGF-II that are internalized from the plasma membrane and trafficked to the 
lysosome for degradation. 
 
D.2.  Lysosome biogenesis 
Lysosomes are acidic membrane-bound organelles that function in degradation 
of cellular macromolecules.  Lysosomes contain over 60 soluble acid hydrolases and 
over 120 accessory proteins.  These proteins are the enzymatic machinery for 
degradation and need to be continuously replenished in the lysosomes (154).  Newly 
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synthesized acid hydrolases undergo specific modifications and follow a specific 
trafficking pathway in order for them to reach their destination in the lysosome.  These 
enzymes are synthesized in the endoplasmic reticulum and undergo co-translational 
glycosylation on specific asparagine residues (N-linkages) (46).  As they continue 
through the ER-Golgi biosynthesis pathway, their N-linked oligosaccharides are 
processed in two steps to produce the terminal mannose 6-phosphate structure.  In the 
first step, N-acetylglucosamine-1-phosphotransferase transfers α-N-acetylglucosamine 
1-phosphate from UDP-N-acetylglucosamine to the 6th carbon of terminal mannose 
residues on biantennary high-mannose structures, forming an intermediate of M6P-
OGlcNAc-acid hydrolase (46, 155, 156).  Then in the TGN, the uncovering enzyme (N-
acetyl-glucosamine 1-phosphodiester-α-N-acetylglucosaminidase removes a GlcNAc to 
expose a M6P moiety (157, 158).  M6P signals on the acid hydrolases are recognized by 
the P-type lectins (M6P/IGF2R and CD-MPR) in the TGN and then sorted to the early 
endosome (46, 158, 159).  Additionally, if these lysosomal enzymes are mis-sorted and 
trafficked to the plasma membrane where they are exocytosed, they can be recaptured 
by the M6P/IGF2R (CD-MPR is unable to bind ligands at slightly alkaline pH) on the cell 
surface and brought back to the early endosome.  At either case, the cytosolic tails of 
the MPRs interact with trafficking proteins and mediate the transport of MPR-containing 
vesicles (46, 159-161).  Upon arrival at the early endosome, the ligands remain bound to 
the MPRs until the acidic pH of <6 is reached in the late endosome, where the MPRs 
release their cargo.  The MPRs then undergo recycling via retrograde transport back to 
the TGN to be used for another round of trafficking newly synthesized M6P-capped 
enzymes, while the acid hydrolases continue from the late endosome to the lysosome 





Figure 1.7: Localization and trafficking of the MPRs.  M6P/IGF2R and CD-MPR are 
found mostly within the intracellular compartments, trafficking newly synthesized acid 
hydrolases from the TGN to the early endosome.  The M6P/IGF2R also binds 
extracellular ligands and internalizes them to the early endosome.  Upon maturation of 
the endosome, ligands dissociate from the MPRs and arrive at the lysosome while the 
receptors are recycled through signals in the cytoplasmic tails.  The MPRs recognize the 
M6P signal on oligosaccarchide chains, which bind to the extracellular domains of the 
receptors.  This figure was originially published in Current Opinion in Structural Biology 
and has been reprinted with permission of the publisher.  Kim, J.J.P., Olson, L.J., 
Dahms, N.M. (2009) Carbohydrate recoginition by the mannose 6-phosphate receptors, 







It is interesting to note that when the M6P/IGF2R has mutations in its EC domain 
that affect M6P-based binding, more lysosomal enzymes are mis-sorted and secreted at 
the plasma membrane, contributing to cellular invasiveness (59), and can result in more 
immature lysosomes that do not contain enough acid hydrolases.  Furthermore, there 
are over 40 diseases related to genetic defects in synthesis, sorting, or targeting of 
lysosomal enzymes, (163), resulting in the storage diseases known as mucolipidoses or 
mucopolysaccharidoses.  This is why proper lysosomal biogenesis is biomedically 
important.  Moreover, diseases such as cancer progression, Alzheimer’s disease, 
rheumatoid arthritis and atherosclerosis have been associated with defects in the 
lysosomal system (164-166). 
 
D.3.  The IGF axis 
The IGF axis is quite complex, comprising multiple cellular transmembrane 
receptors, binding proteins and growth factor peptides that regulate diverse biological 
processes including cell proliferation and survival, death, differentiation, development 
and malignancy (113, 167-169).  The classical IGF axis is composed of two polypeptide 
growth factors (IGF-I and –II), three IGF receptors (IGF1R, insulin receptor isoform A 
(IR-A), and M6P/IGF2R), and six IGF binding proteins (IGFBP) (170, 171).  The IGF axis 
can also be expanded to include regulatory factors such as proteases that cleave the 
IGFBPs and regulate the bioavailability of the IGFs (172) (Figure 1.8).  Insulin can also 
be considered a distant relative of this axis as binding of insulin to IR-A or IGF1R/IR-A 
hybrid receptors can result in mitogenic outcomes as opposed to metabolic outcomes 
through IR-B (173).  Each member of the IGF axis plays a unique role in maintaining 
cellular homeostasis.  The M6P/IGF2R, which transports M6P-glycosylated proteins and 
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non-glycosylated proteins to the lysosome, regulates pericellular levels of IGF-II by 
mediating its degradation in the lysosome (153).  Changes in the M6P/IGF2R regulatory 
activity have been associated with the onset of diseases, such as cancer, diabetes, and 
neurodegeneration (174-177). 
 
D.3.a. The IGFs 
IGF-I and –II are small polypeptide growth factors that act by endocrine, 
paracrine, or autocrine mechanisms to exert mitogenic and anti-apoptotic effects on 
many types of normal and tumor cells (167, 168, 170, 178).  IGF-I and –II (approximately 
7.5-7.6 kDa) are 49% and 47%, respectively, identical in sequence and structure to 
proinsulin, and the two human IGFs share 76% identity (179, 180).  IGFs are expressed 
in numerous organs and tissues and exhibit regulation of expression throughout 
developmental stages.  Transcription of IGF1 is predominantly regulated by growth 
hormone (GH) and synthesized and secreted by the liver (168, 181, 182).  IGF1 
expression is relatively low prenatally and increases postnatally until maximal expression 
is reached around puberty development and early adulthood.  The levels of circulating 
IGF-I remain fairly constant throughout most of adult life but steadily decline with age 
(183).  IGF-I regulates growth of the muscles, tendons, and bones and is the primary 
IGF during adult life (181, 184).  IGF-II has a different expression pattern from IGF-I; it is 
mostly involved in growth of tissues in the fetal development stages and then declines 
postnatally in many mammals (185).  IGF2 expression exhibits regulation by complex 
maternal imprinting, in which the gene shares an enhancer region with the H19 locus 
(186).  Differential methylation allows maternal expression of H19 but only paternal 





Figure 1.8:  The IGF axis is complex with multiple different levels of regulation.  
The IGF receptors are composed of M6P/IGF2R (clearance receptor that clears excess 
IGF-II signal that does not have a tyrosine kinase domain), and the receptor tyrosine 
kinases: IGF1R, IGF1R/IR-A, IR-A, and IR-B.  IR-B is mostly involved in metabolic 
signaling through insulin.  The ligands in this pathway are IGF-II, IGF-I, and insulin that 
are homologous in structure and sequence and bind with varying affinities for their 
receptors.  IGFBPs regulate the stability and bioavailability of the IGFs by binding and 
sequestering them from the receptors.  However, proteases may cleave the IGFBPs, 
which release the IGFs.  IGFBP-3 and IGFBP-5 have an acid labile subunit (ALS) which 





allowing for transcription from a different promoter in adult tissues (53, 188, 189).  
However, dysregulation of the epigenetics of the IGF2 gene can lead to disease 
progression (53) as discussed later in this chapter. 
 
D.3.b.  The IGFBPs 
There are six IGFBPs (labeled IGFBP-1 through -6) that regulate the 
bioavailability of IGF-I and IGF-II.  IGF-I and –II in the circulation are unstable and 
subjected to degradation; thus, the IGFBPs modulate their bioavailability as well as 
extend their half-lives.  IGF-I (20 nmol/L) and IGF-II (90 nmol/L) circulate at substantially 
higher concentrations than insulin (0.5 nmol/L) in adult human blood, but most of the 
IGFs are bound to IGFBPs (169).  The IGFBPs have differing affinities for IGF-I vs IGF-II 
yet negligible affinity for insulin (168, 169, 181).  The IGFBPs are homologous in 
structure and sequence but they each have unique post-translational modifications, 
susceptibility to proteolysis, and preferences for the IGFs (190).  IGFBPs limit IGF 
interactions with the cell-surface receptors IGF1R and IGF1R/IR-A to regulate the effects 
of these ligands. Along with the IGFBPs facilitating the transport of the IGFs in the 
circulation and increasing their half-lives, these binding proteins allow cell type- and 
tissue-specific localization of the IGFs (168).  There has been speculation as to whether 
increased expression of IGFBP-2 and -5 increases cancer risk due to concentrating the 
IGF ligands near the tumor microenvironment or if IGFBPs have activity on their own 
that is not dependent on IGF ligands (169); however, this aspect of IGFBPs is not the 




IGFBPs are expressed in many tissues at various times during development, in 
the adult, and in disease, allowing the change in bioavailability of the IGFs.  For 
example, there is a shift in the IGFBP expression profile of developing mice that occurs 
postnatally and continues to change until the mice are considered adolescent (data 
submitted).  The most predominant IGFBP that appears to serve the greatest role in 
IGF-II regulation is IGFBP-3 in complex with an acid-labile subunit (ALS) that greatly 
extends the half-life (16 hours or longer) of the growth factor compared to other binary 
IGFBP complexes (20-30 minutes) or free ligand (just a few minutes) (190).  Additionally, 
there are specific proteases that cleave the IGFBPs, lowering the affinity of these 
binding proteins for the IGFs and subsequently releasing the IGFs into the extracellular 
environment where they are free to bind the receptors of this axis (190). 
There is also a group of lower-affinity IGF binding proteins that are confusingly 
referred to as being part of the IGFBP superfamily but are classified as IGFBP-related 
proteins, and the consensus in the field is to exclude them from the IGFBP family (190-
192). 
 
D.3.c.  The IGF Receptors 
Multiple cell-surface receptors are included in the IGF axis, each with a different 
biological response to IGF binding.  IGF1R, IR-A, and hybrids of these two receptors are 
responsible for the biological activity of the IGFs, while the M6P/IGF2R functions as a 
clearance receptor for IGF-II.  The IGF1R is fairly specific for IGF-I, having a dissociation 
constant for IGF-I of 0.2 to 1 nM.  The receptor’s affinity for IGF-I is 100- to 1000-fold 
higher than for insulin and 2- to 15-fold higher than for IGF-II (111, 173).  The IGF1R is 
composed of four polypeptide chains held together by disulfide bonds: two α-subunits on 
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the extracellular surface that bind ligands and two transmembrane β-subunits that have 
intrinsic tyrosine kinase activity (193).  Following synthesis, processing and protein 
folding, the IGF1R is transported to the plasma membrane as a heterotetramer, where 
ligand binding in the EC domain causes a conformational change that results in β-
subunit transphosphorylation.  The phosphorylated and activated IGF1R recruits and 
phosphorylates adaptor proteins in the insulin receptor substrate (IRS) family or src 
homology domain-containing (SHC) proteins, which serve as docking sites for effector 
molecules.  This leads to the activation of several downstream pathways, such as the 
classical phosphatidylinositol 3-kinase (PI3K)/protein kinase B (Akt) or extracellular 
signal-regulated kinase 1 and 2/mitogen-activated protein kinase (ERK/MAPK) pathways 
(194).  One such outcome is a decrease in apoptosis activation.  There must be a 
balance between cell division and programmed cell death in order to maintain proper 
development and maintenance of tissues in order to keep pathological conditions at bay, 
such as disruptions in embryogenesis, neurodegenerative diseases, and cancer 
development and progression.  Apoptosis, also known as programmed cell death, is 
necessary to protect the health of an organism.  In cancer, decreased apoptosis can 
lead to faster tumor growth resulting in a greater tumor burden and metastasis.  In the 
classical caspase-dependent apoptosis, there are two pathways that activate cell death: 
intrinsic and extrinsic.  In short, the extrinsic pathway is activated when ligands bind to 
the death receptors on the cell surface that leads to the activation of the executioner 
caspases (namely caspase 3).  The intrinsic pathway results from growth factor 
starvation, DNA damage due to radiation, toxins, and free radicals, or ER stress that is 
sensed by the Bcl-2 family proteins.  These sensors ultimately result in the release of 
cytochrome c from the mitochondria and activation of the executioner caspase-3 (195).  
Endonuclease activation that leads to degradation of chromosomal DNA, protease 
activation that degrades the nuclear and cytoskeletal proteins leading to cytoskeletal 
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reorganization, and extensive morphological changes with nuclear fragmentation and the 
formation of apoptotic bodies are all characteristics of apoptosis (196).  Interestingly, the 
gene expression profile following IGF1R activation can be different depending on which 
ligand binds to and activates the receptor (197). 
In addition to the IGF1R, the insulin receptor (IR) has two isoforms that may play 
a role in the IGF axis:  a more mitogenic isoform (isoform A) and the classical metabolic 
isoform (isoform B).  The IR has a high degree of homology with the IGF1R, with 50-
60% overall identity and 84% identity in the intracellular kinase domain (198).  
Alternative splicing of the IR gene product leads to the two aforementioned isoforms, 
where IR-A lacks 12 amino acid residues correlating to exclusion of exon 11.  IR-B does 
not bind any ligands except insulin with high affinity, while the IR-A is a bit more 
promiscuous and can bind insulin and IGF-II with high affinity, leading to different 
outcomes by ultimately activating the expression of different genes (173, 199).  IR-A is 
thought to be a more mitogenic receptor and has been expressed in many tumor cells 
(173, 200, 201), while IR-B has mainly metabolic functions (202).    Interestingly, IGF-I 
does not bind with appreciable affinity to IR-A.  Due to the high degree of homology 
between the IGF1R and IR, these two hemireceptors can form a heterotetrameric hybrid 
(IGF1R/IR) using one α- and one β-subunit from each hemi-receptor.  IGF-I can bind 
either IGF1R/IR-B or IGF1R/IR-A, but IGF-II can only bind the latter hybrid, while insulin 
does not bind to either hybrid (203), making these receptors complex with a greater 
repertoire of combinatory outcomes.  It is interesting to note that IGF-II responsiveness 
changes with the receptor tyrosine kinase expression.  IR-A expression is increased 
during embryogenesis (200, 204), and the IR-A:IR-B ratio is increased during de-
differentiation.  Taken together, these receptors have overlapping functions, yet they 
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differ in physiological outcomes, tissue distribution, and relative cellular localization 
(205). 
 
D.4.  Role of the M6P/IGF2R within the IGF axis (cell surface actions) 
Numerous studies have sought to elucidate the function of the M6P/IGF2R at the 
cell surface.  As previously mentioned, the majority of the receptor is found within the 
cell, trafficking newly synthesized lysosomal enzymes to the lysosome and recycling 
back to the TGN.  However, the M6P/IGF2R can bind both glycosylated (M6P-bearing) 
and non-glycosylated proteins at the cell surface, where they are endocytosed.  Unlike 
the IGF1R and IGF1R/IR-A hybrids, the M6P/IGF2R lacks intrinsic tyrosine kinase 
activity, and acts as a clearance receptor for an increasing repertoire of ligands.  The 
M6P/IGF2R functions as an endocytic recapture mechanism of M6P-bearing lysosomal 
enzymes that escaped proper sorting at the TGN (46, 90, 206, 207).  In addition to the 
acid hydrolases, the M6P/IGF2R also binds IGF-II at the cell surface, causing it to be 
internalized and degraded in the lysosome which is one way of regulating IGF-II in the 
extracellular space.  Furthermore, the M6P/IGF2R can bind additional ligands that 
include proliferin (208), prorenin (209), thyroglobulin (210), and the latent form of TGF-β 
(46, 133, 211-216).  Binding prorenin by the M6P/IGF2R leads to prorenin cleavage to 
renin, but unlike the canonical activation of the angiotensin-renin pathway, prorenin is 
internalized and degraded; thus, the M6P/IGF2R serves as a clearance receptor for this 
protein (217).  Also upon binding to the M6P/IGF2R, TGF-β can become cleaved by 
hydrolysis from the latency-associated form to mature, active TGF-β (46, 133, 211-216).  
Plasminogen and urokinase-type plasminogen activator receptor (uPAR) bind to the 
M6P/IGF2R, most likely in domain 1; where these proteins complex with M6P/IGF2R.  
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Plasminogen is converted to plasmin, which in turn can proteolytically activate latent 
TGF-β bound to the M6P/IGF2R (46, 132, 133).  Proliferin binds the M6P/IGF2R in a 
M6P-dependent manner and is important for proliferin-induced endothelial cell migration 
and neovascularization in the developing embryo (208, 218).  There is a growing list of 
ligands that are recognized by and bind the M6P/IGF2R that play many different 
biological roles (46). 
 It has been observed in adipocytes and hepatoma cells that insulin stimulation 
shifts the receptor distribution from intracellular trafficking to the cell membrane (219).  
Fibroblasts treated with IGFs or insulin exhibited this same event of receptor 
relocalization (220, 221).  It is thought that the M6P/IGF2R trafficks to the plasma 
membrane in order to compensate for increases in IGF-II from the cell milieu to dampen 
fluctuations in growth factor availability and maintain a steady-state cellular rate of 
growth.  It is important to note that IGF-II binds to the M6P/IGF2R with high affinity 
(KD=0.017-0.7 nM) (168), which is about a 500-fold higher affinity than for IGF-I (KD=0.4 
µM), and insulin does not bind to this receptor (93). 
 
D.4.a.  Binding of multivalent M6P-based ligands: Effects on IGF-II endocytosis 
The M6P/IGF2R in rat adipocytes is constitutively internalized from the plasma 
membrane (t1/2 of 3.5 min) and recycled regardless if ligand was bound or not (151, 153).  
Moreover, receptor internalization mediates IGF-II degradation, which was enhanced 
following insulin stimulation in adipocytes that redistributed the M6P/IGF2R to the 
plasma membrane and allowed more available receptor to take up IGF-II for degradation 
(153).  Studies in the early 1990’s showed that several cell-surface receptors can 
undergo rapid internalization and recycling, which is mediated by a unique tyrosine-
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based sorting motif within the cytoplasmic tail (222-226).  This same motif was 
discovered in the M6P/IGF2R and determined to be necessary for proper internalization 
(227).  Utilizing a panel of cell lines stably expressing wild-type or point mutants of the 
receptor to track the internalization of radiolabeled hGUS, it was determined that a 
functional tyrosine-based motif was critical for hGUS internalization by the M6P/IGF2R 
(t1/2= 45 sec).  A functional internalization signal required an aromatic residue (tyrosine) 
followed by any two amino acids and then a large, hydrophobic residue (YXXφ).  The 
internalization of the M6P/IGF2R was uninhibited when the YSKV sequence (residues 
26 to 29 of the cytoplasmic tail) was either translocated or substituted with another 
tyrosine-based internalization motif from other cell-surface receptors that undergo rapid 
internalization (227).   
Studies on the stoichiometry of multidendate M6P-ligands, monodentate M6P-
based ligands, and non-glycosylated proteins determined that these ligands bind with 
different ratios to the M6P/IGF2R (93).  The multidentate ligands (β-galactosidase and 
high-mannose oligosaccharide bearing two or more M6P groups) and non-glycosylated 
IGF-II bound to the M6P/IGF2R with a 1:1 molar ratio (ligand:receptor), while the 
monodentate ligands (M6P and pentamannose phosphate) bound to the receptor with a 
2:1 ratio.  This was suggestive that the M6P/IGF2R has two M6P-binding sites, in which 
monovalent binding occurs to each site with monodentate ligands.  Moreover, there was 
100- to 1000-fold higher affinity of the receptor for multidentate M6P-based ligands than 
the monodentate M6P-based ligands, indicative of multivalent binding by the 
multidentate ligands that comprises one M6P molecule binding to one M6P-binding site 
on two separate M6P/IGF2R monomers simultaneously (93, 94). 
York et al. observed that the natural-occurring, M6P-based lysosomal enzyme 
(hGUS) stimulated an increased rate of M6P/IGF2R internalization, suggesting that bi- or 
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multivalent interaction of a M6P-based ligand (hGUS) was cross-bridging the 
M6P/IGF2R into a dimeric structure that increases the receptor’s internalization rate 
(131).  Furthermore, the bi- or multivalent binding of hGUS was able to accelerate the 
internalization of IGF-II (t1/2 of 45 sec vs 3 min, respectively).   Additionally, the 
monovalent ligand (M6P) was unable to accelerate the internalization of IGF-II, 
indicating that bivalent interactions may allow the M6P/IGF2R to suppress the 
proliferative actions of IGF-II.    This was the first study to indicate that bivalent M6P-
based ligands can bind to the M6P/IGF2R and increase internalization of the receptor 
and receptor-bound ligands, such as IGF-II, by 3-4-fold (131).  Since monovalent ligands 
(M6P and IGF-II) were unable to produce the same response, it is believed that 
intermolecular, and not intramolecular, cross-bridging of the M6P/IGF2R is important for 
receptor dimerization and increased uptake.  This hypothesis was supported by the 
finding that hGUS stimulated the enhanced internalization rate of the M6P/IGF2R in a 
cell line that was engineered to stably express a mutant form of the receptor that had 
only one functional M6P-binding site per monomer (131). 
These conclusions were made biologically relevant when subsequent studies 
tested these principles with a natural ligand.  Di Bacco et al. demonstrated that 
overexpression of the M6P-glycoprotein cellular repressor of E1A-stimulated genes 
(CREG) could induce G1 cell cycle arrest and inhibit the anchorage-independent growth 
of a teratocarcinoma cell line, NTERA-2, in a M6P/IGF2R-dependent manner (228).  
Furthermore, knockdown of CREG in NIH3T3 fibroblasts promoted cell proliferation by 
increasing IGF-II accumulation in the conditioned medium.  These experiments indirectly 
supported the idea that CREG was affecting pericellular IGF-II bioavailability, but they 
did not prove that the M6P/IGF2R was involved.   Subsequently, it was shown that the 
increased proliferation could be reversed when recombinant human CREG or an αIGF-
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II-neutralizing antibody were added back to the cultured medium (229).  Migration of 
human vascular smooth muscle cells (SMC) is inhibited by down-regulation of activity of 
matrix metalloproteinase-9 (MMP-9) as well as enhanced IGF-II endocytosis mediated 
by CREG binding to the M6P/IGF2R (229).  When CREG was knocked down in these 
cells, the increased IGF-II secretion activated the PI3K pathway, most likely via 
activation of IGF1R.    The direct interaction of CREG with M6P/IGF2R was confirmed by 
immunoprecipitation and immunofluorescence studies (229).  CREG binds directly to the 
receptor between domains 7-10 of the M6P/IGF2R in a glycosylation-dependent 
manner, as multiglycosylated CREG has preferential binding over monoglycosylated 
CREG, and both are displaceable by M6P, suggesting that CREG is binding to domain 9 
of the receptor.  Deglycosylated CREG showed minimal binding to domains 11-13, 
indicating that there is some glycosylation-independent binding of CREG for the receptor 
(228-230), which calls into question how IGF-II is simultaneously able to bind to repeat 
11 of the receptor.  Nonetheless, when a M6P/IGF2R-neutralizing antibody or 
recombinant soluble M6P/IGF2R was added to smooth muscle cells in culture, the 
CREG-induced increase in extracellular IGF-II accumulation was inhibited, suggesting 
that M6P/IGF2R was responsible for enhanced IGF-II internalization in the presence of 
CREG overexpression (231).  Taken together, these studies further supported the role of 
multivalent ligands in cross-bridging the M6P/IGF2R dimeric structure.  Apparently, this 
leads to internalization of IGF-II and decreased cell proliferation in some cells.  If this is a 
universal property of the receptor in many types of cells, particularly tumor cells, it may 





E.  IGF-II in cancer 
IGF-II has contributing roles in development and tumor progression signaling 
through the IGF1R or IGF1R/IR-A in an autocrine or paracrine fashion (232).  Upon 
binding to the EC binding domain, activation of these receptors causes cross-
phosphorylation of the receptor within the tyrosine kinase domain of the carboxyl-
terminal region.  This then leads to the activation of signaling cascades, including 
PI3K/Akt and MAPK/ERK pathways that ultimately promote cell survival and proliferation 
(233).  Under normal conditions, IGF-II is intricately regulated to control IGF-II signaling 
during embryogenesis, development, and in adult tissues (234, 235).  IGF-II is regulated 
on multiple levels including transcriptional regulation through methylation, mRNA 
stability, and IGFBPs.  However, dysregulation of IGF-II-mediated signaling has been 
implicated in many cancers, such as liver, breast, prostate, lung, and colorectal cancer 
as well as neuroblastoma and Wilms’ tumor (236). 
Transcription of IGF2 is regulated by maternal imprinting of the differentially 
methylated region (DMR), restricting expression to the paternal allele (53).  IGF2 has 
four promoters (P1-P4) that allow for tissue-specific transcription.  During embryonal 
development, promoters P2-P4 are responsible for transcriptional start of IGF2, which is 
monoallelic expression.  However, the adult liver expression of IGF2 is from P1 and is 
biallelically expressed, which allows for a relatively high IGF-II expression in the adult 
circulation in humans, compared with rodents (53, 188, 237).  Additionally, loss of 
imprinting (LOI) of the IGF2 gene normally occurs by a decrease in binding of the 
enhancer-blocking element CCCTC-binding factor (CTCF) to the control region, but does 
not necessarily indicate disease (234, 238).  One study determined that healthy Chinese 
babies had 20% of LOI in cord blood cells (239), while a smaller percentage was 
observed in neonates in the USA (234, 240).   
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Conversely, biallelic expression has been extensively observed in many types of 
cancers.  One such cancer type, epithelial ovarian cancer, has hypomethylation of the 
IGF2 DMR compared to normal lymphocyte IGF2 gene (234, 241).  Furthermore, 
hypermethylation of the CTCF binding sites further increases IGF-II expression.  Clinical 
samples of ovarian cancer revealed changes in the methylation of the fetal promoters, 
where patients with methylated P2 and unmethylated P3 had higher IGF-II expression 
and significantly worse prognosis compared to the patients with unmethylated P2 and 
methylated P3 (234, 242).  Patients with the inherited disorder Beckwith-Wiedemann 
syndrome exhibit site-specific mutations that relax the IGF2 imprinting, which leads to 
biallelic expression of IGF2.  The outcome is somatic overgrowth that is associated with 
increased risk of childhood cancers (243, 244).  Wilms’ tumor, a childhood cancer of the 
kidney, was the first tumor to show aberrant IGF2 imprinting (245).  Since then, several 
adult cancers, including liver cancer, have been found to have LOI at the IGF2 locus 
(246, 247).  Moreover, it has also been observed that epigenetic changes of the IGF2 
gene have been linked to IGF-II overexpression and drug resistance in cancer cells 
(234, 248).   
In addition to LOI of the IGF2 (249) gene, whole gene amplifications also occur in 
some cancers.  There was a focal amplification of IGF2 in 7% of tumors studied from 
The Cancer Genome Atlas (TGCA) study of colorectal cancer, leading to increased IGF-
II expression in these tumors.  Furthermore, the miRNA transcript miR-483 was also 
increased, which localizes to an IGF2 intron (234).  Overexpression of miR-483 in a 
Ewing sarcoma cell line did not increase the stability of the IGF2 mRNA, but rather 
increased the number of transcripts (234, 250).  Additional miRNAs may regulate the 
over- or under-expression of IGF2 mRNA (234) indicating that expression of IGF-II is 
intricately regulated in normal tissues, and that dysregulation on different levels may 
47 
 
lead to cancer progression.  IGF2 mRNA binding protein (IGF2BP) is a family of RNA 
binding proteins (IGF2BP1-3) that bind and stabilize the expression of IGF2 transcripts 
(among others) during fetal development.   However, IGF2BP1 and -3 are repressed in 
adult tissues but can be reactivated in cancer (234, 251), and cause dysregulation of 
IGF2 (252, 253).  The regulation of IGF2 mRNA adds another layer of complexity to this 
system that can have detrimental consequences during tumor progression. 
In addition to LOI, gene amplifications, and the role of miRNAs, other factors can 
lead to the overexpression of IGF-II, including transcription factors.  Sonic hedgehog 
(Shh) transcriptionally activates Igf2 in mice by activating Gli, which is a transcription 
factor that induces a number of target genes (254).  Mouse mesenchymal cells treated 
with Shh or transfected with Gli1 have increased Igf2 mRNA expression (255).  
Inactivating mutations in the tumor suppressor gene patched result in constitutive 
activation of Gli with the end result of IGF-II elevation in some rhabdomyosarcomas and 
medulloblastomas (256).  An embryonic stem cell-specific transcription factor, ZFP57, 
binds to the imprinting control region of IGF2, and overexpression of this transcription 
factor leads to anchorage-independent growth of a fibrosarcoma cell line, 3T3.  
Additionally, this transcription factor is increased in tumor samples from pancreas, 
esophagus and breast relative to their normal tissues, leading to overexpression of IGF-
II (234, 257).  E2F3, another transcription factor, regulates IGF2 expression during 
development, specifically binding to P3 and regulating transcription.  E2F3 is 
downregulated postnatally, which is vital for decreased IGF2 expression.  However, this 
transcription factor is overexpressed in some cancers, correlating to an increase in IGF-
II in samples of human bladder and prostate cancers but not in Wilms’ tumor, which 
indicates the complexity of IGF-II expression in malignancies (234, 258).  Other 
transcription factors interplay to regulate the expression of IGF2, which can be 
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dysregulated in tumor progression (234), indicating multiple mechanisms of IGF-II 
overexpression. 
It has been suggested that IGF-II influences tumor growth through an increased 
autocrine or paracrine mechanism (259-261), as circulating IGF-II is increased ~40% in 
patients with hepatocellular carcinoma (HCC) (249, 262).  Many laboratories have 
studied IGF-II in the circulation, including in malignancies of the prostate, breast, colon, 
and liver (263-266).  The IGFBPs regulate bioavailability of IGF-II, and limit the 
interaction of the growth factor with its receptors; thus, one would think that increased 
IGFBP expression would decrease cancer incidence.  Incidentally, it was suggested that 
IGFBPs may contribute to cancer progression in preliminary studies of prostate cancer 
(267, 268).  Additionally, bioavailable IGF-II contributes to IGF1R activation, as small-
molecule inhibitors in murine xenograft transplants of HCC significantly reduced IGF-II-
dependent activation of the IGF1R receptor tyrosine kinase (264).  Furthermore, 
blocking the kinase activity of the IGF1R abolished the formation of aberrant crypt foci in 
an Igf2 LOI murine model, which restored the colonic crypt cells to wild-type proliferation 
rates, but did not affect the wild-type mice.  The authors suggested that the colonic crypt 
cells in the LOI mice were addicted to IGF-II and that this growth factor was essential for 
cellular proliferation, proposing that the dynamics of signal transduction may cause 
epigenetic changes in cancer progression (265, 269).   
In toto, these studies indicate that the regulation of IGF-II is complex and multi-
leveled, with multiple potential steps where dysregulation can lead to tumorigenesis.  It is 
important to disrupt the signaling caused by IGF-II in order to decrease tumor 
progression in cancers that express IGF-II.   To date, the majority of therapies targeting 
IGF-II have focused on targeting the receptor tyrosine kinases, which can have 
increased off-target effects and toxicity (270).  We have developed a novel therapeutic 
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agent to restrict the bioavailability of IGF-II using M6P/IGF2R-mediated internalization 
and degradation of IGF-II, thereby limiting this mitogenic growth hormone to the IGF1R. 
 
F.  M6P/IGF2R’s role as a tumor suppressor: regulating growth and motility 
The M6P/IGF2R regulates lysosomal enzyme targeting, modulates circulating levels of 
glycosylated leukemia inhibitory factor, granzyme B (which regulates cytotoxic T cell-
induced apoptosis), facilitates activation of the growth inhibitor TGF-β, and targets IGF-II 
for degradation.  All of these functions are important for proper cell maintenance, but 
aberrant regulation and disruption in any of these processes has been associated with 
cancer progression, supporting the notion that M6P/IGF2R acts as a tumor suppressor 
(46, 271).  When overexpressed, the M6P/IGF2R suppresses growth both in vitro and in 
vivo, and loss of function is implicated in tumorigenesis (46, 272-276).  Loss of 
heterozygosity at the IGF2R locus has been reported in a number of human tumors, 
including those of the liver (277-280), breast (281-283), lung (284), and ovary (283).  
Additionally, mutations in the remaining IGF2R allele have also been reported in cancers 
(278, 280, 281, 284, 285).  Furthermore, transgenic mice engineered to express soluble 
M6P/IGF2R (deletion of the transmembrane domain) displayed reduced organ size.  
Crossing these mice with mice overexpressing Igf2 resulted in offspring with reduced 
organomegaly that is observed in Igf2 overexpressing mice, indicating that the soluble 
M6P/IGF2R was able to stunt the mitogenic effects of IGF-II (273).  Furthermore, 
M6P/IGF2R mutation or downregulation in mice caused tissue over-growth and perinatal 
lethality.  Knockout of Igf2 revealed viable offspring.  The double mutant knockout (Igf2r 
and Igf2) also produced viable mice yet these mice were smaller than wild-type mice 
(201).  A decrease in cell growth was also seen in JEG-3 choriocarcinoma cells treated 
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with M6P/IGF2R cDNA in vitro and decreased tumor growth in nude mice, that was 
characterized by increased latent TGF-β secretion and activation (274).  Furthermore, 
there was abnormal lysosomal enzyme trafficking in M6p/Igf2r-null mouse mammary 
tumor cell line (66c14), as expected without one of two MPRs, which was rescued upon 
stable transfection of the receptor back into these cells.  With the addition of the 
M6P/IGF2R into these cells, there was no effect on cell proliferation or invasiveness in 
vitro; however, sub-cutaneous injections of these receptor-expressing mammary tumor 
cells into BALB/c mice had inhibited tumor formation, with a 3-fold decrease in 
proliferation and no observable apoptosis (286).   
To date, only one single point mutation (P2379T) has been found in the 
cytoplasmic tail of the M6P/IGF2R, yet there have been several identified in the EC 
domain: in the M6P-binding domain 9 (C1262S, G1296R), domain 10 (Q1445H, 
G1449V, G1464E), and IGF-II-binding domain 11 (G1564R, I1572T, A1618T, G1619R) 
(46). Additionally, point mutations D1317G in domain 9 and Y2024Stop in domain 14 
both result in early stop codons and truncations of the M6P/IGF2R (287).  The majority 
of these mutations and truncations have been characterized with significant alterations in 
M6P and/or IGF-II binding and have been associated with cancer.  This supports the 
hypothesis that the M6P/IGF2R functions as a tumor suppressor, and loss of function to 
the receptor has tumor-promoting properties. 
 
G.  Current therapeutic strategies targeting the IGF axis 
G.1.  Therapies against the IGF axis in clinical trials 
Targeting the IGF axis in cancer has proven to be difficult as this system is quite 
complex.  There are three typical therapy classifications when targeting the IGF axis: 
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monoclonal antibodies (mAbs) against the IGF1R and IGF1R/IR-A; mAbs against IGF 
ligands; and IGF1R tyrosine kinase inhibitors (TKI).  All of these therapies differ in their 
effectiveness, mechanisms of action, and targets.  Examples of each type have entered 
different stages of clinical trials. 
There have been at least eight humanized anti-IGF1R mAbs that have entered 
clinical trials, but several have been discontinued, mostly due to side effects and lack of 
efficacy.  Typically, these mAbs are highly specific for IGF1R and do not cross-react with 
IR, and they usually block the ligand-binding site on the receptor and cause 
internalization and degradation of the receptor.  Anti-IGF1R mAbs are typically well 
tolerated as a monotherapy, but hyperglycemia is a common side effect.  Early clinical 
trials indicate that these therapies have target effects that include down-regulation of the 
IGF1R, increases in human growth hormone (GH) and IGF-I, and can increase 
circulating insulin levels (270, 288).  The mAbs in Ewing sarcoma treated in Phase 1 
trials induced complete or partial responses, which led to a series of phase 2 and 3 
trials.  The most common examples of mAbs against the IGF1R are figitumumab, 
cixutumumab, and ganitumab, which are all used as monotherapies or in combination 
therapies with or without chemotherapy.  Even though initial studies showed promise, 
these mAb therapies still had low success rates, with the largest study having a 
complete or partial response rate of only 10% and a median overall survival of 7.6 
months (270).  These therapies have also been used in phase 1 and 2 trials in other 
cancers, such as those of the liver, thymus, prostate, liver, thymus, adrenal cortex and 
lung.  Again, all of these studies had varying responses to the treatment but with 
marginal improvements (270, 289).  This class of drug target often leads to insulin 
resistance, hyperinsulinemia, and hyperglycemia.  The mechanism of the adverse side 
effects is believed to occur as a result of increased GH secretion and some IGFBPs due 
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to a direct blockage of IGF1R in the pituitary, disrupting the feedback regulation (288). 
The various studies in these cancer cell models using IGF1R-targeted mAb therapy 
suggest that inhibition of the receptor is beneficial for a small subset of patients. 
TKI against IGF1R have a range of specificities for the receptor, as many can 
inhibit other receptor tyrosine kinases; linsitinib and BVP 51004 are the most specific for 
the IGF1R (270).  Typically, the mechanism of action of these inhibitors is by competition 
for the ATP-binding site within the kinase domain of these receptors (288).  There is a 
high degree of homology between the IGF1R and IR isoforms, so targeting the IGF1R 
frequently interferes with IR signaling.  The cross-reactivity is usually not detrimental in 
tumors that have over-activation of IGF1R, IR-A, or IGF1R/IR-A.  However, interference 
with IR-B, the receptor responsible for regulating metabolic processes, can cause 
significant side effects, such as hyperglycemia and can contribute to the metabolic 
syndrome (270).  Unfortunately, many of these studies resulted in little to no 
improvement of the treatment versus the control. 
There are fewer studies on the IGF-neutralizing mAbs.  These mAbs function by 
binding the IGFs and preventing their subsequent binding and activation of the receptor, 
and are able to inhibit without affecting the glucose metabolism (288).  MEDI-573 is the 
first antibody that neutralized both IGF-I and –II in clinical trials (290) and does have 
promise, but further clinical trials are needed. 
 
G.2.  Current therapeutics targeting IGF-II and M6P/IGF2R in cancer 
Many groups have proposed different approaches to target the M6P/IGF2R as a 
treatment option in cancer.  Work done by Poelstra’s group utilized the M6P/IGF2R as a 
conduit for uptake of ligand-carrier toxins.  In this model, human serum albumin was 
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modified with M6P groups and conjugated to cytotoxic drugs such as doxorubicin.  The 
ligand-carrier toxin was then internalized by binding the M6P-binding sites of the 
M6P/IGF2R in hepatic stellate cells, and the toxin was subsequently released to the cell 
interior via the lysosome.  The internalization of this ligand-carrier toxin was specific for 
the M6P/IGF2R, as doxorubicin by itself is not internalized nearly as effectively as the 
ligand-carrier toxin.  This drug was internalized in tumors and various organs such as the 
liver, lungs, spleen, kidney, stomach, and small intestine, but did not internalize in the 
fat, testis, bladder, thymus, brain, skin, muscle, bone, colon, prostate, heart, or large 
intestine (291, 292). 
In addition to using the M6P/IGF2R as a conduit for drugs to enter specific cells, 
the receptor can be used to limit cellular migration and invasion by improved targeting of 
lysosomal enzymes.  It has been noted that the expression of M6P/IGF2R in receptor-
deficient murine squamous cell carcinoma cells had decreased invasion, restoration of 
dense lysosomes, and reduced anchorage-independent proliferation and tumor growth 
(293).  Additionally, a functional IGF-II-binding site is not required for the inhibition of 
growth and invasion, suggesting that these effects were independent of IGF-II; however, 
a functional domain 3 was required for these effects (294).  Additionally, M6P/IGF2R-
deficient fetal rat liver cells hyper-secrete lysosomal enzymes such as cathepsins, which 
degrade the EC matrix, but expression of the receptor restores the functional 
intracellular transport of lysosomal enzymes to the lysosomes, thereby reducing invasion 
(295). 
Another therapeutic approach is to suppress cell growth by sequestering and 
degrading IGF-II, such as by means of ligand traps.  Modified sM6P/IGF2R and IGFBPs 
have been designed to function as such ligand traps.  Soluble M6P/IGF2R administered 
to an IGF-II-overexpressing colon cancer mouse model rescued the colon cancer 
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phenotype (296).  Furthermore, domain 11 of the M6P/IGF2R is the high-affinity IGF-II-
binding domain, and a single substitution of Glu1554 to a lysine increases the affinity for 
IGF-II by 6-fold, and the fusion with the carboxyl-terminal human IgG1 Fc domain 
increases the affinity for IGF-II and the half-life of the ligand trap to a greater extent 
(297).  Proliferation was inhibited in HaCaT human keratinocytes and Igf2-/- mouse 
embryonic fibroblast cells by treatment with this ligand trap.  Additionally, a modified, 
protease-resistance IGFBP-2 has been shown to bind IGF-I and –II with high affinity and 
inhibit cancer cell proliferation in breast cancer cells (298).  The difference of using a 
modified IGFBP over a modified sM6P/IGF2R is that the IGFBP can bind and sequester 
both IGF-I and -II, whereas the receptor can sequester only IGF-II. 
M6P-based ligands can target the M6P/IGF2R by stabilizing the dimeric receptor 
and increasing the rate of ligand-receptor internalization, thereby internalizing IGF-II as a 
passenger ligand that becomes degraded in the lysosome.  Work done in our laboratory 
has synthesized a panel of high-affinity, bivalent M6P-based ligands that are discussed 
in chapter III of this dissertation.  We have evidence that our ligands bind to the 
M6P/IGF2R and promote accelerated internalization of IGF-II from the conditioned 
medium of cancer cells.  Additionally, these ligands reduce cell viability in both a M6P- 
and IGF-II-dependent manner.  We, in collaboration with the Berkowitz laboratory, have 
developed a panel of M6P-based ligands that would be resistant to inactivating 
hydrolysis catalyzed by proteases, glycosidases and phosphatases.  However, we have 
not yet achieved bivalent binding with these bidentate molecules.  Nevertheless, 
targeting the M6P/IGF2R to clear the IGF-II signal from the pericellular milieu remains a 
promising approach to inhibiting IGF-II-dependent growth of cancer cells. 
Autocrine and paracrine growth-factoring signaling loops within the tumor 
microenvironment play a significant role in influencing tumor progression.  Interrupting 
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these signals from the stroma may benefit cancer therapy.  Cancer stem cells (CSCs) 
are exposed to IGF-II in a paracrine fashion from cancer-associated fibroblasts, and this 
signal induces the IGF-II-mediated events that ultimately result in increased Nanog and 
Oct3/4 transcription to promote the CSC phenotype (299).  Disruption of this paracrine 
loop can lead to differentiation of the CSC, which would increase its responsiveness to 
chemotherapy.  In summary, there are numerous potential alternative therapeutic 
approaches to target IGF-II-dependent growth of cancer cells that may be more 
efficacious than the IGF1R approaches that have failed or had low success in clinical 
trials. 
 
H.  Summary 
In summary, the M6P/IGF2R is mostly involved in lysosome biogenesis, 
trafficking acid hydrolases to the lysosome.  It also internalizes EC proteins and is 
implicated in many diseases and cancer.  The M6P/IGF2R undergoes constitutive 
internalization, yet multivalent ligands are able to accelerate the receptor’s rate of 
internalization as well as any passenger ligands, namely IGF-II.  It is believed that these 
multivalent ligands are able to stabilize the receptor dimer, which either by receptor 
clustering or a conformational change in the cytoplasmic tail to offer a better 
presentation of the internalization signal, internalizes the complex more prominently.  We 
wanted to take advantage the known receptor properties in order to exploit the 
M6P/IGF2R as a novel therapeutic target in IGF-II-dependent cancers.  Thus, our 




1. Develop a panel of high-affinity, bivalent ligands that function in cross-
bridging the dimeric receptor and decrease IGF-II from the cell milieu, 
thereby inhibiting the IGF-II-dependent growth of cancer cells. 
2. Develop and test a panel of hydrolase-, phosphatase-, and protease-
resistant M6P-based surrogates that can stabilize the dimeric M6P/IGF2R 
and function as a more clinically relevant anti-cancer agent. 
3. Characterize the ligand binding properties of the putative MPR from D. 
discoideum to understand a) the differences between this receptor and 
the mammalian M6P/IGF2R, and b) the possible common ancestral origin 













































A. Preparation of pentamannosyl 6-phosphate (PMP)-derivatized pseudoglycan 
proteins and peptides 
The yeast Pichia holstii (NRRL-Y2448) produces a secreted phosphomannan 
when grown under aerobic conditions in a nitrogen-limited medium that used D-glucose 
as the carbon source and contains an excess of orthophosphate.  The phosphomannan 
is composed of a highly branched, high-molecular-weight (5-39 x 106) phosphomannan 
core (PC).  Oligosaccharide chains composed principally of repeating PMP are linked 
α(1,6) to the terminal phosphate of the PC and make up approximately 90% of the 
phosphomannan.  These side chains, which are capped by unphosphorylated residues, 
are susceptible to mild-acid hydrolysis of the phosphodiester linkages producing 
products consisting of the PC and PMP. 
A.1. Preparation of phosphomannan 
Hydrolysis of phosphomannan was carried out by a modification of Murray and 
Neville’s protocol (300) as previously described (301).  Briefly, prior to hydrolysis, 1 g of 
phosphomannan was weighed into a 250 mL Erlenmeyer flask fitted with a stopper and 
rehydrated overnight in an aqueous solution containing 1% KCl at 4°C.  The rehydrated 
phosphomannan was warmed to RT (room temperature) and the hydrolysis was carried 
out for 6-10 h in a boiling water bath heated to 100°C at a concentration of ~50-100 g/L, 
pH 2.2-2.5 using 1 M HCl as the catalyst and in the present of 1% KCl.  Throughout the 
course of the hydrolysis, the pH was closely monitored and found to rise slightly (up to 
pH 3) over the first hour of the reaction as the phosphomannan went back into solution 
and as HCl vaporized.  Therefore, the pH was readjusted, as needed, to pH 2.2-2.5 by 
addition of 1 M HCl.  Additionally, re-addition of preheated water to the bath over the 
course of the hydrolysis was necessary to compensate for loss to evaporation.  
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Following the hydrolysis, the reaction was cooled to RT and neutralized (pH 6.9-7.0) with 
1 N NaOH.  After neutralization of the hydrolysate, the pH was adjusted to 9.0-9.5 with 1 
M NaOH, followed by separation of the PMP from the PC by ultrafiltration through a 
10,000 nominal molecular weight cuff-off membrane (MWCO) (Amicon Ultra-15, 
Millipore, Billerica, MA).  The PMP and salts permeated through the membrane while the 
high-molecular-weight PC was retained.  The filtrate was further purified by ion-
exchange chromatography on DEAE-Sepharose resin equilibrated with 0.01 M 
NH4HCO3.  The PMP bound to the resin while unphosphorylated products washed 
through.  PMP was eluted off the column with 0.25 M NH4HCO3 and the pooled fractions 
containing PMP were concentrated and desalted by reverse membrane filtration and 
then lyophilized to dryness.  The resultant white powered was stored in a desiccator at -
20°C. 
B. Preparation of PMP-derivatized proteins and peptides 
Conjugation of PMP to various proteins and peptides was carried out according 
to the procedure of Braulke et al. as modified previously (144, 302).  Bovine serum 
albumin (BSA), insulin (INS), lysyl-tyrosyl-lysine (KYK) tripeptide, and seryl-tyrosyl-lysine 
(SYK) tripeptide were conjugated with PMP previously in the laboratory and not 
discussed in this dissertation.  PMP was coupled to ovalbumin (OVA) by incubation at 15 
mg/ml concentration in the presence of 0.2 M PMP and 160 mM NaCNBH3 at 37°C for 4-
5 days.  The resultant PMP-OVA product of this reductive amidation was dialyzed 
against 50 mM HEPES, pH 7.4, 150 mM NaCl using Pierce Slide-A-Lyzer® Dialysis 
Cassettes G2 (10K MWCO).  The size and overall purity of the PMP-OVA was 
measured using SDS-PAGE and compared to the absorbance at 280 nm (A280).  The 
resolved gels were stained with Coomassie blue R250 for protein detection.  Successful 
derivatization of PMP to ovalbumin was determined by comparing the molecular weight 
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shifts of the PMP-modified protein to lanes containing underivatized protein.  PMP-BSA 
was done previously following the same protocol.  The PMP-peptide products were 
synthesized previously in the lab and were purified on a 30 mL QAE Sephadex A25 
column and eluted by stepwise increases of the salt concentration from 0 to 1 M NaCl of 
a 10 mM HEPES, pH 7.4 buffer.  Fractions were collected and PMP-derivatized peptides 
were monitored by absorbance of tyrosine at 285 nm.  The size and overall purity of the 
PMP-peptides was measured using MALDI-TOF mass spectrometry (UNMC Mass 
Spectrometry and Proteomics Core Facility). 
C. Preparation of 125I-labeled tracers 
C.1. Preparation of 125I-IGF-II 
Iodination of IGF-II was carried out by a modification of the Chloramine-T method 
as described by GroPep (Bulletin #3001: Procedure for Iodination of IGFs; 
http://www.gropep.com.au/index.php/article/view/109/1/21).  Briefly, aliquots (6 µg in 15 
µL 5 mM HCl) of recombinant human IGF-II (Bachem; Torrance, CA) were diluted in 0.3 
M sodium phosphate buffer (60 µL), pH 7.4, and incubated for 30 min with 2.0-2.5 mCi 
(~20 µL) of carrier-free Na125I (PerkinElmer Life Sciences; Boston, MA).  The resulting 
reaction mix was combined with a 0.4 mg/mL solution of Chloramine-T (20 µL) (Sigma; 
St. Louis, MO), mixed thoroughly, and incubated for 60 s at room temperature (RT) (to a 
specific activity of ~30-60 Ci/g).  At the end of the incubation, the oxidation reaction was 
quenched by addition of a 0.6 mg/mL solution of sodium metabisulfite (20 µL).  The 
sample was thoroughly mixed, allowed to incubate for 5 min at RT, then prepared for 
size exclusion chromatography by adding 200 µL column buffer (phosphate buffered 
saline (PBS); 10 mM sodium phosphate, pH 7.4; 150 mM NaCl) containing 1% BSA.  
The 125I-IGF-II was separated from the free iodine on a 30 mL Sephadex G-50 column 
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equilibrated with column buffer.  The fractions containing radiolabeled IGF-II were 
collected, pooled, and stored at -20°C. 
C.2. Preparation of 125I-PMP-BSA and 125I-hGUS 
Aliquots of PMP-BSA (25 µg) and hGUS (15 µg) were iodinated to specific 
activities of ~50-150 Ci/g by incubation in 0.3 M sodium phosphate buffer, pH 7.4, with 2 
mCi Na125I in IODOGEN tubes (Pierce, Rockford, IL) pre-coated with the oxidizing agent, 
1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril, for 15 min, according to the manufacturer’s 
specifications.  The product was separated from free iodine on a Sephadex G-50 column 
equilibrated with PBS + 1% BSA.  The iodinated PMP-BSA and hGUS were collected 
from the flow-through fractions and stored at -20°C. 
C.3. Preparation of 125I-soluble M6P/IGF2R 
Soluble M6P/IGF2R (sM6P/IGF2R) was purified as described in section E below.  
Approximately 20 µg of lyophilized sM6P/IGF2R was dissolved in 0.3 M sodium 
phosphate buffer, pH 7.4, and added to a pre-wetted IODOGEN coated tube.  The Na125I 
(1.5 mCi) was then added, followed by a 15 min incubation.  The radiolabeled 
sM6P/IGF2R was purified on a Sephadex G-50 column.  Radioactive fractions from the 
void volume were pooled and stored at -20°C until use. 
D. Preparation of PMP-Sepharose 4B 
To make PMP-Sepharose, PMP was first conjugated to (p)-aminophenyl-
ethanolamine (PAPEA), also called 2-(4-aminophenyl)-ethylamine, to provide a primary 
amine for coupling to cyanogen bromide (CNBr)-activated Sepharose 4B (Sigma) as 
previously described (303).  PMP (50 mg) was incubated with 0.5 mL of PAPEA for 16 h 
at RT.  To complete the coupling reaction, 12 mg of NaBH3 was dissolved in 1.5 mL of 
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100% ethanol and added to the reaction.  This mixture was incubated at RT for 5 h, and 
remaining NaBH3 was quenched on ice with the addition of 4 mL H2O and glacial acetic 
acid to a pH of 5.6.  The product was lyophilized, and PMP-PAPEA was separated from 
unreacted PAPEA on a 30 mL Sephadex G10 column equilibrated in 50 mM ammonium 
acetate, pH 6.0.  The purified PMP-PAPEA was lyophilized and stored -20°C until use.  
A PMP-Sepharose resin coupled to a density of 10 mg protein per ml resin was prepared 
using CNBr-activated Sepharose 4B (Sigma) following the manufacturer’s instructions. 
E.  Purification of sM6P/IGF2R from fetal bovine serum (FBS) 
Soluble bovine M6P/IGF2R was purified from FBS by the procedure of 
Valenzano et al. (304) as modified by Byrd et al. (141), with additional modifications.  In 
brief, an aliquot of serum was diluted with an equal volume of buffer to yield final 
concentrations of 25 mM HEPES, pH 7.4, 0.15 M NaCl, 0.1% Triton X-100, 5 mM β-
glycerophosphate (column buffer conditions).  This diluted serum was incubated with 
PMP-Sepharose 4B resin, end-over-end, overnight and then poured through a 10 mL 
column.  The column was subsequently washed with 5 x 5 mL of column buffer, 5 x 5 mL 
column buffer supplemented with 10 mM G6P, and eluted with 5 x 5 mL 10 mM M6P.  
The fractions containing purified receptor were identified by SDS-PAGE with Coomassie 
blue R-250 staining and pooled.  The pooled material was dialyzed to remove M6P, 
lyophilized and stored at -20°C.  Analysis of material purified by these methods using gel 
filtration chromatography and native gel electrophoresis indicated that the receptor is 
present as both a monomer (~70%) and a dimer (~30%) (141). 
E.1. Coupling of sM6P/IGF2R to Sepharose 4B 
sM6P/IGF2R-Sepharose 4B resin was used in ligand binding assays and 
prepared by coupling the purified, redissolved sM6P/IGF2R to CNBr-activated 
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Sepharose 4B according to the manufacturer’s instructions.  For coupling, 1 g of CNBr-
activated Sepharose 4B dry resin was rehydrated in 15 mL of 1 mM HCl for 15 min at 
RT, then washed with 4 x 10 mL of 1 mM HCl followed by 2 x 10 mL of coupling buffer 
(0.1 M NaHCO3, pH 8.0, 0.5 M NaCl).  The wet resin cake (~3 mL volume) was 
transferred to a tube containing 1.2-1.4 mg of purified receptor dissolved in 5 mL of 
coupling buffer.  The mixture was incubated on an end-over-end mixer a 4°C for 16 h for 
coupling.  Uncoupled sites on the resin were blocked by incubation at 4°C with 0.5 M 
glycine, pH 8.0, to produce a final affinity reagent of ~0.5 mg M6P/IGF2R per mL resin 
beads.  This material was stored as a 50% slurry at 4°C in 25 mM HEPES, pH 7.4, 0.15 
M NaCl, 0.02 mM NaN3, 0.05% Triton X-100 until use.  Prior to use, the resin was 
washed in assay buffer twice to remove the NaN3. 
F. Measurement of IC50 values by radioligand displacement analysis 
A sM6P/IGF2R-Sepharose 4B resin-based radioligand displacement assay was 
used to evaluate the ability of each of the PMP-ligands to bind the receptor.  Aliquots (20 
μL) of receptor resin (50% slurry) were incubated with 1.5 nM 125I-PMP-BSA or 125I-
hGUS (used as tracers) in the presence of increasing concentrations of PMP-
pseudoglycan ligands (1 pM to 10 µM) in assay buffer (50 mM HEPES, pH 7.4, 0.15 M 
NaCl, 0.05% Triton X-100) in a volume of 0.2 mL per tube, for 16 h at 4°C on an end-
over-end clinical mixer.  As positive and negative controls, parallel assays were done 
that had increasing concentrations of M6P (0.1 μM to 10 mM) or G6P (1 to 10 mM), 
respectively.  The resin pellets were collected by centrifugation for 1 min at 6,000 x g at 
4°C, and were washed with 2 x 1 mL of assay buffer. The tips of the tubes containing the 
resin pellets were cut and quantified in a WIZARD 1470 Automatic Gamma Counter 
(PerkinElmer, Inc.). The data were converted into percent binding values based on 
comparison with the ligand-free controls (designated as 100% radioligand binding). The 
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competitive binding data were graphed as semi-log plots of percent binding vs. 
concentration of M6P, G6P, or the PMP-ligands.  Best-fit curves were generated by 
nonlinear regression analysis using Prism GraphPad software (San Diego, CA), which 
also estimated the IC50 values, the concentration that displaces 50% of radioligand 
binding.  Values for relative binding affinity (RBA) for the PMP-ligands were normalized 
to M6P for a given experiment and are reported as the mean of at least three replicate 
experiments. 
G. Expression of M6P/IGF2R constructs 
Transient expression of soluble receptors was done in HEK 293 cells.  
Transfection was carried out by a modification of the calcium phosphate method as 
described previously (305).  At 24 h post-transfection, the medium was replaced with 
serum-free Dulbecco’s modified Eagle medium (DMEM) followed by incubation for 3 
days to permit the cells to condition the medium.  To recover the secreted, epitope-
tagged soluble receptors, the conditioned medium was recovered and cellular debris 
was pelleted on a tabletop centrifuge at 7000 RPM.  The medium was supplemented 
with 1 mM PMSF and 1 mM sodium fluoride, and concentrated to ~250 µL using Amicon 
Ultracel 10K centrifugal filters as per the manufacturer’s specifications, and then stored 
at -20°C until use.  For full-length receptors, cells were harvested three days post-
transfection and lysates were prepared by solubilization with 50 mM HEPES, pH 7.4, 1% 
Triton X-100, 1 mM MgCl2, 1 mM PMSF, and PIC as previously described (116).  After 
conditioned media and lysates were prepared, 25 µL aliquots were electrophoresed on 8 
or 10% SDS-PAGE gel under reducing conditions and immunoblotted with -FLAG M2 




H. Immunoprecipitation of soluble mini-receptors with M2 α-FLAG affinity resin 
and competitive binding analysis of PMP-ligands 
Aliquots of HEK 293 cell conditioned media and lysates, containing equimolar 
amounts of expressed FLAG-tagged soluble receptors as determined by the 
bicinchoninic acid assay, were incubated with 6 µL of packed M2 affinity resin in 
HEPES-buffered saline (HBS; 50 mM HEPES, pH 7.4, 0.15 M NaCl) plus 1% BSA and 5 
mM M6P with mixing for 16 h at 4°C.  The resin was collected by centrifugation at 8,000 
x g for 30 s.  The resulting resin pellets were washed four times with 1 mL HBS 
containing 0.05% Triton X-100 (HBST).  The immunoprecipitated soluble receptors were 
incubated with 2 nM 125I-PMP-BSA in the presence of increasing concentrations of the 
PMP-ligands (0 mM, or 1 pM to 10 µM) in assay buffer with mixing for 4 h at 4˚C.  Resin 
pellets were processed and the binding data were quantified and calculated as 
described above for the receptor-resin experiments. 
I. SDS-PAGE and immunoblot analysis 
All SDS-PAGE gels run were 6%, 10%, or 10-16% gradient maxi- and mini-gels.  
Samples were prepared in 2x loading buffer (5% SDS, 10% sucrose, 100 mM Tris, 
0.02% Bromophenol Blue) with or without dithiothreitol (DTT) as a reductant and boiled 
for 5 min before loading the gel.  Gels were run at 6 mA overnight or 28 mA for 4 h and 
transferred to BA85 nitrocellulose membrane (Schleicher & Schuell, Keene, NH, USA).  
The blots were blocked in 4% nonfat dry milk in 50 mM HEPES, pH 7.4, 150 mM NaCl, 
0.1% Tween-20, and probed with the appropriate primary antibody (Table 2.2) overnight 
and appropriate goat α-rabbit or goat α-mouse secondary antibody coupled to HRP 
(1:40,000).  The resulting antibody complex was developed using enhanced 
chemiluminescence (ECL) and detected by means of autoradiography and quantified 
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using Li-Cor C-DiGit® Blot Scanner (Li-Cor Biosciences, Lincoln, NE, USA) and Image 
Studio Lite Software.  
 
J. Cell viability studies 
To investigate kinetics and dosage of PMP-pseudoglycan ligand effects on 
cultured cells, growth studies were performed using a modification of the previously 
described MTT vital dye assays (306).  Briefly, cells were seeded into 96-well plates at 
100 to 1,000 viable cells/well, in full serum-containing medium.  The cells were 
incubated for 24 h at 37°C before switching to reduced serum (1-3% FBS) for 
acclimation prior to drug treatment.  At this point for the time course studies, designated 
day 0, a set of wells was subjected to the MTT assay while the remaining wells were 
incubated with reduced-serum medium supplemented with the various treatments 
indicated in the figures (vehicle control, M6P, PMP-ligands or IGF-II) and continued for 
1-5 days.  MTT at a concentration of 1 mg/mL in phenol red-free medium was added to 
culture wells for an incubation period of 3 h at 37°C, 5% CO2.  Wells containing purple 
formazan were solubilized with isopropanol and the absorbance of 100 µL solution was 
measured  using a SpectraMax 190 (Molecular Devices, Sunnyvale, CA, USA) at 570 



































1:1000 Abcam ab8093 
Cyclin D1 Rabbit 
polyclonal 
1:500 Santa Cruz sc-718 
ERK1/2 Rabbit 
polyclonal 

















1:500 Novus NB1002220SS 
MCL-1 Rabbit 
polyclonal 





































1:1000 Santa Cruz sc-28226 
Table 2.1: Primary antibodies used for immunoblot analysis. 
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K.  IGF-II degradation studies 
K.1. IGF-II detection via SDS-PAGE and slot blot analysis 
To detect IGF-II through imunnoblotting, an IGF-II standard curve was diluted in 
serum-containing medium or concentrated conditioned medium was run on a 10-16% 
SDS-PAGE under reducing conditioned and transferred to BA85 nitrocellulose 
membrane.  The blot was probed for α-IGF-II antibody.  To concentrate the conditioned 
medium, medium collected from cells was concentrated to 800 µL via Amicon Ultra 
centrifuge filters or by lyophilization.  Concentrated conditioned medium was 
electrophoresed and probed as described above.   
For the slot blot analysis, an IGF-II standard curve supplemented with a known 
amount of 125I-IGF-II was added to a slot-blot apparatus that was connected to the in-
house vacuum system, which drew the fluid down into the BA85 membrane.  The IGF-II 
was contained in either HBS or 10% FBS-containing medium as a carrier.  The blot was 
exposed to autographic film. 
 K.2. Trichloroacetic acid (TCA) precipitation of IGF-II 
IGF-II from medium not exposed to cells was precipitated by a trichloroacetic 
acid protein precipitation assay.  Medium (3% FBS) containing both unlabeled IGF-II (60 
ng) and 500,000 cpm 125I-IGF-II was incubated with 50% TCA (20% total volume) at 4°C, 
end-over-end, overnight.  Samples were pelleted at 13,200 rpm, 4°C, 25 min.  The 
supernatants were discarded and the pellets were washed twice with cold acetone.  The 
washed pellets were then resolubilized in SDS-PAGE loading buffer supplemented with 
NaOH to account for the acidic pH.  Samples were then electrophoresed, transblotted to 
nitrocellulose, and the blots exposed to autographic film. 
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K.3. Size exclusion chromatography and 125I-IGF-II radioimmunoassay (RIA) 
The detection of IGF-II was performed using size-exclusion chromatography 
followed by an IGF-II radioimmunoassay (RIA) as previously described with some 
modifications (307). SK-N-AS, Capan-1 or JEG-3 cells were seeded in 6-cm dishes in 
complete medium and grown at 37°C in a humidified 5% CO2/95% air atmosphere 
overnight.  The medium was replaced with low-serum (3%) medium and cells were 
grown for an additional 24 h.  Cells were then treated with 100 nM PMP-OVA with or 
without 10 nM IGF-II in 1% serum medium.  Conditioned medium was collected at 24 or 
48 h, and was supplemented with 1 mM PMSF and 10 mM NaF before concentration via 
lyophilization.  Concentrated conditioned medium was reconstituted in 1 M acetic acid 
and centrifuged at 9,000 x g for 5 minutes.  The supernatant fraction was collected and 
immediately run on a 100-mL size-exclusion column containing Bio-Gel P-10 (mesh 50-
100) and eluted in 0.1 M acetic acid in 2-mL fractions.  Fractions containing IGF-II were 
collected and lyophilized.  IGF-II was reconstituted in 200 µL 1 mM HCl, and aliquots of 
15 or 30 µL were used in a radioimmunoassay (RIA).  For the RIA, 15 µL of Protein A-
Sepharose resin (50% slurry) was added to 1 mL blocking buffer (1% BSA, 25 mM 
HEPES, 150 mM NaCl, pH 7.4) for 5 min on ice, and centrifuged at 6,000 x g for 1 min 
before the buffer was aspirated.  Rabbit IGF-II antibody (20 ng/µL) of was incubated with 
the resin in RIA buffer (50 mM sodium phosphate, 0.1% NaCl, 0.1% EDTA disodium 
salt, 0.1% sodium azide, 0.05% Tween 20, pH 7.5) for 16 h at 4°C on an end-over-end 
clinical mixer.  The IGF-II-conjugated Protein A-Sepharose resin was washed twice in 1 
mL RIA buffer via centrifugation at 6,000 x g, 4°C.  An IGF-II standard curve was made 
using increasing concentrations of IGF-II (0 ng to 1000 ng) in 5 mM HCl.  The IGF-II 
standard curve and unknown samples were diluted in 30 µL 1 mM HCl before being 
added to the resin containing RIA buffer.  Tracer 125I-IGF-II was added to each tube to 
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0.3 nM and the tubes were incubated for 16 h at 4°C on an end-over-end clinical mixer.  
The resin pellets were washed twice in 1 mL RIA buffer as described above, and the tips 
of the tubes containing the resin pellet were cut and quantified in a WIZARD 1470 
Automatic Gamma Counter (PerkinElmer, Inc.). The data were converted to binding 
percentages and graphed as semi-log plots of percent binding vs. concentration of IGF-II 
as described above for the competitive binding assays.  The concentrations of IGF-II in 
the unknown samples were determined from the semi-log plot and converted to the 
amount of IGF-II in the total sample. 
K.4. 125I-IGF-II Internalization assay with TCA precipitation 
HuH-7, Capan-1, and SK-N-AS cells were seeded into 24-well plates.  After 24 h 
and again at 90% confluency, cells were treated with 100 nM PMP-OVA, 100 or 200 nM 
IGF-II, 100 nM PMP-OVA, 100 or 200 nM IGF-II, 50 nM sM6P/IGF2R, 50 nM 
sM6P/IGF2R + 100 nM IGF-II, 10 mM M6P, or 10 mM M6P + 100 nM IGF-II and 
compared to the vehicle control (HBS + HCl) along with radiolabeled IGF-II and cold-
carrier IGF-II in 3% FBS-containing medium.  Each treatment had 0.3 nM 125I-IGF-II to 
visualize the degradation of exogenous IGF-II as a result of the treatments.  The low 
concentration was chosen as it was enough radioactive counts to determine slight 
differences between the groups without being high enough to overwhelm the cells and 
illicit its own activation response.  Additionally, 1 nM of cold carrier IGF-II was provided 
to the cells to protect the radioligand from adsorption to matrix surfaces that bind IGF-II, 
such as vitronectin within the EC matrix (308) or IGFBPs in the medium.  In the IGF-II 
treatment group, 100-200 nM concentration was chosen in order to inhibit degradation of 
125I-IGF-II by out-competing the radioligand for the available receptor binding domains; 
thus, there would be more radioactive counts in the conditioned medium correlating to 
intact 125I-IGF-II as the assay progresses.  Furthermore, sM6P/IGF2R and M6P were 
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used as controls to also inhibit the assay.  The M6P would competitively displace our 
PMP-OVA ligand from the M6P-binding sites of the M6P/IGF2R on the cell membrane; 
thus, the receptor would internalize at a slower rate than when PMP-OVA binds, 
resulting in a slower degradation of 125I-IGF-II.  The sM6P/IGF2R acts as a ligand trap 
and scavenges any bioavailable IGF-II in the medium, such as 125I-IGF-II.  Since there is 
only one available IGF-II-binding domain within the soluble receptor, it can sequester 
only 1 molecule of ligand, which would manifest as IGF-II sparing, i.e., there would be 
more intact 125I-IGF-II in the conditioned medium.  Cells were treated with 900 µL of 
medium containing their respective treatments and allowed to internalize the 125I-IGF-II 
for 6, 24, 48, or 72 h.  At the different time points, two aliquots (250 µL and 50 µL) were 
withdrawn and frozen at -20°C until further use.  Cells were treated in triplicate and each 
well was compared to itself among the different time points.  For clarity, the first tube at 
each time point represented the first control well, which eliminates potential pipetting 
error between the wells upon addition of the radiolabled IGF-II-containing treatment. 
Following treatments and collection of the conditioned media at all time points, 
TCA precipitation was performed on the conditioned media to determine the amount of 
radioactivity that is soluble (representing degraded IGF-II) and insoluble (intact IGF-II).  
The 200 µL aliquots were thawed and 150 µL of 10% BSA (2.3% final concentration) 
were added as bulk carrier prior to addition of 300 µL 100% TCA (46% final 
concentration).  Samples were vigorously vortexed and incubated on ice for 1 h.  TCA 
precipitates intact IGF-II (as demonstrated in experiments validating the assay), so the 
soluble and insoluble fractions were separated via centrifugation at 13,200 rpm, 4°C, 10 
min.  The supernatants were immediately drawn off and collected in 5 mL gamma 
counter tubes.  The bottoms of the tubes containing the pellets that represent the 
precipitated, intact IGF-II with carrier protein were cut off and collected into 5 mL gamma 
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counter tubes.  Both TCA fractions were counted on a WIZARD 1470 Automatic Gamma 
Counter (PerkinElmer, Inc., Waltham, MA) and compared to the total counts in the 50 µL 
aliquots (multiplied by 4 to account for the differences in aliquot size).  Each sample from 
the same well was normalized before the mean and the standard error of mean (SEM) 
were calculated for each treatment at each time point.  Radiolabled IGF-II was incubated 
in cell-free medium for the duration of the assay to validate the amount of precipitable 
IGF-II.  There was approximately 70% precipitable IGF-II in all time points (0, 24, 48, 72 
h), indicating that our radioligand is stable and our assay is valid since any effect seen 
will be due to processing by the cells.  Additionally, the sum of the recovered 
supernatant and pellet was approximately 80-100% of the total counts added to the 
assay. 
L. Cell Cycle Analysis using flow cytometry 
JEG-3, Capan-1, and SK-N-AS cells were seeded into 4 cm dishes.  Once cells 
reached 70% confluency, cells were treated with the various treatments for 0-48 h.  At 
the different time points, cells were harvested, and fixed in 70% ethanol for 15-60 min on 
ice.  The ethanol was washed away with FACS buffer (1x PBS, 5% FBS), and then the 
cells were stained with Telford Reagent (1x PBS, 57.5 mM EDTA, RNAse A, 37.4 mM 
propidium iodide (PI), 0.1% Triton X-100) for 1 h or overnight.  Cells were filtered using 
flow cytometry tubes, and data were collected visualizing PI staining on the Calibur I in 
the Flow Cytometry Core Facility (UNMC). 
For JEG-3 cells that were synchronized via a serum deprivation protocol prior to 
cell cycle analysis, cells were seeded as above except once the cells reached 30% 
confluency, they were washed in DPBS and serum starved (0.1% FBS) for 48-72 h.  
Cells were then released into the various treatments in 1% FBS-containing medium. 
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For SK-N-AS cells that were synchronized using a double thymidine block, cells 
were seeded as above, but after 24 h the medium was changed to full medium 
containing 3 mM thymidine.  After 16 h incubation, the cells were released into 3% 
serum medium for 8 hours before another thymidine block (3 mM in 3% serum medium).  
After 16 h, the cells were released into the treatments in 1% FBS-containing medium. 
For BrdU incorporation using the APC BrdU Flow Kit (BD Pharmagen, San Jose, 
CA), SK-N-AS cells were seeded into 6-cm dishes.  The serum was reduced (3% FBS) 
after 24 h, and the cells were allowed to grow for an additional 24 h.  Cells were treated 
with various treatments in 1% FBS-containing medium for 24 h.  Prior to harvesting, 
BrdU was added directly to the conditioned medium, and cells were allowed to 
incorporate the label into their DNA for 3 h.  Cells were harvested and fixed, DNA 
cleaved, and stained following the manufacturer’s instructions.  Cells were then analyzed 
on a Calibur III flow cytometer analyzing the APC and 7AAD staining. 
M. Apoptosis analysis studies 
M.1. DAPI staining of apoptotic nuclei 
Cells were seeded into 24-well plates, and once 70% confluency was reached, 
the cells were incubated with the treatments in 3% FBS-containing medium.  DAPI (1 
µL/well) was added directly to the conditioned medium.  The plates were gently rocked 
for 10 seconds and incubated at 37°C, 5% CO2 for 10 min.  Representative images (3-6 
images) of the DAPI fluorescence and phase contrast were taken on a Leica DMI6000B 
(Leica Microsystems, Buffalo Groove, IL) fluorescent microscope.  The number of 
apoptotic nuclei, as determined by fragmented and blue staining, and total number of 
cells were counted, and the percentage of dead cells was determined.  The mean of the 
treatment groups were compared to the control. 
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M.2. Caspase 3/7 activity assay 
Capan-1, S2-013, and SK-N-AS cells were seeded into 96-well black, clear 
bottom plates, similar to the MTT assay in section J.  After 24 h, the serum was stepped 
down for an additional 24 h before treatments.  24 h following the treatments, Apo-
ONE® Homogeneous Caspase 3/7 Activity Assay (Promega, Madison, WI) was 
performed according to manufacturer’s instructions.  The fluorescence at 499/521 nm 
was determined by a Tecan Infinite® M200 Pro fluorescent spectrometer 
(Tecan,Systems, Inc, San Jose, CA). 
M.3. Annexin V and PI staining of apoptotic and necrotic cells  
JEG-3, HuH-7, and Capan-1 cells were grown in 6-cm dishes.  After 24 h, the 
serum was reduced (3% FBS) and the cells allowed to grow for an additional 24 h.  Cells 
were then treated in 3% FBS-containing medium for 6-24 h.  At each time point, the cells 
were harvested, washed in cold 1x PBS, and stained following the TACS annexin V 
(Trevigen, Gaithersburg, MD) protocol provided by the manufacturer.  Cells were then 
analyzed on a Calibur III flow cytometer to visualize annexin V and PI staining. 
N. Migration assays 
N.1. Scratch wound-healing assay 
Capan-1 and HuH-7 cells were seeded into 6-well plates.  Once the cells 
reached 80% confluency, 3 scratches were made in each well using a pipet tip (time 
point 0) prior to treatment.  Phase contrast images (2 per scratch; 6 per well) were taken 
every 24 h until the 96 h time point on a Leica fluorescent microscope.  The area of the 
wound area was measured using ImageJ (University of Wisconsin-Madison, Madison 
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WI) and the mean of means were determined.  The rate of wound closure of the 
treatment groups was compared to that of the control. 
N.2. Transwell migration assay 
Capan-1 and HuH-7 cells were seeded into 24-well plate inserts in 100 µL 
volume in serum-free medium containing the PMP-OVA treatment or vehicle control.  
The well below the membrane insert contained 600 µL of 3% FBS-containing medium 
with or without 10 nM IGF-II.  After 48 h to allow the cells to migrate, the inserts were 
retrieved, cells were fixed in isopropanol and the tops of the membranes were swabbed 
of cells.  The cells were then treated with DAPI, washed once in 1x PBS, and mounted 
on slides.  Representative images (3 images) of the DAPI fluorescence and phase 
contrast were taken on a Leica fluorescent microscope.  The number of cells that 
migrated was counted, and the treatments were compared to the control. 
O. Chemical synthesis of hydrolase-resistant M6P-surrogates 
O.1. General overview of chemical synthesis 
Chemical synthesis for our M6P-based surrogates were carried out by Xiang Fei 
and Guillaume Malik from the laboratory of our collaborator, David Berkowitz at the 
University of Nebraska-Lincoln.  The first panel of synthetic, hydrolase- and 
phosphatase-resistant M6P-based ligands was synthesized by Xiang in his doctoral 
work, while the second panel was a collaborative effort of Xiang and Guillaume.  For 
details on the synthesis, please refer to Xiang Fei’s dissertation, chapter IV of this 
dissertation, and previous papers (Fei X and Berkowitz 2008).  In short, the ligands were 
synthesized using different chemistry to control the linker orientation and tether length 
using polybutylene glycol and polyethylene glycol units. 
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 P. Radioligand displacement analysis of M6P-surrogates 
These assays and graphical analysis was performed as described in section F 
with the following changes: the concentration of M6P analogues (0 mM, or 0.0001 to 1 
mM). 
Q. Generation of Dictyostelium discoideum MPR-FLAG expression-constructs 
A recombinant cDNA construct encoding a 442-amino-acid-residue portion 
(residues 578-1020) of the 2441-residue Dictyostelium discoideum-MPR (DDMPR) 
protein sequence (NCBI Accesion: XP_635466) was previously made in our laboratory 
by Dr. Chris Connelly.  The gene sequence encoding the endogenous protein (NCBI 
Accession: XM_630374.1) is located on chromosome 5 within the D. discoideum 
genome.  The 1326-nucleotide (nt) sequence encoding a part of the putative EC region 
of the DDMPR, corresponding to the 442-residude putative M6P-binding region of the 
protein, was designed to contain a 24-nt sequence encoding a C-terminal FLAG-epitope 
tag (DYKDDDDK) with 6-nt EcoRI and XbaI resctriction enzyme sites of the 5’ and 3’ 
ends, respectively, flanking the coding region.  The optimized codon usage-adjusted 
insert (synthesized by GenScript Corporation (Piscataway, NJ)) was excised out of the 
pUC57 vector and cloned into the eukaryotic expression vector, pCMV5 (provided by Dr. 
David Russell, University of Texas Southwestern Medical Center, Dallas, TX).  The 
pCMV5 vector had been previously engineered in our laboratory to destroy the EcoRI 
site in the multiple cloning sequence, to yield a pCMV5RIX vector (116).   
The cDNA constructs prepared in bacterial expression vectors are shown in 
Table 2.2 and Figure 5.2.  The two bacterial expression vectors used were pCOLD-GST 
and pET-22b(+).  The pCold-GST vector was provided by Dr. Steve Caplan of BMB and 
encodes a 6x histidine (His)-tag and 26-kDa GST fusion at the N-terminal region of the 
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insert.  This vector is unique in that it is a cold-shock vector that expresses the insert at 
low temperatures (18 °C) following induction, which prevents the transcription of leaky 
genes at 37°C (309).  Additionally, this vector can be used to purify the protein of interest 
by either the GST- or His-tags, with human rhinovirus 3 C protease site (Leu-Glu-Val-
Leu-Phen-Gln|Gly-Pro) and Factor Xa site (Ille-Glu-Gly-Arg) following their respective 
tags.  After cleavage, a purified protein without the tags can be achieved.  The pET-
22b(+) vector (Novagen,, EMD Millipore, Billerica, MA)  has a C-terminal His-tag.  This 
unique vector has an N-terminal pelB signal for periplasmic localization, which increases 
solubility of the protein (310), and the signal peptidase cleavage sequence allows for 
cleavage just upstream of the insert.  Additionally, there is a C-terminal His-tag 
sequence that allows for purification using a Ni2+-NTA resin column. 
The inserts listed in Table 2.2 were cloned into the pCOLD-GST vector using a strategy 
previously reported in our laboratory (144).  In short, the human MP6/IGF2R mini-
receptor inserts (1-3F, 7-9F, and 11-13F) were restricted digested out of the pCMV5RIX 
vector using EcoRI at 5’ end and XbaI at the 3’ end.  The resulting fragments were 
ligated into the pCOLD-GST vector that contained the 5’ half of sequence encoding 
repeat 1 of the human M6P/IGF2R that also contains the signal sequence.  The DDMPR 
R1-3F was PCR-amplified out of the pUC57 vector and ligated into an opened pCOLD-
GST vector containing the first half of repeat 1 of the M6P/IGF2R, using EcoRI and XbaI.  
Diagnostic cuts were made to validate that we achieved the correct inserts into our 
vectors. 
The DDMPR R3F insert was engineered to express bacterial codon usage and 
synthesized as a 477-base pair (bp) gBOCK by Intergrated DNA Tecnhologies (IDT, 
Coralville, IA), and contained a FLAG-tag sequence at the 3’-end.  We engineered an 
SpeI cutsite into the gene for single cut restriction analysis.  The gBlock was digested 
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with NcoI at the 5’-end and XhoI at the 3’ end.  The vector containing our DDMPR R3F 
insert was validated using SpeI and sequencing. 
R. Expression of the DDMPR and mini-receptor constructs 
R.1. Expression of DDMPR R1-3F construct 
Transient expression of DDMPR R1-3F was done in HEK 293 or 293T cells.  
Transfection was carried out by a modification of the calcium phosphate method as 
described previously (305).  At 24 h post-transfection, the medium was replaced with 
serum-free DMEM followed by incubation for 3 days to permit the cells to condition the 
medium.  To recover the secreted, epitope-tagged DDMPR, the conditioned medium 
was recovered and cellular debris was pelleted on a tabletop centrifuge at 7,000 RPM  
The medium was then concentrated to ~250 µL using Amicon Ultracel 10K centrifugal 
filters as per the manufacturer’s specifications or lyophilized and stored at -20°C until 
use.  To compare secreted vs non-secreted DDMPR, cells were harvested three days 
post-transfection and lysates were prepared as described in section G.  Additionally, 
conditioned medium and lysates were analyzed as described in section G. 
R.2. Bacterial expression of GST- or His-tagged proteins 
The expression plasmids constructed in pCOLD-GST and pET-22b(+) vector 
constructs as described in section N.1 were transformed into Rosetta 2 E. coli 
competent cells, using a standard transformation procedure based on the transformation 
protocol by New England Biolabs  Transformed cells were plated on LB agar plates 
containing the appropriate antibiotic(s) as listed in Table 2.2.  The plates were incubated 
overnight at 37°C, and a single colony from each plate was used to inoculate 50 mL of 
Luria broth (LB) medium containing appropriate antibiotic(s) and incubated overnight at 
37°C, 250 rpm.  Larger 250 mL to 1 L LB cultures containing the appropriate antibiotic(s) 
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were inoculated with the overnight starter culture and grown at 37°C, 250 rpm.  Once the 
culture reached an optical density at O.D.600 = 0.6, a sample of culture was taken for 
SDS-PAGE analysis and the culture was inducted with 0.25 to 1 mM Isopropyl β-D-1-
thiogalactopyranoside (IPTG) (final concentration).  IPTG is a mimic of allolactose that 
binds the lac repressor and allows for expression of T7 RNA polymerase and the protein 
of interest.  Following induction, the cell culture was allowed to grow for another 3-4 h in 
the conditions listed in Table 2.2.  A post-induction sample was removed for SDS-PAGE 
analysis, and the pre- and post-inducing aliquots were compared by loading equal 
amount of protein by normalizing to 500 µL with an O.D.600 = 0.5.  The sample was 
centrifuged at 13,000 rpm for 1 min and resuspended in 15 µL 2x loading buffer, boiled 
for 5 min and analyzed following the electrophoresis protocol followed by Coomassie 
blue R-250 staining.  The induced culture was harvested by centrifugation at 10,000 rpm 
for 15 min.  The supernatant was discarded and the cell pellet was stored at -20°C for 
future use. 
S. Purification of His/FLAG-tagged mini-receptors  
Following expression of our proteins of interest, the proteins were purified via 
their His-tags.  The bacterial cell pellets were resuspended in a lysis buffer (10 mL per 
100mL to 1 L of culture: 10 mL 1x PBS, 2 m M PMSF in isopropanol, 1% NP-40, 1 m M 
DTT, 1:1600 His-tag protease inhibitor cocktail (PIC).  Cells were lysed on a French 
Press, and the cellular debris removed from the lysate via centrifugation (16,500 rpm, 1 
h, 4°C).  An aliquot of the supernatant and pellet representing the soluble and insoluble 
fractions, respectively, were electrophoresed on either a 10% or 15% SDS-PAGE gel 
and stained with Coomassie blue. 
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For purification of the soluble fraction, the supernatant was applied to a Ni2+ 
column pre-equilibrated with ÄKTA Buffer A (1x PBS, 20 mM imidazole, and 1 DTT at 
pH 7.4).  ÄKTA Buffer A contains a low concentration of imidazole that reduces non-
specific binding to the resin column. Imidazole rings in the His-tag have two lone pair 
electrons that chelate to the metal ions in the column; thus, the protein of interest may 
be purified using this strategy with increasing concentrations of imidazole for elution.  
The column was washed with 4 column volumes (20 mL) following the sample injection 
with ÄKTA Buffer A, and the His-tagged proteins were eluted with a gradient of ÄKTA 
Buffer B (1 M imidazole and 1 mM DDT, at pH 7.4.  The fractions containing protein 
were indicated as peaks in the elution profile, and these fractions were analyzed using 
SDS-PAGE.  The fractions containing the protein were pooled and dialyzed in dialysis 
buffer (1x PBS with 1 mM DTT) to remove the imidazole.  Slide-A-Lyzer dialysis 
cassettes with a 10,000 MWCO were used, and the samples were dialyzed in 2x 2L of 
dialysis buffer at 4°C for 4 h and then 16 h with gentle stirring. 
For purification of the insoluble fraction, the pellet was re-solubilized in ÄKTA 
urea Buffer A (1x PBS, 6 M urea, 20 mM imidazole, 28.5 mM 2-mercaptoethanol (β-ME), 
1% Triton X-100, at pH 8.0-8.4).  After re-solubilizing the pellet at 4°C, end-over-end, 
overnight, any remaining insoluble particles were pelleted at 16,500 rpm, 4°C, 1 h.  The 
re-solubilized fraction was purified following the soluble fraction purification with the 
following change: ÄKTA Buffer B was substituted with ÄKTA urea Buffer B (1x PBS, 6 M 
urea, 1% Triton X-100, 1M imidazole, at pH 8.0-8.4). 
The N-terminal GST-tag was not removed until after refolding.  To remove the 
GST-tag, the proteins were cut with Turbo 3 C (Accelagen; San Diego, CA, USA) (2 
units/1 µL; 1 unit/ 100 µg), end-over-end, 4°C, for 24-72 h.  Aliquots of before and after 
cleavage were analyzed via SDS-PAGE and Coomassie blue staining. 
81 
 
T. Refolding of His/FLAG-tagged mini-receptors 
The proteins purified from the insoluble fraction were completely unfolded due to 
DTT and the high concentration of urea.  Refolding occurred in one of several refolding 
buffers as listed in Table 2.3.  The protein refolding followed one of two protocols. 
1. Direct dilutions: 
Protein was allowed to unfold in ÄKTA urea Buffer A for 1 h at 4°C.  Protein was 
diluted directly with volumes (1:0 control; 1:1; 1:5; 1:10; 1:20) of refolding buffer, briefly 
vortexed to mix, then allowed to rest at 4°C for 24-48 h for refolding.  Conversely, only 
half of the refolding buffer was added at 12 h while the second half was added at 24 h.   
2. Dialysis: 
Protein was dialyzed in refolding buffer supplemented with decreasing 
concentrations of of urea (4 M, 2 M, 1 M, 0 M) over the course of 6 days.   
After following either protocol for protein refolding, the refolded protein was dialyzed 
in dialysis buffer (1x PBS or 1x TBS) in a two-step process overnight.  Following dialysis, 
the protein was subjected to biophysical or functional assays to determine proper and 










Vector Mw (kDa) Mw (kDa) 
+GST 
Cell Line Antibiotics Induction 
DDMPR 
R1-3F 








pCOLD-GST 51.1 78 JRC3 Amp/Cam 18°C 
250 rpm 
1-3F pCOLD-GST 49.4 77 C41 Amp 18°C 
250 rpm 
1-3F pCOLD-GST 49.4 77 JRC1 Amp/Cam 18°C 
250 rpm 
1-3F pCOLD-GST 49.4 77 JRC3 Amp/Cam 18°C 
250 rpm 
7-9F pCOLD-GST 49.4 76 C41 Amp 18°C 
250 rpm 
7-9F pCOLD-GST 49.4 76 JRC1 Amp/Cam 18°C 
250 rpm 
7-9F pCOLD-GST 49.4 76 JRC3 Amp/Cam 18°C 
250 rpm 
11-13F pCOLD-GST 54 81 C41 Amp 18°C 
250 rpm 
11-13F pCOLD-GST 54 81 JRC1 Amp/Cam 18°C 
250 rpm 




pET-22b(+) 18.3  BL21 Amp 37°C 
250 rpm 
 
Table 2.2: Bacterial expression constructs were transformed into E. coli Rosetta 2 
competent cell strains. 
Received from Dr. Paul Sorgen, UNMC: C41, JRC1, JRC3, BL21 
Recieviend from Dr. Steve Caplan, UNMC: pCOLD-GST 
Abbreviations are as follows: C41, C41(DE3)pLysS; JRC1, C41(DE3)pRARE2pLysS; 






Refolding recipe, pH 8.0 Buffer* 
50 mM Buffer* Tris 
1 mM EDTA MES 
1 M L-arginine MOPS 
0.1 mM PMSF HEPES 
3.7 mM Cystamine Glycine 
6.5 mM Cysteamine 2-mercaptoethylamine 1x PBS 
 
Table 2.3: MPR mini-receptor refolding buffer conditions.  The refolding buffer 
recipe contained the components in the left column, where the buffer* was substituted 














U. PMP-Sepharose pull-down assay 
Aliquots of HEK 293 cell conditioned media and lysates or soluble and re-
solubilized pellet fractions from E. coli cells, containing equimolar amounts of expressed 
FLAG-tagged soluble receptors as determined by the bicinchoninic acid assay, were 
incubated with 5 µL of packed PMP-Sepharose 4B resin in (IMM2 buffer: 50 mM 
HEPES, pH 7.4,  0.15 M NaCl, 0.05% Triton X-100, pH 7.4) plus 1% BSA with or without 
increasing concentrtions of 5 mM M6P (0 mM to 20 mM) with mixing for 16 h at 4°C.  
The resin was collected by centrifugation at 8,000 x g for 30 s.  The resulting resin 
pellets were washed twice with 1 mL IMM2 buffer.  The resin complex was 
immunosorbed to 10% SDS-PAGE gels and probed with -FLAG M2 antibody (1:1000) 
or α-His-tag antibody (1:1000) and processed as previously mentioned. 
V. 125I-PMP-BSA ligand blot analysis 
Samples were prepared as for SDS-PAGE immunoblots in section I, except 
under non-reducing conditions (absence of DTT in the sample buffer).  After 
electrophoresis, proteins were transferred to transferred to BA85 nitrocellulose 
membrane under non-reducing conditions (15 mM Tris, pH 8.3, 120 mM glycine).  Blots 
were stripped of SDS in Ligand A buffer (10 mM TRIS, pH 7.4, 150 mM NaCl, 0.05% 
NaN3, 3% NP-40) for 30 min, end-over-end, 4°C, blocked in Ligand B (10 mM TRIS, pH 
7.4, 150 mM NaCl, 0.05% NaN3, 1% BSA) for 2 h, end-over-end, 4°C, and probed in 
radioligand (Ligand B, 0.01% Tween-20, 2 million cpm or 0.5 nM 125I-PMP-BSA) 
overnight, end-over-end, 4°C.  After 3 x 15 min washes in Ligand C (10 mM TRIS, pH 
7.4, 150 mM NaCl, 0.05% NaN3, 0.1% Tween-20), end-over-end, 4°C, blots were dried 
and detected by means of autoradiography and quantified using Typhoon 9410 
PhosphorImager analysis (Amersham Biosciences Corp., Piscataway, NJ, USA). 
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W. Statistical Methods 
Comparative analysis among multiple experimental groups were done using a 
one-way analysis of variance (ANOVA) with Dunnett’s test as a post-hoc analysis that 
compared specific group means (e.g. PMP-ligands, IGF-II, etc.) to a control group mean 

































Exploitation of the Ligand-Binding Properties of the Mannose 6-Phosphate/Insulin-like 






The material covered in this chapter is the topic of the following article in preparation 
authored by: 










A.  Summary 
The M6P/IGF2R binds M6P-capped ligands and IGF-II at different binding sites 
within the EC domain and mediates ligand internalization and trafficking to the lysosome.  
Multivalent M6P-based ligands can cross-bridge the M6P/IGF2R which increases their 
rate of internalization, permitting IGF-II binding as a passenger ligand and subsequent 
trafficking to the lysosome, where the IGF-II is degraded.  This unique feature of the 
receptor can be exploited to design novel therapeutic agents against IGF-II-dependent 
cancers that will lead to decreased bioavailable IGF-II within the tumor 
microenvironment.  Our studies demonstrate that our bivalent M6P-based ligands bind to 
the M6P/IGF2R with high affinity and decrease growth of cancer cells by causing an 
accelerated increase of IGF-II internalization and degradation. 
 
B.  Rationale 
The main function of the M6P/IGF2R is in lysosomal biogenesis by transporting 
newly synthesized lysosomal enzymes and other M6P-capped glycoproteins from the 
TGN to the lysosome.  Additionally, the receptor captures other glycosylated and non-
glycosylated ligands from the cell surface and internalizing these ligands for transport to 
the lysosome for degradation.  The M6P/IGF2R at the cell surface is constitutively 
internalized regardless of bound ligand (6, 153, 160, 161).  However, it was noted that 
the homotetrametic lysosomal enzyme β-glucuroidase (hGUS), which has multiple M6P-
capped oligosaccharides, increased the rate of internalization of receptor-bound IGF-II; 
this accelerated internalization was attributed to the multiple M6P glycosylations on the 
lysosomal enzyme that were able to cross-bridge the M6P-binding sites on M6P/IGF2R 
monomers, stabilizing the dimeric receptor.  This dimerization of the M6P/IGF2R 
accelerates the rate of internalization of bound ligands 3-4-fold (131), although the exact 
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mechanism by which this occurs is unknown.  Monovalent ligands for the M6P/IGF2R, 
such as M6P and IGF-II, are unable to produce this effect, supporting the hypothesis 
that dimerization or oligomerization of the M6P/IGF2R is important for rapid 
internalization, which monovalent ligands are unable to achieve.  Moreover, the cellular 
repressor of E1A-stimulated genes (CREG), which is a secreted M6P-capped 
glycoprotein, can facilitate the internalization and disposal of IGF-II in the lysosome by 
regulating M6P/IGF2R; this caused a cell-cycle arrest in NIH 3T3 fibroblasts, human 
vascular smooth muscle cells, and a teratocarcinoma cell line, NTERA-2 (228, 229, 
311).  Altogether, these studies suggest that binding of multivalent M6P-capped ligands 
to the M6P/IGF2R enhances the receptor’s rate of internalization of IGF-II leading to 
decreased cell growth/proliferation.  Our hypothesis is that this functional activity of the 
M6P/IGF2R may be exploited to design novel treatments for IGF-II-dependent cancers.  
To our knowledge, there have not been any studies to directly test whether bi- or 
multivalent M6P-based ligands could enhance the internalization rate of M6P/IGF2R-
IGF-II complex through direct binding of the M6P-binding sites that inhibits IGF-II-
dependent growth of cancer cells. 
Our laboratory has designed a panel of bi- and multidentate M6P-based ligands 
of decreasing molecular size and number of M6P moieties to evaluate their ligand-
binding properties for the M6P/IGF2R.  The aim of the current study was to assess the 
effect of these high-affinity, bivalent ligands on IGF-II-dependent cell growth and their 
ability to deplete IGF-II from the conditioned medium.  The long-term goal of this project 
is to utilize these compounds as a potential therapeutic agent for the treatment of IGF-II-
dependent cancers. Previously, two panels of phosphatase-resistant, M6P-based, 
bidentate compounds were synthesized, but none were able to bind the receptor with 
high affinity indicative of bivalency (312, 313).  The lack of effectiveness of these ligands 
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has been attributed to the design, with insufficient distance between or improper 
orientation of the M6P groups to permit interaction with two M6P-binding sites on the 
receptor dimer simultaneously.  Thus, we synthesized a panel of multidentate 
pentamannosyl 6-phosphate (PMP)-based pseudoglycoproteins and –peptides as proof-
of-principle studies.  This panel of PMP-ligands was designed to have decreasing 
molecular sizes and number of M6P moieties to determine the smallest possible M6P-
based ligand that could achieve high-affinity, bivalent binding for the M6P/IGF2R, 
allowing for stabilization of the receptor dimer and accelerated internalization of IGF-II as 
a passenger ligand.  One of the most important features of these ligands is that the 
protein and peptide scaffolds constrain the conformational flexibility of the PMP 
functional groups to allow more favorable orientation for binding to the receptor.  
Radioligand displacement analysis indicate that these PMP-ligands bound to the 
M6P/IGF2R with high affinity compared to the monovalent binding of M6P, indicating 
achievement of bivalent binding.  Our cell growth studies suggest that these compounds 
can decrease IGF-II-dependent cell viability in a number of cancer cell lines.  
Additionally, this reduction of cell viability from PMP-ligand treatment can be attributed to 
the internalization and degradation of extracellular IGF-II, as evidenced by our 125I-IGF-II 
degradation assays.  The subsequent mechanism of growth suppression has not been 
definitively elucidated, but apoptosis, cell cycle arrest, and migration are all possible 
mechanisms that need to be investigated further.  To our knowledge, we have designed 
the first panel of high-affinity, bivalent M6P-ligands for the M6P/IGF2 that can decrease 





C.  Results 
C.1.  Synthesis and purification of pentamannosyl 6-phosphate (PMP) ligands 
We synthesized a panel of ligands varying in molecular size to determine the 
minimal size needed to achieve high-affinity binding in order to cross-bridge the 
receptor.  Pentamannosyl 6-phosphate (PMP), derived from the yeast natural byproduct 
phosphomannan, was coupled by reductive amidation to protein scaffolds of different 
sizes as previously reported (144, 152).  PMP is hydrolyzed from P. holsii 
phosphomannan, and the PMP chain structure contains five mannose rings that are 
coupled through α(1,3) linkages, where the distal mannose ring (furthest from the 
reducing end) has a phosphate on the sixth carbon and the proximal two mannose rings 
are linked through an α(1,2) linkage (300, 301).  The most proximal mannose ring is then 
coupled through the reducing end to any free amine group on the protein or peptide 
scaffold. 
Our lab has coupled PMP to a panel of proteins consisting of albumin (PMP-
BSA), ovalbumin (PMP-OVA), and insulin (PMP-INS).  We have also chemically linked 
PMP to two tripeptides: lysyl-tyrosyl-lysine (PMP-KYK) and seryl-tyrosyl-lysine (PMP-
SYK).  After the coupling phase, the PMP-pseudoglycoproteins were purified by dialysis 
and analyzed by SDS-PAGE; Coomassie staining of the gels revealed that the purified 
products’ molecular masses showed upward shifts corresponding to their predicted 
masses based on the known molecular masses of the core proteins and assuming 100% 
derivatization of PMP to bovine serum albumin (BSA), OVA, and INS (Table 3.1).   The 
PMP-glycopeptides were purified by anion-exchange and size-exclusion 
chromatography to apparent homogeneity by the criterion of SDS-PAGE with 
Coomassie staining, and analyzed by MALDI-TOF mass spectrometry, which suggested 
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that the PMP-peptides were heterogeneous in size with mass differences corresponding 






PMP-ligand Precursor Predicted MW Approximate PMP Groups 
PMP-BSA Bovine Serum Albumin 90,000 24 
PMP-OVA Chicken Egg Ovalbumin 58,000 13 
PMP-INS Bovine Insulin 8,800 3 
PMP-KYK Lysyl-Tyrosyl-Lysine 3,600 3 
PMP-SYK Seryl-Tyrosyl-Lysine 2,400 2 
 
Table 3.1: PMP-pseudoglycoproteins and –peptides.  The panel of PMP-ligands was 
designed to encompass a molecular size range to determine the smallest M6P-based 
ligand capable of high-affinity binding to the M6P/IGF2R.  For BSA, ovalbumin and 
insulin, molecular weights (MW) were measured by migration on reducing SDS-PAGE.  









C.2.  Validation of PMP-Ligand binding to the M6P/IGF2R 
The PMP-pseudoglycoproteins and peptides were validated for their ability to 
bind to the bovine M6P/IGF2R and characterized for their binding properties.  In 
previous studies, using radioligand displacement assays where 125I-PMP-BSA used as 
the tracer, all PMP-ligands were able to bind to the soluble bovine M6P/IGF2R that was 
immobilized to Sepharose 4B resin.  In this assay, a high concentration of M6P was able 
to competitively displace the PMP-ligands from the receptor with IC50 values in the nM 
range.  M6P alone is used as a control for monovalent binding (with a KD near 8 µM (93), 
while G6P is used as a negative control because the 2-hydroxyl group is in the 
equatorial state and prevents formation of a key hydrogen bond enabled by the axial 
state.  Nevertheless, binding of PMP-OVA (Figure 3.1) as well as the other PMP-ligands 
(data not shown) exhibited a non-linear regression curve that shifted to the left, indicative 
of high-affinity, bivalent binding.  The IC50 and RBA values indicate that PMP-OVA 
binds with nM affinity similar to hGUS (Table 3.2).  These ligands produced affinity 
consistent with a bivalent mode of binding for the M6P/IGF2R that was similar but not 
quite as high as hGUS. 
In order to produce bivalent binding, these ligands must cross-bridge the dimeric 
M6P/IGF2R.  In a previous gel-shift assay done by Dr. Chris Connelly during his doctoral 
work, PMP-BSA was able to stabilize the dimeric, soluble M6P/IGF2R, as the molecular 
mass of the receptor shifted to a mass that was unable to be clearly resolved on the gel 
(data not shown).  As PMP-BSA concentration increased, the amount of monomeric, 
soluble M6P/IGF2R decreased.  However, PMP-BSA did not shift the monomeric 
receptor to a dimeric form as well as hGUS (data not shown), indicating that hGUS may 
be more efficient at inducing dimerization while PMP-BSA is able to stabilize a pre-
formed dimeric structure while having reduced ability to initiate dimerization.  Also of 
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note, hGUS has the preferred α(1,2) linkages between the distal and penultimate 
mannose rings while PMP-BSA has α(1,3) linkages that gives up some affinity for the 
receptor. 
The pseudoglycoprotein ligand PMP-BSA shows a preference for binding to the 
M6P-binding site in domain 3, as indicated by mutagenesis and pull-down studies 
previously done by Dr. Connelly (data not shown).  FLAG-tagged constructs bearing 
mutations in the M6P-binding sites or truncated forms of the receptor deleting M6P-
binding sites (128) were designed to regulate the number of available M6P-binding sites 
per receptor.  Using a FLAG-tagged pull-down approach, the binding of PMP-ligands to 
the receptor constructs was determined.  PMP-OVA and PMP-SYK have preferential 
binding to domain 3 over domain 9, but each binds with lower affinity than the positive 
control natural ligand, hGUS.  It is important to note that hGUS had some binding for 
domain 9 even though it primarily binds through domain 3, suggesting that hGUS may 
have a different binding mechanism than our PMP-ligands. 
In order to determine if PMP-ligands can inhibit cell viability, we first determined 
the stability of the PMP-ligands in serum-containing medium.  Our ligands are heavily 
phosphorylated, making them susceptible to phosphatase cleavage, which would render 
them incapable of altering cell viability due to their inability to bind the M6P/IGF2R.  To 
validate that our ligands are stable throughout the duration of a multi-day cell culture 
experiment, we incubated radiolabeled PMP-BSA with different concentrations of serum-
containing medium at 37 °C and compared ligand integrity at different time points to that 
of 125I-PMP-BSA in a serum-free control (Figure 3.2).  Aliquots taken over the course of 
this study were resolved on SDS-PAGE, and the gel was dried and analyzed by 
autoradiography.  Over the course of 24 hours, the intensity and migration of 125I-PMP-




Figure 3.1.  Competitive Binding Analysis of PMP and PMP-OVA in Displacement 
of PMP-BSA from M6P/IGF2R-Sepharose.  M6P is the reference for monovalent, low-
affinity binding.  G6P is the negative control.  hGUS is a reference for bivalent, high-
affinity binding.  PMP has the same low, monovalent binding affinity as M6P.   PMP-
OVA’s shift to the left indicates higher affinity of this ligand and is a potential for 
bivalency.  These data are representative of three replicate experiments; the binding 
parameters calculated from the data are shown in Table 3.2. 
 
Ligand IC50
a, µM (n) RBAb 
M6P 4.6 ± 0.99 (3) 1 
G6P > 10,000 (3) N.A. 
PMP 7.5 (1) 0.62 
PMP-OVA 0.015 ± .011 (3) 620 ± 155 
hGUS .002 (1) 1643 
Table 3.2: Binding Properties of PMP-Ligands for M6P/IGF2R.   
a.  IC50 values for competitive displacement of radiolabeled PMP-BSA from the receptor 
(n = # of trials). b. RBA = relative binding affinity, normalized to free M6P. 



























PMP-ligands are stable in conditions that mimic those that would be used in cell culture 
experiments.  To determine whether the stability of the radioligand declines with time 
following incubation with cells, Capan-1 (human pancreatic adenocarcinoma cell line) 
cells were incubated with 400,000 cpm 125I-PMP-BSA under reduced (1%) serum 
conditions for up to 48 h.  Aliquots of the conditioned medium at different time points 
were then immobilized in a soluble M6P/IGF2R-Sepharose 4B assay with or without 5 
mM M6P, which competitively displaces the 125I-PMP-BSA, and then the radioactivity 
was counted on a gamma counter (Figure 3.2).  At the 1-h time point, some of the 
radioactive counts were absent from the conditioned medium, indicating that some of the 
ligand was internalized.  After 6 hours, the internalization appeared to stabilize with only 
a slow decrease in counts throughout the 48-h assay.  The addition of M6P to the pull-
down assay displaced the radioactive counts, indicating that the assay was indeed 
pulling down the 125I-PMP-BSA ligand. Thus, we concluded that our ligand is stable for at 
least 48 h in vitro. 
 
C.3.  PMP-ligands decrease viability of cells in culture 
Our laboratory previously used a short-term growth assay to determine whether 
the high-affinity binding of the PMP-ligands to the M6P/IGF2R can induce cytotoxic 
effects similar to those observed with CREG.   A mouse L-cell fibroblast cell line that 
stably over-expressed wild-type bovine M6P/IGF2R was used, since this cell line was 
also used by York et al. to demonstrate that multivalent M6P-ligands induce rapid uptake 
of IGF-II by the M6P/IGF2R (131).  In Dr. Chris Connelly’s doctoral work, mouse L-cells 
incubated with as little as 10 nM PMP-OVA or PMP-SYK had a significant inhibition of 
cell viability over a 4-day time course.  M6P up to a concentration of 10 mM did not 








Figure 3.2: Resistance of PMP-ligands to degradation.  A) 125I-PMP-OVA was added 
to serum containing medium or serum-free (SF) medium for up to 24 h.  Aliquots were 
resolved by SDS-PAGE.  PMP-OVA was stable in serum-containing medium for up to 24 
h, as degradation of the radioactive material was not seen in this cell-free assay.  B) 
Mouse L-cells were incubated with 125I-PMP-BSA for up to 48 h.  Aliquots of the 
conditioned medium were taken at the indicated time points and subjected to a 
sM6P/IGF2R-Sepharose 4B pull-down to determine the amount of radioactive counts 
able to bind the resin.  M6P (10 mM) was used to competitively displace the 125I-PMP-
BSA to determine the amount of radioactive counts contributing to specific M6P-based 
binding to the immobilized receptor, which indicates the integrity of the PMP-ligand 
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treatment, it was able to rescue the reduction on cell viability due to competitive 
displacement of the bivalent ligand.  This indicated that the PMP-ligands were binding to 
the M6P/IGF2R in a M6P-dependent manner.  It is hypothesized that these PMP-ligands 
function by depleting excess IGF-II from the cell milieu by way of the M6P/IGF2R.  In the 
mouse L-cells, 10 nM IGF-II slightly increased the cell viability, but this growth factor was 
able to completely rescue the decrease in cell viability back to the level of the control.  
Therefore, decreased cell viability caused by the PMP-ligands is both a M6P- and IGF-II-
dependent phenomenon. 
Mouse L-cells were utilized for these proof-of-principle studies due to their high 
over-expression of the M6P/IGF2R.  Given our long-term goals for the use of these 
ligands, various human cancer cell lines were used as more relevant models to study the 
PMP-ligand effects.  Hepatocellular carcinoma (HuH-7) and choriocarcinoma (JEG-3) 
cells were initially used as several studies demonstrated that these cell lines express all 
the requisite components of the IGF-axis as well as exhibit an IGF-II-driven autocrine 
loop (264, 274, 314).  Previous work by Dr. Connelly demonstrated that these two 
cancer cell lines responded to the PMP-ligand treatment in the same manner as the L-
cells (data not shown).  PMP-OVA at a concentration of 200 nM was able to significantly 
reduce the cell viability, and addition of 10 mM M6P reversed the effects.  However, it 
was necessary to increase the concentration of PMP-ligands 20-fold higher than what 
was needed in the mouse L-cells in order to see a significant inhibition of cell viability in 
HuH-7 and JEG-3 cells.  This may be due to the fact that the mouse L-cells have a 
higher concentration of M6P/IGF2R on the cell surface than the cancer cell lines or that 




We next wanted to validate the activity of our PMP-ligands in various types of 
cancer cell lines to determine if our ligand is effective in treating these cancers.  Our lab 
determined through western blotting the expression of M6P/IGF2R in multiple cancer cell 
lines (Figure 3.3).  Additionally, two well-differentiated adenocarcinoma cell lines, S2-013 
and Capan-1 (315) expressed the receptor well.  Dr. Connelly determined through RT-
PCR that S2-013 cells express high levels of IGF-II, but Capan-1 cells express very little 
to no IGF-II (data not shown).This would provide both autocrine and paracrine loop 
model systems for our studies.  Both pancreatic cancer cell lines responded well to IGF-
II and -I, with increased cell viability in response to as little as 0.01 nM IGF-II.  Using 
soluble M6P/IGF2R as an IGF-II ligand-trap, S2-013 did not show a decrease in cell 
viability, indicating that this cell line produces enough IGF-II to overcome the trap or that 
the growth factor may be working in an intracrine fashion, i.e. not fully released into the 
milieu before being recaptured by the cell, that a ligand-trap did not affect the cell 
growth.  In contrast, Capan-1 had a moderate decrease in cell viability when treated with 
soluble M6P/IGF2R over a five-day assay (Figure 3.4).  These data suggest that Capan-
1, which relies on the IGF-II in the medium, has some dependency on IGF-II for growth, 
but this cell line is not solely dependent on the IGF-II pathway for mitogenesis and 
survival.  Accordingly, treating Capan-1 with 50 nM PMP-OVA revealed a moderate 
decrease in cell viability, not quite to the extent as the ligand-trap (Figure 3.4).  
Furthermore, the PMP-OVA treatment did not affect the cell viability of S2-013 cells, 








Figure 3.3: M6P/IGF2R expression by cancer cell lines.  A) Lysates of various cancer 
cell lines were subjected to SDS-PAGE and immunoblot analysis, probing with α-CD222 
antibody. Pancreatic cancer cell lines: MiaPaCa-2, PANC-1, S2-013, Capan-1; prostate 
cancer cell lines: DU145, PC-3, LNCaP; hepatocellular carcinoma cell lines: HuH-7, 
HepG2; colon cancer cell lines: CBS, GEO, HT-29; neuroblastoma cell line: SK-N-AS; 
fibrosarcoma cell line: HT-1080, choriocarcinoma cell line: JEG-3; human embryonic 
kidney cells: HEK 293; mouse L-cells are a kidney fibroblast cell line.  Notice that our 
stable human M6P/IGF2R expression cell line (mouse L-cell) had lost the expression of 









Figure 3.4: Inhibition of pancreatic cancer cell growth by multivalent M6P-based 
ligands.  A) Capan-1 and B) S2-013 were differentially responsive to IGF-II and the IGF-
II ligand trap, sIGF2R (sM6P/IGF2R).  Capan-1 grew better in response to IGF-II than 
S2-013, and this growth was inhibited by sequestering IGF-II. C) IGF-II was able to 
partially rescue the growth inhibition effect caused by soluble M6P/IGF2R.  D) PMP-OVA 
inhibits the IGF-II-dependent growth of Capan-1 cells, which is rescued by the addition 
of exogenous IGF-II. 
 






















































We next wanted to determine whether other pancreatic cancer cells could be 
targeted by our PMP-ligands.  The moderately poorly differentiated pancreatic 
carcinoma cell lines MiaPaCa-2 and PANC-1 were used to lend further support to the 
use of our ligands against pancreatic cancer.  These two cell lines did not respond to 
IGF-II and soluble M6P/IGF2R functioning as a ligand trap, indicating that these cell 
lines are not IGF-dependent and would not be good models for our studies. 
We next expanded our studies outside of the digestive tract (i.e., liver and 
pancreas) and focused on another major cancer type, prostate.  DU145, a moderately 
differentiated prostate carcinoma cell line, was used as a representative prostate cancer 
cell line, as it has been shown to be IGF-II-responsive and express the necessary 
components of the IGF axis (178).  Prostate cancer has a relatively high overall five-year 
survival rate, yet it is still the second-leading cause of cancer death in men, according to 
the American Cancer Society.  In the early stages of prostate cancer progression, the 
prostate cancer cells are dependent on androgen and express the androgen receptor 
(316), which allows androgen-deprivation therapy to be an effective treatment option.  
However, many patients progress to a castration-resistant prostate cancer, which leads 
to over-activation of the androgen receptor (AR)-dependent pathway and further drives 
metastasis.  The IGF-axis may play a role in the progression of prostate cancer following 
androgen-deprivation therapy (317).  Therefore, we were interested in knowing if our 
PMP-ligands can inhibit prostate cancer cell growth and serve as a potential therapeutic 
agent for advanced forms of prostate cancer.  DU145 cells do not express AR and thus 
may serve as castration-resistant prostate cancer cell line.  DU145 responded 
moderately well to PMP-OVA treatment (data not shown).  PMP-ligands may decrease 
cell viability in prostate cancer cells that are dependent on IGF-II.  
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The IGF-axis is highly expressed in the developing and mature central nervous 
system.  The IGFs are important in neurodevelopment and neuroprotection (318).  
However, it is also known that IGF-II is a major autocrine contributor to neuroblastoma 
growth and promotes resistance to retinoic acid (RA), a metabolite of vitamin A that 
functions through RA receptors to modulate transcription of genes and is a known 
neuronal differentiation molecule (319).  We thus utilized the embryonal neuroblastoma 
cell line, SK-N-AS, to determine if PMP-ligands can also function in this system.  This 
poorly differentiated cancer cell line expresses all of the major components of the IGF-
axis (IGF-II, IGF1R, and M6P/IGF2R), including IGF-II functioning in an autocrine loop 
(203).  SK-N-AS cells were slightly, but not significantly, sensitive to the PMP-OVA 
treatment at 100 nM concentration.  Additionally, the cell lines that we have tested are 
summarized in Table 3.3. 
Taken together, these data may suggest that our ligands function best in well-
differentiated IGF-II-dependent cancer cells, with the most prominent response being a 
cancer that is easily accessible through the bloodstream, in which the tumor has high 
expression of the M6P/IGF2R, such as hepatocellular carcinoma.  However, our PMP-
ligands are not limited to this type of cancer, as it proved effective on many types of 








Cell Line Cancer Type Differentiation Ligand Trap 
Response 
Capan-1 Pancreatic WD ++ 
S2-013 Pancreatic WD - 
MiaPaCa-2 Pancreatic PD-MD - 
PANC-1 Pancreatic PD - 
HuH-7 Hepatocellular WD ++ 
JEG-3 Choriocarcinoma WD ++ 
DU145 Prostate MD + 
SK-N-AS Neuroblastoma PD + 
 
Table 3.3: Comparison of cancer cell lines and their response to ligand trap 
(sM6P/IGF2R) or PMP-ligand treatment.  The cell lines from different sources had a 
different response to the ligand trap (sM6P/IGF2R) or PMP-ligand treatment as indicated 
by -, no response; +, mild response; ++, moderate response.  Abbreviations: WD, well 














C.4.  PMP-ligands decreased IGF-II in the conditioned medium of cancer cells 
Since the effect of PMP-ligands on cells is M6P-dependent, indicating that the 
PMP-ligands bind to the M6P/IGF2R through a M6P-binding site, and IGF-II-dependent 
as indicated by add-back of IGF-II, which rescues the effect, we hypothesized that the 
PMP-ligands work to deplete IGF-II from the medium.  To detect the low concentrations 
of IGF-II in the conditioned medium, we employed many approaches until we were able 
to achieve the highest sensitivity to detect minute differences in the level of IGF-II among 
media conditioned by cells from different treatment groups. 
Capan-1, S2-013, and HuH-7 cells were treated with 10 nM IGF-II or the vehicle 
control, HBS (HEPES buffered saline).  Conditioned medium (CM) was collected 72 
hours after treatment and proteins were separated under reducing conditions on 15% or 
8-16% SDS-PAGE gels and then immunoblotted with rabbit αIGF-II antibody.  The 
sensitivity of the αIGF-II antibody was estimated to be about 3.75 ng based on detection 
of recombinant IGF-II from a serial dilution that was electrophoresed without being 
exposed to cells (Figure 3.5A), but was not sensitive enough to directly detect IGF-II in 
the conditioned medium after exposure to Capan-1, S2-013, or HuH-7 cells (data not 
shown).  The samples were then concentrated 16-fold using ultracentrifugation, which 
improved electrophoresis by eliminating salts.  However, there was only about a 50% 
recovery of the IGF-II from the centrifugal concentrators as determined by 
immunoblotting of an internal control using the αIGF-II antibody (Figure 3.5B).  Recovery 
was not improved following washes with a salt-free Tris-EDTA buffer (data not shown).  
Fresh CM from the cells was then concentrated via lyophilization, which worsened the 
electrophoretic separation causing smearing of the proteins.  Again, the antibody was 
not sensitive enough to detect differences in the IGF-II from the concentrated CM.  




Figure 3.5:  Detection of IGF-II through immunoblot and dot blot analysis. A) A 
standard curve for IGF-II was made by SDS-PAGE and immunoblotting with an αIGF-II 
antibody, where the lowest detection limited achieved was 3.75 ng.  B) The amount of 
IGF-II recovered from conditioned medium by concentration using centrifugal filters was 
determined by spiking IGF-II before or after concentrating.  There was less than 50% 
recovery from the concentrators.  C) Dot blot analysis of decreasing cold carrier IGF-II 
and 125I-IGF-II in serial dilutions in either HBS or 10% FBS DMEM as a carrier.  The 




dot blot method.  We estimated that IGF-II detection was in the range of 0.6-3 ng using 
radiolabeled IGF-II as an internal control, with only a 30% recovery of 125I-IGF-II in 10% 
serum-containing medium that was not exposed to cells (Figure 3.5C).  Using CM from 
cells, the amount of IGF-II was undetected, indicating that this approach was not 
sensitive enough (data not shown).  This may be due to the prevalence of too many 
proteins adhering to the nitrocellulose membrane, reducing the possibility of IGF-II to 
bind.  We then needed to find an alternative detection method with high sensitivity. 
We next tried to concentrate and partially purify aliquots of 3% serum-containing 
medium spiked with 500,000 cpm 125I-IGF-II using a trichloroacetic acid (TCA) protein 
precipitation followed by electrophoresis and immunoblotting.  Unfortunately, this did not 
work either, as the TCA could not be removed from the protein pellet even with acetone 
washing, and subsequent electrophoresis of the re-dissolved proteins was impossible 
(data not shown). 
To improve detection of IGF-II, we miniaturized a chromatographic purification 
procedure followed by radioimmunoprecipitation assay (RIA) as previously done by Park 
et al. with some modifications (307).  Fresh 1% serum-containing medium was 
lyophilized and reconstituted in 1 M acetic acid and run through a BioGel P10 gel 
filtration column using a 0.1 M acetic acid mobile phase.  Fractions were collected for 2 
min per tube and protein concentration was analyzed using the absorbance at 280 nm.  
After conditioning the column for several runs, radiolabeled IGF-II with unlabeled IGF-II 
carrier was fractionated.  IGF-II consistently eluted between fractions 17-24 from this 
column (Figure 3.6A).  In subsequent experiments, these pooled fractions were 
lyophilized and reconstituted in 1 M HCl before IGF-II concentrations were determined 
via radioimmunoassay (RIA).  These experiments indicated that our sensitivity in this 










Figure 3.6: IGF-II concentration determined by size exclusion chromatography and 
125I-IGF-II RIA. A)  The bulk protein eluted from the size exclusion column fractionated 
into two predominant peaks: large, excluded proteins in fractions 7-10 and small, 
included proteins in fractions 30-40 as indicated in the blue line.  125I-IGF-II was used to 
determine the fractions in which IGF-II elutes, which was in fractions 17-24.  The peak 
before and the peak after the 125I-IGF-II represent components of the IGF-II preparation, 
radiolabeled BSA and degraded fragments, respectively. B) 125I-IGF-II RIA determined 
that amount of IGF-II recovered in the assay using medium spiked with 50-150 ng of 
cold IGF-II and 0.3 nM 125I-IGF-II. C) The 125I-IGF-II RIA was too insensitive and 






















































































conditioned media of cells, Capan-1, SK-N-AS and JEG-3 cells were seeded in 6-cm 
dishes and treated with 200 nM PMP-OVA, 10 nM IGF-II, 200 nM PMP-OVA + 10 nM 
IGF-II, or vehicle control (HBS).  After 24 h, the conditioned media were collected and 
lyophilized.  IGF-II in the samples was determined following the aforementioned column 
fractionation protocol.  All treatment conditions produced IGF-II values that were well 
within the IGF-II RIA standard range of detection, but were all comparable (Figure 3.6C).  
Temporal studies in Capan-1 and JEG-3 revealed that this assay was again not 
sensitive enough to detect the differences, if any, in the very low IGF-II concentrations in 
the CM. 
Han et al. were able to see internalization of IGF-II with overexpression of CREG 
in human vascular smooth muscle cells, using a mouse IGF-II ELISA kit (231).  
Furthermore, knock-down of CREG or blocking the ability of IGF-II to bind to the 
M6P/IGF2R using neutralizing antibodies reversed the IGF-II internalization effect.  
However, Han et al. did not do the key experiment to demonstrate that CREG is 
decreasing IGF-II in the medium by binding to the M6P/IGF2R through a M6P-based 
mechanism that is displaceable with M6P.  Knowing that we had not yet achieved an 
assay sensitive enough to detect minute differences in IGF-II in the conditioned medium 
of cultured cells, we decided to take an indirect internalization yet direct degradation of 
IGF-II assay approach.  We added 125I-IGF-II tracer to the low-serum (3%) growth 
medium at time zero of the treatment period, and then tracked recovery in the 
conditioned medium for up to 72 h by counting the TCA-soluble and insoluble radioactive 
material remaining in the conditioned medium over time.  Intact IGF-II precipitates when 
the CM is treated with 46% TCA while any low-molecular weight (degraded) radiolabeled 
fragments of IGF-II are recovered in the supernatant.  The rationale behind this 
approach is that M6P/IGF2R-mediated uptake of the labeled IGF-II by cells followed by 
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intracellular ligand degradation would tend to deplete the intact IGF-II from CM and 
increase the amount of radiolabeled breakdown products released. 
To test this approach, SK-N-AS, HuH-7 and Capan-1 cells were grown in 24-well 
plates until near confluency.  The treatments were initiated by adding low-serum medium 
supplemented with 0.3 nM 125I-IGF-II and 1 nM cold carrier IGF-II.  Cells were treated 
with 50-100 nM PMP-OVA, 100 or 200 nM IGF-II, 10 mM M6P, 50 nM sM6P/IGF2R, 
combinations of the treatments, or vehicle control HBS.  Aliquots were taken at 0, 6, 24, 
48, and 72 h time points.  The purpose of adding the cold carrier IGF-II was two-fold: 1) 
it served to block binding of the radiolabeled IGF-II to binding proteins and non-specific 
extracellular binding surfaces and proteins, such as vitronectin (308) and 2) to simulate a 
reasonable concentration of pericellular IGF-II as might be encountered in vivo.  
Additionally, we increased the concentration of IGF-II to 100-200 nM in the treatment 
groups in order to function as a negative control to completely displace the radiolabeled 
IGF-II from the receptor, thereby increasing the amount of 125I-IGF-II in the insoluble 
pellet (intact 125I-IGF-II).  From our results we were able to indirectly detect 
internalization of 125I-IGF-II from the CM and directly detect degradation of the 
radiolabled growth factor in all cell lines tested, including HuH-7, Capan-1, SK-N-AS, 
JEG-3, and S2-013.  The 125I-IGF-II was internalized, degraded, and secreted back into 
the conditioned medium at a steady rate over the course of the assay as seen by a time-
dependent increase in radioactive counts in the TCA supernatant and a corresponding 
decrease of counts in the TCA pellet in HuH-7 cells (Figure 3.7A).  With the addition of 
PMP-OVA, there was an increase in IGF-II internalization as indicated by a sharp drop in 
the amount of TCA-precipitable IGF-II compared to the control after 2-3 days of 
incubation with the PMP-OVA.  Additionally, there was a more pronounced increase of 
radioactive material in the TCA supernatant (degraded IGF-II) when PMP-OVA was 
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added to the cells.  Interestingly, the overwhelming concentration of IGF-II (100-200 nM) 
behaved similarly to the control instead of protecting the 125I-IGF-II from degradation.  
However, when PMP-OVA and IGF-II are co-incubated, the multivalent M6P-based 
ligand is able to further promote IGF-II internalization and degradation, although not as 
strongly as the PMP-OVA alone.  Furthermore, M6P and sM6P/IGF2R partially inhibited 
PMP-OVA’s effect on internalization of the 125I-IGF-II.  In all treatment groups throughout 
the course of the assay, the radioactive material in the TCA supernatant and pellet 
yielded approximately an 80-100% recovery in amount of total cpm added to the assay 
(Table 3.3).  Therefore, from our 125I-IGF-II internalization assay, we can conclude that 
PMP-ligands are able to bind to the M6P/IGF2R and promote internalization and 

















Figure 3.7: Precipitation of 125I-IGF-II from CM by trichloroacetic acid (TCA). HuH-7 
cells were seeded into 24-well plates in complete medium and allowed to attach for 24 h 
before switching to reduced-serum medium supplemented with the various treatments 
plus 0.3 nM 125I-IGF-II and 1 nM cold carrier IGF-II.  The treatments were: IGF-II (100 
nM), PMP-OVA (100 nM) ± IGF-II (100 nM), or vehicle control.  At the indicated times, 
aliquots of the conditioned medium were treated with TCA (46% final concentration).  
After incubation on ice for 1 h, the samples were centrifuged and the amounts of 
radioactivity recovered in the pellet and supernatant fractions were measured.  A) These 
data were converted to percent recovery based on input radioactive IGF-II and plotted as 
indicated.  PMP-OVA treatment caused a significant increase radioactive material in the 
soluble fraction and a significant decrease in that of the insoluble fraction at both 24 h 
and 48 h compared to the control at 24 h and 48 h.  Data represent mean ± SEM (n=4); 
*, P<0.001.  B) The ratio of the TCA-soluble to TCA-insoluble radioactive material 
recovered at each time point was calculated and plotted vs. time for each treatment 















































































































Time Point % Recovery, Soluble % Recovery, Insoluble 
0 h 19.0 70.1 
24 h 21.6 69.8 
48 h 22.4 69.5 
72 h 23.4 66.2 
 
 
Table 3.3: Percentage of precipitable 125I-IGF-II in medium over the course of the 
125I-IGF-II degradation assay. The soluble fraction is the TCA supernatant (degraded 
IGF-II).  The insoluble fraction is the TCA precipitated protein (intact IGF-II). Medium 
was incubated in dishes and was not exposed to cells to determine the stability of the 
125I-IGF-II over the course of the study.  Since cells are not present to degrade the 125I-
IGF-II, the percent recovery of the radioligand from each fraction remained constant.  
Thus, we are able to determine the amount of radioactive counts that are attributed to 












C.5.  PMP-ligand effect on apoptosis in cancer cells 
Upon activation of the IGF1R or hybrid of IGF1R/IR-A via IGF-II binding, several 
different downstream signaling pathways can become activated.  One such final end-
state effect mediated through the PI3K/Akt survival pathway is decreased apoptosis, or 
programmed cell death.  To determine if PMP-ligands stimulate apoptosis due to IGF-II 
depletion, we performed a series of apoptotic studies.  Capan-1 and S2-013 pancreatic 
cancer cell lines and SK-N-AS neuroblastoma cells were seeded into 24-well plates and 
treated with 100 nM PMP-OVA, 10 nM IGF-II, PMP-OVA + IGF-II, or vehicle control 
HBS.  A set of wells was also treated with 400 µM palmitic acid as a positive control for 
apoptosis (320).  After 24 or 48 hours, cells were treated with DAPI, a fluorescent stain 
that binds A-T-rich regions of DNA, and tends to accumulate to a higher concentration 
indicated by increased fluorescence intensity in cells undergoing apoptosis (321, 322).  
Apoptotic and total cells were counted manually under fluorescence microscopy.  
Capan-1 cells treated with 100 nM PMP-OVA exhibited about a 5-fold higher number of 
apoptotic nuclei compared to the control (Figure 3.8A and 3.8C).  The addition of 10 nM 
IGF-II eliminated the increase in apoptosis back to the level of the vehicle control, while 
IGF-II on its own had fewer apoptotic nuclei than the control.  S2-013 cells had an 
overall similar response as the Capan-1 cells, with a 2.5-fold increase in apoptotic nuclei 
over the control in the PMP-OVA treatment and a slight but non-significant decrease in 
IGF-II-treated cells (Figure 3.8B and 3.8C).  The SK-N-AS cells had a higher resting 
number of apoptotic nuclei per 100 cells than the other cell lines, yet PMP-OVA 
increased the number of apoptotic nuclei approximately 3-fold compared to the control.  
The IGF-II-treated cells had a non-significant reduction in apoptotic nuclei while the add-
back of IGF-II again rescued PMP-OVA’s pro-apoptotic response (Figure 3.8B and 












Figure 3.8: Effects of PMP-OVA and IGF-II on apoptosis of cancer cell lines.  
Cancer cells were treated as indicated prior to DAPI staining of apoptotic nuclei.  A) 
Capan-1 cells were treated for 24 h and 48 h and B) S2-013 and SK-N-AS were treated 
for 24 h.  Cells were stained with DAPI and representative images were taken through 
fluorescence and phase contrast channels.  Apoptotic nuclei that appeared enlarged 
with bright staining or fragmented were counted manually from a field of 70-150 total 
cells.  C) The quantification of DAPI staining from the three cell lines tested with their 
respective SEM values plotted, (n=3). PMP-OVA treatment in Capan-1 and SK-N-AS 
cells had significant differences compared to control, p<0.001.  D) S2-013, Capan-1, and 
SK-N-AS cells were treated for 24 h before the caspase 3/7 activity assay was used to 
















































































To confirm via a biochemical indicator that apoptosis is induced by PMP-ligand 
treatment, S2-013 and Capan-1 cells and SK-N-AS cells were seeded into black, clear-
bottom 96-well plates.  Following a 24-hour incubation period of 100 nM PMP-OVA, 10 
nM IGF-II, PMP-OVA + IGF-II, or vehicle control HBS, a caspase 3/7 activity assay was 
performed following manufacturer’s instructions.  Interestingly, there was no significant 
increase in caspase activation in the S2-013 cell line, in contradiction to the DAPI 
staining, as all treatment conditions were lower than that of the control (Figure 3.8D).  
However, all treatment groups (PMP-OVA, IGF-II, and PMP-OVA + IGF-II) were 1.7-2-
fold higher in caspase 3/7 activity compared to the control in the Capan-1 cells.  
Moreover, SK-N-AS cells showed no significant change in the caspase 3/7 activity 
among the various treatment groups (Figure 3.8D).  From these data, the slight increase 
in apoptotic nuclei detected in the DAPI staining assay does not appear to be correlated 
with caspase 3/7 activation. 
To further investigate the role of apoptosis, we performed immunoblot analysis of 
different apoptotic markers in cell lysates following treatment with the aforementioned 
groups after a 24-hour incubation period.  Poly ADP ribose polymerase (PARP) is a 
nuclear-resident family of proteins involved in DNA repair that detects single-strand DNA 
breaks (SSB) by binding to the break and inducing a conformational change to recruit 
the DNA repair machinery.  In apoptosis, PARP is a downstream target of caspase 3 
and becomes cleaved, rendering it inactive and unable to bind to damaged DNA (323).  
We therefore looked at PARP1 to determine if the 116-kDa active protein is cleaved to 
89 kDa after PMP-OVA treatment.  Immunoblots of cell lysates treated with the various 
treatment groups.  The S2-013 pancreatic cancer cell line had a slight steady-state 
activation of PARP cleavage, and PMP-OVA slightly increased this activation (Figure 
3.9A and 3.9C).  Cells treated with the pan-caspase inhibitor Z-VAD-FMK (50 µM), 
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without the addition of PMP-OVA, showed no cleavage of PARP, but PMP-OVA slightly 
increased the PARP cleavage back to that of the control.  Leupeptin (230 µM) is a 
protease inhibitor that inhibits cysteine, serine, and threonine peptidases, such as 
cathepsins.  To determine if the slight apoptotic activation was a result of a caspase-
independent mechanism, we inhibited cathepsins with leupeptin, which increased the 
PARP cleavage, and PMP-OVA slightly though non-significantly synergized with 
leupeptin to enhance this effect.  Staurosporine (2 nM) is a kinase inhibitor (protein 
kinase C IC50=3 nM; cAMP-dependent protein kinase IC50=8 nM; p60v-src IC50=6 nM; IR 
IC50= 61 nM; IGF1R IC50=6,150 nM (324)) that was used as a positive control for 
apoptosis.  SK-N-AS neuroblastoma cells did not have a significant difference in PARP 
cleavage among the treatment groups and the control apart from the staurosporine 
treatment (Figure 3.9B and 3.9C). 
Myeloid cell leukemia-1 (Mcl-1) is a protein homologous to B-cell CLL/lymphoma 
2 (Bcl-2) and promotes cell viability, which mediates Bcl-2 antagonist killer (Bax) activity.  
Higher expression of Mcl-1 protects the cell from apoptosis (325-328).  Higher 
expression of Mcl-1 in tumor cells leads to poorer prognosis in patients with certain 
cancers, such as of the breast (327).  Alternatively, suppression of Mcl-1 expression in 
gastric cancers can increase the effectiveness of apoptosis-promoting chemotherapy 
(325) but knockout in normal murine hepatocytes leads to liver damage caused by 
increased apoptosis (326).  We investigated the expression of Mcl-1 using αMcl-1 
immunoblots that probed for both the long and short isoforms, where the long isoform 
enhances cell survival by inhibiting apoptosis and the short promotes apoptosis.  
Immunoblots probing for Mcl-1 were inconclusive for the S2-013 cell line, as we were 
unable to achieve a clear image with this antibody (Figure 3.9A).  Interestingly, it 
appears as if the cells express both isoforms under almost all of the conditions, except 
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staurosporine treatment, in which case cells expressed the long (cell survival) while the 
short (pro-apoptosis) was not detected.  We expected that the results for staurosporine 
would have been reversed.  SK-N-AS cells also showed interesting results, in which 
PMP-OVA treatment expressed the Mcl-1 long isoform more than any other treatment 
(Figure 3.9B and 3.9D).  IGF-II-treated cells, which we expected to have enhanced 
survival, expressed the short isoform, while staurosporine had very limited detection of 
either isoform yet normalized to higher expression of the short isoform.  The data from 
the Mcl-1 blots confound our DAPI staining data. 
The pro-apoptotic protein p53 upregulated modulator of apoptosis (PUMAα/β) 
inhibits cell growth by increasing apoptosis.  S2-013 pancreatic cancer cells expressed 
PUMA under all treatments.  Additionally, all treatments had elevated PUMA expression 
compared with the control, with even greater levels in the conditions treated with 
inhibitors against cathepsins (leupeptin), caspases (Z-VAD-FMK), or kinases 
(staurosporine) (Figure 3.9A and 3.E).  Treatment with these inhibitors increased 
activation of apoptosis, and co-treatment with PMP-OVA may further enhance the effect.  
However, PMP-OVA alone showed only a mild increase over the control, and rescue 
with IGF-II brought the levels of PUMA back to that of the control.  Staurosporine did not 
have as dramatic an impact on PUMA as it otherwise does on PARP cleavage, and 
















Figure 3.9: Effect of PMP-OVA and IGF-II on markers of apoptosis in cancer cells.  
A) S2-013 and B) SK-N-AS cells were incubated with various treatments: PMP-OVA at 
100 nM, IGF-II at 10 nM, Leupeptin (Leu) at 230 µM, the proteasome inhibitor FMK at 50 
µM, and staursporine at 2 nM.  Whole-cell lysates were prepared after 24 hours and 
subjected to immunoblot analysis to determine status of apoptosis markers. C) PARP 
cleavage of S2-013 and SK-N-AS; D) MCL-1 long (pro-survival) and short (pro-
apoptosis) isoforms of SK-N-AS; E) PUMA of S2-013 cells; and F) Cyclin D1.  The MCL-

































































































































































To further test if apoptosis is the cause of reduced cell viability, fluorescently 
labeled annexin V and propidium iodide (PI) staining using flow cytometry to visualize 
early and late stage apoptosis vs necrosis was used.  Annexin V is a calcium-dependent 
phospholipid-binding protein that specifically binds to phosphatidylserine (PS) residues 
on the outer cell membrane of cells targeted to undergo apoptosis.  The scramblase Xk-
related protein 8 (Xkr8), which is a type of flipase, flips PS from the inner to the outer 
leaflet of the plasma membrane when apoptosis is initiated (329).  Annexin V binds to 
the outer leaflet of the cell membrane and the allophycocyanin (APC) conjugated to 
annexin V fluoresces at a wavelength of 650/660 nm which indicates the stage of 
apoptosis.  PI is a fluorescent molecule that intercalates DNA and is a representative of 
total DNA content, which fluoresces at 535/617 nm.  With annexin V and PI staining, 
cells without staining for either molecule are the live population.  Cells stained with low 
annexin V but high PI are early-stage apoptotic cells, while cells with high annexin V and 
high PI staining are late-stage apoptotic cells.  The population that stains with high PI but 
low annexin V is considered to be the necrotic cells, i.e., the cells that are lysed quickly 
that do not have time for Xkr8 to flip the PS for annexin V to bind.  JEG-3 cells were 
treated with 200 nM PMP-OVA and compared to vehicle control (HBS) and the positive 
apoptosis control treatment, staurosporine (2 nM), and were analyzed on a Calibur III 
flow cytometer after 6 and 24 h treatments.  Unfortunately, the JEG-3 cells that were 
used for this experiment exhibited an unusually high background staining of annexin V 
that confounded interpretation of the results, as there was a high necrotic population 
following annexin V + PI staining in contradiction to the status of the cells prior to 
staining (Figure 3.10A).  Annexin V with PI staining was then repeated using Capan-1 
and HuH-7 cell lines.  These cell lines had better results than the JEG-3, but still had an 
increase in the necrotic population, even in the control group, indicating an issue with the 
staining protocol.  Nonetheless, there was an increase (8.2%) in early apoptosis with a 
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decrease of total cell viability (80%) following the 6-hour staurosporine treatment in the 
Capan-1 cells, which indicates that our positive control for apoptosis worked in this cell 
line.  However, there was no change between the 200 nM PMP-OVA treatments at 6 
and 24 hours and the control in the different subpopulations (Figure 3.10C).  In the HuH-
7 cells, there was not a change in the subpopulations within the staurosporine-treated 
cells and the 200 nM PMP-OVA or control groups, suggesting that this was a failed 
experiment, as any results could not be considered a true representation since the 
positive control for apoptosis did not work (Figure 3.10B).  These studies were 
performed only once in each cell line and would need to be repeated to have a proper n 
value in order to do statistical analysis for determination of the apoptotic effect from 
PMP-ligand treatments.  
In toto for the cell death studies, PMP-ligand treatment on its own may slightly 
increase apoptosis compared to the vehicle control in IGF-II-dependent cancer cells.  
However, the results do not fully agree from experiment to experiment using different 
biomarkers for cell death, which may be accounted for by differences in responsiveness 
to IGF-II, potency of different ligand preparations, or loss of the IGF-II-dependent growth 












Figure 3.10: Effects of PMP-OVA on apoptosis of cancer cell lines using annexin V 
staining and flow cytometry analysis.  A) JEG-3 choriocarcinoma, B) HuH-7 
hepatocellular carcinoma, and C) Capan-1 pancreatic carcinoma cells were treated with 
PMP-OVA or the positive apoptosis inducer staurosporine for 6 to 24 h and then stained 
with annexin V and 7AAD prior to flow cytometry analysis.  Viable (black), early 
apoptosis (blue), late apoptosis (purple), and necrotic (red) cells were gated and the 























































































To determine if autophagy may play a role either by decreasing apoptosis and 
increasing cell survival in control cells or if our PMP-ligands interfere with autophagy that 
they initiate cell death, we investigated the formation of autophagosomes.  To study this, 
we used a series of confocal and fluorescent microscopy approaches as well as 
immunoblot analysis of LC3-I conversion to LC3-II, mTOR activation, and subsequent 
p70S6 kinase activation, which is a main effector targeted by activated mTOR (330). 
SK-N-AS cells were grown to 70-80% confluency and then treated with 200 nM 
PMP-OVA, 10 nM IGF-II, 200 nM PMP-OVA, + 10 nM IGF-II, or vehicle control (HBS) for 
24 hours.  Whole-cell extracts were prepared and subjected to immunoblot analysis.  
IGF-II increased mTOR phosphorylation compared to control, but PMP-OVA did not 
affect phosphorylation of mTOR (Figure 3.11A and 3.11B).  The addition of the IGF-II 
ligand trap (soluble M6P/IGF2R) decreased phosphorylation of mTOR, as predicted.  
These results were extended to the phosphorylation of mTOR’s substrate, p70S6K, 
where IGF-II enhanced phosphorylation of this protein but PMP-OVA did not have much 
of an effect.  The decreased activation of mTOR in the sM6P/IGF2R cells was not seen 
in the phosphorylation of p70S6K (Figure 3.11A and 3.11C).  In the LC3 immunoblot, 
SK-N-AS cells experience a steady-state of conversion of LC3-I to LC3-II.  All treatments 
had slightly more LC3-II than the control but differences were not significant (Figure 
3.11A and 3.11D).  However, these data do not necessarily indicate changes in 
autophagy flux, as LC3-II becomes degraded by autophagy (331).  Furthermore, there 
may not be an issue with the autophagosome formation but the fusion of 






Figure 3.11: Effect of PMP-OVA on autophagy markers in SK-N-AS cancer cells.  
A) Immunoblots of autophagy markers: LC3 conversion, and phosphorylation of mTOR 
and the mTOR target p70S6K.  Quantification of change caused by the treatments 
compared to control for B) mTOR phosphorylation normalized to total mTOR; C) p70S6K 
phosphorylation normalized to total p70S6K for both the upper (80 kDa) and lower (75 
kDa) bands; and LC3-I conversion to LC3-II. 
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We next grew SK-N-AS cells on collagen-coated coverslips for 
immunofluorescent microscopy.  We treated the cells with 100 nM PMP-OVA and 
vehicle control HBS with or without 50 nM bafilomycin for 24 h.  Bafilomycin is an 
inhibitor of vacuolar-type H+-ATPase that blocks the maturation of autophagosomes by 
preventing the fusion of autophagosomes with lysosomes (332).  The bafilomycin was 
then washed out and cells were incubated with their treatments for an additional 1 to 9 h.  
The cells were fixed, permeablized and incubated with an α-LC3 (marker of 
autophagosomes) antibody and LAMP1 (marker of lysosomes) antibody.  Cells were 
then incubated with secondary antibodies conjugated to AlexaFluor 488 (LC3) and 568 
(LAMP1) as well as DAPI to stain the nucleus.  The subcellular compartments were then 
visualized on a confocal microscope.  Initial studies did not reveal much difference 
among the various treatment groups when comparing the autophagosome size and 
number to the lysosomes (data not shown).  There was also not a distinct difference in 
colocalization of the two markers, indicating that there was not a significant difference in 
autophagy among the different treatments.  Interestingly, the morphology of the PMP-
OVA-treated groups had changed slightly compared to the control or other treatment 
groups.  The PMP-OVA-treated cells were more elongated with a disordered plasma 
membrane, and the nuclei appeared to be larger and more bi- and multinucleated 
compared to the control.  The experiment was repeated using phalloidin (a dye that 
binds specifically to elongated actin filaments) and DAPI staining to visualize any actin 
cytoskeleton rearrangement that may occur due to PMP-OVA treatment, and the cells 
were viewed on both confocal and fluorescent microscopes (Figure 3.12).  Upon 
treatment with PMP-OVA, the actin cytoskeletal structure appeared to reorganize in 
more parallel bundles that appeared to avoid the nuclei while the control actin 
cytoskeleton revealed a cell that was more at rest with actin bundles crossing different 




Figure 3.12 Anomalous effect of PMP-OVA on the actin cytoskeleton.  Actin 
filaments were stained with phalloidin (green) and the nuclei were stained with DAPI 
(blue) to visualize morphological changes and actin bundling as a result of treatment of 
the cells with 200 nM PMP-OVA for 24 h.  Cells treated with PMP-OVA displayed 








OVA treatment, similar to the previous studies.  In conclusion from these studies, PMP-
ligand treatment affects the cancer cells in some way, but whether it is downstream of 
IGF-II depletion or an off-target effect of the ligand directly is still not known and would 
need to be investigated further. 
 
C.6.  PMP-ligand effect on cell cycle progression in cancer cells 
Our laboratory has seen that PMP-ligand treatment reduces cell viability, but it is 
unknown what the underlying mechanism that decreases cell number is.  Mitogenic IGF-
II activation of IGF1R and IGF1R/IR-A leads to accelerated cell cycle progression and 
proliferation via mitosis (203).  The cell cycles of S2-013, SK-N-AS, JEG-3, Capan-1, 
and HuH-7 cancer cell lines were investigated using flow cytometry by three different 
methods. 
Initial experiments examined cell cycle progression in S2-013 cells following 100 
nM PMP-OVA treatment with or without 10 nM IGF-II, 10 nM IGF-II, or vehicle control 
HBS and compared to the apoptotic positive control staurosporine using propidium 
iodide (PI) staining, which binds DNA following permeabilization of the plasma 
membrane prior to analysis on a Calibur I flow cytometer.  Results revealed small, but 
not significant differences within the G0/G1 and G2 phases between the PMP-OVA- and 
control-treated groups, with only a slight yet non-significant decrease in the S-phase of 
PMP-OVA-treated cells (Figure 3.13A).  There was a distinct G2 cell cycle arrest in the 
positive control staurosporine.  The lack of cell cycle arrest following PMP-OVA 
treatment may be due to the fact that S2-013 cells are not responsive to IGF-II or our 
PMP-ligands.  The cell cycle arrest analysis was then performed using SK-N-AS cells.  
The control and PMP-OVA-treated cells were comparable, but the PMP-OVA cells had a 
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slight increase in the G2 but not the subsequent decrease in G1 that would further 
support cell cycle arrest (Figure 3.13B).  The lack of a significant difference in the cell 
cycle phases between the treatment groups may be due to the fact that these cells were 
asynchronous with pools of cells in various points of their cell cycle, and they progress 
through their cell cycle relatively slowly (doubling t = 39 h).  To test the effect in 
synchronized cells, we did a double thymidine block over the course of 40 h before the 
cells were treated with 200 nM PMP-OVA and compared to vehicle control (HBS).  A 
plate of cells was collected and fixed every 2 hours until 12 h as well as a 24 h time point 
before staining with PI following flow cytometry analysis.  Much to our disappointment, 
the cell cycle histograms of PMP-OVA appeared very similar to the histograms 
representing the control (Figure 3.13C).  There was not a gradual progression through 
the cell cycle phases that may be attributed to the slow progression of these cells or that 
these cells were not released from the double thymidine block.  JEG-3 cells were used 
for their faster cell cycle progression (doubling t ≈ 24 h); these cells were synchronized 
after serum deprivation for 72 hours, and then treated with 200 nM PMP-OVA or vehicle 
control (HBS).  The histograms of the two groups over the course of the study revealed a 
progression through the cell cycle in which the PMP-OVA-treatment lagged slightly 
behind the control (Figure 3.13D).  At the 10-h time point, the PMP-OVA-treated cells 
had a slight decrease in the G1 phase with a slight increase in the G2 phase compared 
to the control that progressed to a greater difference at 24 h.  This indicates that the 
PMP-OVA is causing a slower cell cycle progression in JEG-3 cells, but is not 
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Figure 3.13: Analysis of the effects of PMP-OVA on the cell cycle in S2-013 and 
SK-N-AS.  Unsynchronized A) S2-013 pancreatic cancer cells and B) SK-N-AS 
neuroblastoma cells were treated with 200 nM PMP-OVA, 10 nM IGF-II, 230 µM 
leupeptin (leu),  50 µM Z-VAD-FMK (FMK), 2 nM staurosporine, combinations of these 
or control (HBS) for 24 h prior to PI staining and flow cytometry analysis.  Each bar 
depicts the number of cells gated in each cell-cycle phase in the various treatment 
groups. C) SK-N-AS neuroblastoma cells were synchronized using a double thymidine 
block prior to 24 h incubation with 200 nM PMP-OVA or the control. D) JEG-3 
choriocarcinoma cells were synchronized using a 48 h serum deprivation protocol prior 
to 24 h incubation with 200 nM PMP-OVA or the control.  Both SK-N-AS and JEG-3 cells 
were fixed and stained at the time indicated before flow cytometry analysis.  These cell 









Table 3.4: Summary of flow cytometry analysis of PI-stained S2-013 and SK-N-AS. 
Unsynchronized cancer cells were treated as indicated in Figure 3.14.  These data are 
tabulated as percentage of cells gated in G0/G1, P, or G2/M phases. 
 
 
 S2-013   SK-N-AS   
Treatment G0/G1 S G2/M G0/G1 S G2/M 
Control 40 48 12 56 26 18 
PMP-OVA 43 44 13 57 22 21 
IGF-II 42 38 20 57 24 19 
PMP-OVA + IGF-II 39 47 14 53 23 24 
Leupeptin 44 47 9 57 24 19 
PMP-OVA + Leu 42 46 12 54 25 22 
FMK    67 17 15 
PMP-OVA + FMK    63 19 19 
Staurosporine 15 51 35 45 24 19 
DMSO 41 41 18 57 34 20 
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Although PI staining alone through flow cytometry analysis is one of the standard 
methods of cell cycle progression, this type of analysis visualizes total DNA content 
within the different phases at a certain point in time.  However, it does not take into 
consideration the number of cells that have progressed through DNA synthesis to 
different phases.  We were interested to see how many cells were currently undergoing 
DNA replication following treatment by using 5-bromo-2’-deoxyuridine (BrdU) 
incorporation coupled with PI staining and analysis using flow cytometry.  BrdU is a 
homolog of thymidine that is incorporated into the DNA during DNA synthesis in 
replicating cells.  Following a fixation/permeabilization and DNA nicking step, a 
fluorescently tagged antibody recognizes incorporated BrdU in the DNA.  SK-N-AS cells 
were treated for 24 h with 100-200 nM PMP-OVA with or without 10 nM IGF-II, 10 nM 
IGF-II, or the cell cycle inhibitor paclitaxel (5 or 50 nM) and compared with the vehicle 
control.  Following a 3-h incubation with BrdU, the cells were fixed and permeabilized, 
treated with DNase and an αBrdU-APC antibody, and analyzed on a Calibur III flow 
cytometer.  Studies have shown that when cells are treated with paclitaxel at a 
concentration below the IC50 value, cells undergo G2/M cell cycle arrest (333); treatment 
with higher concentrations induce apoptosis.  Therefore, we used two concentrations to 
find which provided cell cycle arrest without inducing apoptosis.  When SK-N-AS cells 
were treated with 5 nM paclitaxel for 24 h, there were more cells in G2/M with fewer in 
G0/G1, indicative of a G2/M block.  Paclitaxel at 50 nM for 6 h was also able to induce 
G2/M cell cycle arrest, but it was not as dramatic as the cells treated with the longer, 
lower concentration (Figure 3.14).  PMP-OVA at 200 nM had fewer cells in the G0/G1 
phase, although there was not a corresponding increase in the S- or G2/M phases.  This 
study was performed only once in one cell line and needs to be validated to determine if 







Figure 3.14: BrdU incorporation of SK-N-AS following treatments to determine cell 
cycle progression.  Actively dividing cells incorporated BrdU into their DNA, and a 
APC-lablled BrdU and 7AAD stain indicated the cell cycle phase of cells.  Notice that 
200 nM PMP-OVA and 24 h of 5 nM paclitaxel had fewer cells that could be gated, 
























































































To investigate the signaling that influences cell cycle progression, immunoblots 
of key effectors in the Akt and ERK pathways were performed to measure possible 
activation by phosphorylation.  SK-N-AS cells were grown to 70-80% confluency and 
treated with 100 nM PMP-OVA, 10 nM IGF-II, PMP-OVA + IGF-II, 10 nM sM6P/IGF2R, 
sM6P/IGF2R + IGF-II, or vehicle control (HBS) for 24 hours.  Whole-cell extracts were 
then subjected to SDS-PAGE followed by immunoblot analysis.  The phosphorylation of 
Akt at Thr308 or Ser473 was not noticeably different among the treatment groups 
compared to control (Figure 3.15).  However, there was an increase in ERK1/2 
phosphorylation as a result of IGF-II treatment.  Furthermore, PMP-OVA did not affect 
ERK1/2 phosphorylation, but it appears that IGF-II is signaling through the MAPK/ERK 
pathway upon activation of the receptor tyrosine kinases in these cells.  Additionally, p53 
in SK-N-AS cells was investigated, as this protein is an important master regulator of the 
cell that has many targets, including cell cycle arrest and initiation of apoptosis (334).  
However, there was no change in p53 levels among the different treatments and further 
investigation of the literature revealed that this cell line has a mutant but inactivated p53 
protein; thus, p53 is not regulating the cell cycle or apoptosis in these cells at all.  Cyclin 
D1 protein levels in both cell lines were also not significantly different from the control 
cells (Figure).  This may be because the whole-cell lysates used in these immunoblots 
were from non-synchronized cells.  Clearer results of more minute differences may be 
obtained by first synchronizing the cells prior to treatment. 
 In summary, our cell cycle analyses indicate that it appears as if IGF-II 
signals through the MAPK/ERK pathway in these cells, but the presence of PMP-
OVA does not inhibit this signaling.  Additionally, there may be a slight slow-down in 











Figure 3.15: Effect of PMP-OVA on mitogenic and survival response to PMP-OVA 
treatment in SK-N-AS cells.   Cells were treated with 200 nM PMP-OVA, 10 nM IGF-II, 
10 nM sM6P/IGF2R (sIGF2R), or combinations for 24 h and compared to the control 
(HBS).  A) Immunoblot analysis of cell lysates probing for effectors of mitogenic and 
survival signaling.  Quantification of phosphorylation of B) Akt at Thr308 and Ser 473 
and C) ERK1/2.  Note the scale difference between pAkt and pERK, as pAkt appears to 
have a higher basal activity in all treatments, but pERK seems to have a higher 









cell cycle arrest.  These experiments need to be validated with synchronized cells to 
determine if the PMP-ligands are truly regulating the cell cycle. 
 
C.7.  PMP-ligand effect on migration of cancer cells 
To determine if PMP-ligands affect the migration potential of cancer cells, we 
performed scratch wound healing assays and transwell migration assays using 
microscopy and fluorescent microscopy, respectively.  HuH-7, Capan-1, and JEG-3 cells 
were seeded into 6-well plates and grown to 80% confluency.  Three scratches per well 
were made using a sterile pipette tip and 6 images per well were taken, designated as 
the 0 hour time point.  Cells were treated with 100 or 200 nM PMP-OVA, 10 nM IGF-II, 
or vehicle control HBS.  Images were taken every 24 hours until 96 hours.  Interestingly, 
PMP-OVA did not inhibit the migration potential of the cancer cells but rather increased 
the rate of wound closure.  This may be due to the fact that such a high concentration of 
PMP-ligand was used that may have caused a more chemotactic response and closure 
of the wound.  Additional studies using lower concentrations of PMP-ligand need to be 
performed to validate the wound closure data. 
In the transwell migration assay, HuH-7 cells were seeded into 24-well inserts in 
serum-free medium and inserted into the well of the 24-well plate, which contained the 
treatments (100 nM PMP-OVA, 10 nM IGF-II, PMP-OVA + IGF-II, or vehicle control 
HBS) in 3% serum-containing medium.  After 24 hours, the membranes were retrieved, 
cells were fixed and stained with DAPI, and the membranes were imaged under 
fluorescent microscopy.  In this preliminary study that was performed only once, PMP-







Figure 3.16: Effect of PMP-OVA on migration of cancer cell lines.   
A) A representative set of images from a 96-h scratch assay of Capan-1 cells.   
B) A representative set of images from a 48-h transwell assay of HuH-7 cells. 
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Interestingly, IGF-II did not enhance the migration as we expected. These preliminary 
results need to be validated with more replicates and additional cell lines. 
 
D.  Discussion 
The M6P/IGF2R functions to transport acid hydrolases to the lysosome as well 
as traffic extracellular M6P-tagged glycoproteins and non-glycosylated proteins to the 
lysosome for degradation.  These proteins bind to the receptor at different binding sites, 
where M6P-tagged proteins bind with high affinity to repeats 3 and 9, lower affinity to 
repeat 5, with very low binding to repeat 15, while IGF-II binds to repeat 11 with the aid 
of the fibronectin-like type II domain (FnII) of repeat 13 (46, 101, 279).  Having these 
distinct binding domains allows the M6P/IGF2R to be multifunctional.  Multivalent M6P-
based biding accelerates the M6P/IGF2R internalization rates 3-4-fold above its steady-
state constitutive internalization, while simultaneously allowing IGF-II to bind to a 
separate location and act as a passenger ligand (131).  This enhanced internalization 
was due to ligand-induced M6P/IGF2R dimerization, which may occur through 
increasing receptor’s internalization signals within the cytoplasmic tail or a 
conformational change that allows the internalization signal to be presented in a more 
optimum manner (131).  Furthermore, the M6P-modified glycoprotein, CREG, could bind 
to the M6P/IGF2R and induce cell cycle arrest via increased internalization of IGF-II from 
the cell milieu (163, 228, 229, 335).  To date, no studies have clearly characterized this 
multivalent binding interaction and subsequent IGF-II degradation, but this led us to 
exploit the M6P/IGF2R as a potential therapeutic approach in targeting IGF-II-dependent 
cancers.  Having a role in development and differentiation, IGF-II expression is often 
increased in cancers (243-247, 336).  Therefore, our laboratory developed and tested a 
panel of pseudoglycoprotein ligands with varying molecular sizes and number of M6P 
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moieties to determine whether high affinity, bi- or multivalent M6P-based ligands could 
bind to the M6P/IGF2R and decrease cell viability.  The goal of this study was to 
determine if these high-affinity M6P-based ligands could force internalization, 
degradation and consequent depletion of extracellular IGF-II and thereby decrease cell 
viability. 
There have been only a few studies that have targeted the M6P/IGF2R as a 
therapeutic measure.  Human serum albumin modified with M6P moieties has been 
used to target the M6P/IGF2R as a conduit to deliver both anti-fibrotic and anticancer 
drugs into cells (337, 338).  Also, synthetic M6P-mimetics have been developed that 
bind to the M6P/IGF2R with similar or slightly better affinity than the monovalent ligand 
M6P (312, 313, 339, 340), but some of these mimetics did not have cytotoxic effects on 
cells (340).  Therefore, to date there are no reports of synthetic M6P-based ligands that 
are capable of binding the M6P/IGF2R with bivalent binding similar to the natural ligand 
hGUS.  Consequently, we are the first lab to our knowledge to design such ligands to 
help provide proof-of-principle evidence that they may be useful in treating IGF-II-
dependent cancers.   
Tong et al. determined that a ligand bearing two M6P moieties bound to the 
M6P/IGF2R with 100-1000-fold higher affinity than what the monovalent M6P is able to 
achieve (93).  Previous studies determined that our PMP-ligand panel does bind to the 
M6P/IGF2R with high-affinity implying bivalency, fulfilling this increased affinity 
requirement (Figure 3.1); even the smallest bidentate PMP-tripeptide (PMP-SYK) could 
achieve bivalency.  Moreover, these ligands can stabilize the dimeric M6P/IGF2R and 
bind to M6P-binding repeats on different monomers of the dimeric receptor, which is also 
required for rapid internalization of the M6P/IGF2R as seen with hGUS (131).  These 
ligands were also able to decrease cell viability in a M6P- and IGF-II-dependent manner.  
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The aim of the current study was to determine if IGF-II in the conditioned medium was 
internalized and degraded in a similar fashion as CREG (163, 335) and to delineate the 
effect(s) these PMP-ligands have on cellular function. 
Incubation with the PMP-ligand PMP-OVA reduced viability of mouse L-cells and 
two cancer cell lines (HuH-7 and JEG-3).  This was dependent on binding through the 
M6P moieties of our PMP-ligand as M6P competitively displaced our ligand.  
Furthermore this effect appeared to decrease cell viability through the depletion of IGF-
II, as exogenous IGF-II rescued the growth inhibition effect.  We therefore applied the 
cell viability assay in several cancer cell types.  We first screened cells for their ability to 
respond to exogenous, recombinant IGF-II and determined whether they have an intact 
autocrine or paracrine loop (Figures 3.4).  In summary, cells that were poorly 
differentiated tend to be less IGF-II-dependent and had a decreased responsiveness to 
our PMP-ligands.  These included the pancreatic carcinoma cell lines MiaPaCa-2 and 
PANC-1, and the prostate carcinoma cell line DU145.  Several cell lines responded 
moderately well, which happen also to be moderately-to-well differentiated cancer cell 
lines.  These include pancreatic adenocarcinoma cell line Capan-1, hepatocellular 
carcinoma cell line HuH-7, choriocarcinoma cell line JEG-3, and embryonal 
neuroblastoma SK-N-AS.  However, the well-differentiated cell line S2-013 did not have 
much of a response, indicating that all well-differentiated cancer cells may not be equal. 
The poorly differentiated cell lines may have additional genetic alterations that allow for 
more aggressive cell growth, resistance to therapy, and lack of IGF-II-dependency 
making it difficult for the PMP-ligands to overwhelm the cells with IGF-II-deprivation and 
decreased cell viability.  They may also have a higher basal activation of the receptor 
tyrosine kinases that make it more difficult to inhibit the activation of these receptors and 
subsequent pro-survival signals.  The moderately well differentiated cells may have 
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more intact IGF signaling and a greater dependency on IGF-II, even in cell systems that 
produce their own IGF-II, that our PMP-ligand treatment deprives the cells of 
endogenous and exogenous IGF-II more readily, leading to the greater decrease in cell 
viability.  If this is true, then our ligands will work most effectively in perhaps earlier-stage 
tumors that have not lost their differentiation status and that retain dependency on IGF-
II.  Additionally, the differences in response to PMP-ligand treatment in the various 
cancer cell lines could also be partly explained by the number of available M6P/IGF2R 
on their plasma membranes.  The cancer cell lines all have varying concentrations of 
M6P/IGF2R on their plasma membranes, which allows for varying potentials of PMP-
ligand binding to a dimer or oligomer.  In the case of IGF-II-dependent tumors that do not 
express the M6P/IGF2R, our ligands may still work at inhibiting tumor growth by 
targeting cells within the tumor microenvironment that express M6P/IGF2R, such as 
normal fibroblasts or cancer-associated fibroblasts (CAFs), and thereby decrease IGF-II 
in the tumor EC matrix via a bystander effect.  However, this would need to be 
investigated further. 
In order to validate that our PMP-ligands work the same way as CREG, in which 
multivalent M6P-ligands inhibit cell viability by increasing the rate of internalization of 
IGF-II (163, 228, 229, 335), we needed to design an internalization assay sensitive 
enough to detect the minute changes in IGF-II within the conditioned medium following 
the different treatments.  Our 125I-IGF-II internalization assay followed by TCA-based 
precipitation revealed that 100 nM PMP-OVA was able to deplete intact IGF-II from the 
medium and increase the amount of radiolabeled species derived from IGF-II 
degradation (Figure 3.7).  These observations strongly imply that the PMP-ligand 
treatment accelerated the internalization and subsequent degradation of 125I-IGF-II from 
the conditioned medium compared to the vehicle control.  IGF-II is precipitable in TCA as 
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demonstrated by our validating assay, so the increase in radioactive material in the TCA 
supernatant fraction reflects the amount of 125I-IGF-II that was internalized and 
degraded, with the soluble remnants secreted back out into the conditioned medium.  As 
expected, the addition of 100 nM IGF-II protected the 125I-IGF-II tracer from this process, 
as indicated by increased radioactive counts in the TCA pellet.  Much to our surprise, 
cells that are not as responsive to our PMP-ligands still have a slight enhancement of 
125I-IGF-II internalization following treatment with the multivalent M6P-based ligand.  This 
may be due to the cells expressing the M6P/IGF2R on their plasma membranes despite 
the lack of IGF-II stimulation of the receptor tyrosine kinases. 
It is evident that our synthetic, multivalent M6P-based ligands bind to the 
M6P/IGF2R and accelerate IGF-II internalization, but the mechanism by which cell 
viability was decreased appears to be a complex story following IGF-II depletion.  
Apoptosis is occurring at a basal level in the cancer cells we investigated.  PMP-OVA 
treatment appears to increase the number of apoptotic nuclei in IGF-II-dependent cancer 
cells, but may not be completely dependent on caspase 3 activation.  The depletion of 
IGF-II from the cell milieu would cause decreased activation of the IGF1R and IGF1R/IR-
A hybrids.  Since inhibiting apoptosis and promoting survival are downstream outcomes 
of receptor tyrosine kinase activation, it is expected that apoptosis would increase.  
However, we did not see a significant activation of pro-apoptotic proteins from PMP-OVA 
alone.  This may not be attributed to an increase of apoptosis initiation but rather cells 
are unable to inhibit the progression of apoptosis following exposure to our multivalent 
M6P-based ligands.  Apoptosis is reversible to a point, until it reaches a point of no 
return (341).  Perhaps our ligands cause the cells to have a deficiency in reversing the 
apoptosis initiation.  In the apoptotic immunoblot analysis, PMP-OVA alone did not have 
much of an effect but enhanced the MCL-1 and PUMA protein quantification in response 
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to leupeptin or Z-VAD-FMK.  This raises the possibility that PMP-OVA may work 
synergistically with another drug in a combination approach.  This is a possibility that 
would need further investigation. 
 Autophagy is a cellular process that can result in caspase-independent cell 
death.  We investigated the conversion of LC3-I to LC3-II between PMP-OVA-treated 
cells and control.  There was not a significant change in LC3 conversion that was 
noticed in immunoblots of whole cell lysates or immunofluorescent staining of the cells.  
However, this does not indicate that autophagy flux is unchanged, as there could be an 
issue with the fusion of autophagosomes to lysosomes, which was not investigated in 
our studies. 
Migration and wound closure studies were only preliminary investigations and 
need to be addressed further.  However, our data support the need to validate these 
studies.  The scratch wound healing assay gives the impression that PMP-OVA 
treatment may accelerate the rate of closure.  However, this may be a chemotactic 
phenomenon given the high concentrations of the ligand used, and that this preparation 
was different from the ligand used in earlier scratch assays.  Much to our surprise, IGF-II 
did not enhance the closure of the wound in our assays.  Conversely, PMP-OVA 
seemed to attenuate the migration of cells across the membrane of a transwell assay, 
but it did not inhibit migration completely.  IGF-II also did not enhance migration in this 
study.  It is hoped that additional studies will clarify these contradictory results. 
In conclusion, our studies further contribute to the understanding of high-affinity, 
multivalent M6P-based binding to the M6P/IGF2R and the subsequent implications for 
cancer cell biology.  Based on these data and what we currently know about the receptor 
biology, rapid internalization of the M6P/IGF2R occurs through dimerization, where 
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multiple contacts of the monomers across the EC domain are made (140).  This 
dimerization is stabilized with multivalent M6P-based ligands that bind to the M6P-
binding sites on each monomer of the receptor dimer.  Our PMP-ligands are believed to 
bind to repeat 3 on the receptor dimers and mediate the accelerated internalization of 
IGF-II.  Our hypothesis is supported by work done using CREG, a glycoprotein with 
multiple M6P moieties, and hGUS, a highly glycosylated lysosomal hydrolase.  However, 
further studies need to be done to determine the exact mechanism by which the 
depletion of IGF-II from the cell milieu reduces cell viability following treatment with our 
PMP-ligands.  We have designed the first synthetic high-affinity, bivalent M6P-based 
ligands that bind to the M6P/IGF2R, providing support for exploiting this receptor in IGF-
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A.  Summary 
Bivalent M6P-based ligands bind to the M6P/IGF2R with high affinity and cause 
increased internalization and subsequent degradation of IGF-II in the lysosome, which 
has potential as a novel therapeutic approach against IGF-II-dependent cancers.  Our 
laboratory has synthesized a panel of high-affinity, bivalent ligands to target the 
M6P/IGF2R; however, our ligands are susceptible to hydrolysis by phosphatases, 
rendering them ineffective in an in vivo system, such as mouse or human.  Thus, in 
collaboration with Dr. David Berkowitz’s lab in the Department of Chemistry at the 
University of Nebraska-Lincoln, we synthesized phosphatase- and protease-resistant 
analogs of M6P-based ligands.  Two panels of bidentate mannose 6-phosphonate 
ligands (termed “molecular rulers”) have been synthesized using different chemical 
strategies and their binding to the M6P/IGF2R was examined.  The first set of ligands 
used different linker structures to determine if the linker influences binding of the M6P-
based surrogates to the M6P-binding site.  Our data indicate that the linkers in the cisoid 
conformation produce better binding than those in the transoid conformation.  The 
second set of M6P-based surrogates had varying tether links to determine the distance 
required to span the M6P binding sites of the dimeric M6P/IGF2R.  Increased binding 
affinity is correlated with increased tether length until a certain number of atoms is 
achieved, after which the affinity decreased most likely due to conformational flexibility 
and instability of the tether linker.  Although our M6P-based surrogates bind the 
M6P/IGF2R, we were unable to produce true bivalent interaction, as determined through 
competitive displacement assays in comparison with the known monovalent binding of 
M6P.  However, synthesis of a phosphatase-resistant ligand for the M6P/IGF2R could 
impact the treatment of IGF-II-dependent cancers by offering a more stable molecule 
that, if it binds with high-affinity and increases the internalization rate of IGF-II, can be an 
effective chemotherapeutic agent. 
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B.  Rationale 
The M6P/IGF2R binds M6P-capped ligands with high affinity and traffics them to 
the lysosome, while IGF-II binds to a separate EC domain of the receptor and is 
internalized and degraded in the lysosome.  Having separate binding sites for the 
different types of ligands allows this receptor to function as a novel tumor suppressor 
that can be exploited as a possible therapeutic target against IGF-II-dependent cancers.   
Our PMP-ligands discussed in chapter III of this dissertation bound to the M6P/IGF2R 
with high-affinity bivalency that was able to decrease cell viability by internalization of 
IGF-II and subsequent degradation of the growth factor.  A shortcoming of our panel of 
M6P-based ligands is that they are susceptible to degradative activities—hydrolysis by 
glycosidases, proteases and phosphatases, and thus may not survive in the circulation 
long enough to target a tumor.  Therefore, we set out to design a panel of M6P-mimetics 
that would bind with high affinity to the M6P/IGF2R yet resist hydrolysis and degradative 
inactivation. 
It was determined that there are two M6P-binding sites per monomer of 
M6P/IGF2R (93).  Simultaneous contacts with two separate M6P groups on distinct 
oligosaccharides or a single oligosaccharide with at least two M6P caps can bind to the 
M6P/IGF2R’s binding sites with high affinity (95).  This interaction can improve the 
binding affinity by 100- to 1000-fold by lowering the dissociation constant, when 
compared to a monovalent interaction, such as binding of M6P alone.  The increased 
binding affinity of the M6P-containing ligands for the M6P/IGF2R promotes 
intermolecular cross-bridging interactions by the oligosaccharide occupying M6P-binding 
sites on both monomers of a dimeric receptor (93).  A lysosomal enzyme containing 
multiple M6P moieties, human β-glucuronidase (hGUS), is able to increase the rate of 
125I-IGF-II internalization while a bivalent synthetic tripeptide can bind both M6P-binding 
sites on the same M6P/IGF2R monomer simultaneously is unable to accelerate the rate 
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of internalization through intramolecular contacts (131).  This indicates that the 
accelerated internalization of the M6P/IGF2R results from intermolecular cross-bridging 
as opposed to intramolecular interactions. 
Greater binding affinity of the M6P moiety to the M6P/IGF2R can be achieved 
with an α(1,2)-glycosidic linkage between the ultimate and penultimate mannose groups 
on the oligosaccharide.  There is a slight reduction when this linkage is α(1,3) (95).  
Additionally, a synthetic panel of multivalent ligands for the M6P/IGF2R that was 
prepared using a glycopeptide approach demonstrated that compounds containing two 
M6P residues bonded to a core peptide of three to five amino acid residues were more 
suitable for high-affinity binding to the M6P/IGF2R (342).  This suggested that bivalent 
binding was occurring.  Incidentally, further investigation showed that the affinity of the 
high-affinity tripeptide was attributed to anthranilic acid on the lysine ε-amino group that 
increased binding by 1500-fold compared to M6P.  Removal of this anthranoyl group 
decreased the binding affinity by 20-fold (342), indicating that this group was a 
contributor for the high-binding affinity, possibly through interactions with a hydrophobic 
patch near the M6P-binding site on the receptor.  As expected, this compound was 
unable to stabilize a dimeric M6P/IGF2R (131).  Thus, there is currently no small 
synthetic compound able to bivalently bind to the M6P/IGF2R through an entirely M6P-
based approach. 
Work presented herein is a continuation of previous studies (312, 313) using new 
approaches to produce M6P-based synthetic ligands.  Our goal, in collaboration with the 
Berkowitz laboratory from the University of Nebraska-Lincoln, was to synthesize 
phosphatase- and hydrolase-resistant M6P-based surrogates that would bivalently bind 
to the cell-surface M6P/IGF2R with high affinity and increase IGF-II internalization by 
cells; thus, these compounds would function as a more stable therapeutic agent against 
IGF-II-dependent cancer than our PMP-ligands. 
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In the first set of phosphatase-resistant M6P-mimics, replacing the phosphate 
with a phosphonate (Figure 4.1) appeared to bind the M6P-binding sites of the 
M6P/IGF2R with similar IC50 and RBA values of M6P, while malonyl ether and malonate 
had decreased affinities for the receptor (312).  The advantage of the phosphonate is 
that by eliminating the esters and amide bonds of the phosphate, greater resistance to 
hydrolysis and proteolysis is increased.  In order to improve efficacy to work against IGF-
II-dependent growth of cancer cells, these ligands must bind with high affinity, i.e., 
bivalently to the M6P/IGF2R.  However, these ligands bound to the M6P/IGF2R with an 
affinity equivalent to M6P, indicating monovalent binding.  These studies indicated that 
phosphonates are able to bind to the receptor but the tether length of 4 carbons was too 
short to allow the ligand to span the dimeric M6P/IGF2R to produce bivalent binding 
(312). 
The second set of M6P-surrogate ligands was synthesized with increasing tether 
lengths of 6 to 36 atoms, most of which were carbon (313).  Work done by the Dahms 
group estimated that the distance between the M6P-binding sites in domains 3 and 9 of 
the M6P/IGF2R is about 45 Å apart, while they estimated that the interphosphate 
distance between M6P groups on a bis-phosphorylated oligosaccharide is about 30 Å 
(343).  In contrast, the estimated distance between the two phosphorus atoms on each 
of the synthetic M6P-mimetic ligands was 16-26 Å, indicating that they may be too short 
to span the dimeric M6P/IGF2R or even to span the two M6P-binding sites within one 
monomer of the receptor (313).  As such, these ligands bound to the M6P/IGF2R with 
just slightly better affinity than M6P. 
Thus, we wanted to synthesize a panel of ligands that would be able to cross-
bridge the dimeric receptor in order to produce bivalent binding.  Using 125I-PMP-BSA 
displacement assays with immobilized sM6P/IGF2R, we determined the relative binding 











Figure 4.1: ChemDraw schematic drawing of M6P (left) and mannose 6-
phosphonate (right).  The methylene replaces the methylester bond, improving 














laboratory.  Unfortunately, these ligands all bounds with affinities near that of M6P, 
indicating that we still have not yet achieved bivalent binding to the M6P/IGF2R.  There 
may be other factors at play besides tether length, such as orientation of the 
phosphonates or flexibility in the tether that may result in the inability of bivalent binding 
to occur.  Thus, we set out to further our understanding of the binding of the M6P-based 
ligands for the M6P/IGF2R. 
 
C.  Results 
C.1.  Synthesis of bidentate mannose 6-phosphonate surrogates 
Xiang Fei and Guillaume Malik in the Berkowitz lab synthesized a panel of 
mannose 6-phosphonate surrogates using a combination of five different types of 
chemistries to create diversified ligands (Figure 4.2). The monomeric precursor 4’-azido 
butyl α-D-mannosyl 6-phosphonate underwent a series of reactions yielding the 
diversified linkers, while polybutylene glycol (PBG) served as the tether.  Global 
debenzylation of two aza-ylide intermediates yielded compounds with either an amide 
linkage (amide linkage: BL1) or a triphenylphosphine trapped between the amide linker 
and tether (amide-triphenylphosphine linker: BL2).   The copper(I)-catalyzed azide-
alkyne cycloaddition (CuAAC), or otherwise known as “click chemistry” focuses on 1,4-
triazole.  Using this chemistry, linkage diversity could be introduced to any azide-
terminated molecule (1,4-triazole linker: BL3) (344, 345).  Another form of CuAAC, 
Ru(II)-mediated AAC (RuAAC) was also used to target 1,5-triazole as a linker (1,5-
triazole linker: BL4).  Additionally, Sharpless-Demko cycloaddition/SNAr sequence (346) 
could be used to provide tetrazole ligands and was conducive to assembly of ligands 
with spacers of variable length (1,5-tetrazole linker: BL5) (Figure 4.2A).  Additionally, 
polyethylene glycol (PEG) was used as a tether to yield a set of ligands under the same 
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conditions as BL5 in order to vary the tether lengths (BL6-BL10).  By altering the ligation 
chemistry, five different linkages were assembled to form ten ligands with variable tether 
lengths (Figure 4.2B). 
 
C.2.   Receptor binding properties of the varying polybutylene glycol-linked 
mannose 6-bisphosphonate surrogates 
The RBAs of the synthetic M6P-based surrogates for the M6P/IGF2R were 
determined by 125I-PMP-BSA displacement assays in the presence of increasing 
concentrations of unlabeled synthetic ligands (Figure 4.3, Table 4.1).  Many features of 
the synthetic ligands influence the binding of these ligands for the receptor, such as 
number of hydrogen bond donors and acceptors that affect the extent of hydration, 
molecular weight, and shape/trajectory of the linker.  The IC50 values and RBAs for the 
compounds with BL1, BL3, BL4, and BL5 (compounds XF-VIII-99, XF-VI-100, XF-VIII-1, 
and XF-XV-25, respectively) linkers were all similar to slightly better than those values of 
M6P.  However, the slight increase in binding of these ligands for the receptor may be 
attributed to the availability of two M6P-binding sites per mole of receptor available for 
binding, rather than to enhanced interaction with the receptor.  Thus, these synthetic 
ligands do not appear to be producing bivalent binding that spans the dimeric 
M6P/IGF2R.  The synthetic ligand with BL2 linker (XF-XV-77) had IC50 and RBA values 
worse than those of M6P itself, suggesting that the proximal structures in the ligand 
interfered with binding.  When comparing the features of these ligands, it appears as if 
the ligand shapes influence the RBA values the most.  The cisoid (bent) link (BL4 and 
BL5) is favored over transoid (linear) link (BL2 and BL3).  For example, the 1,5-triazole 
linkage (BL4) had an RBA that was 3-fold higher than the 1,4-triazole linkage (BL3).  
Furthermore, amide bonds have conformational flexibility and can freely rotate between 










Figure 4.2. Schematic drawings of the M6P-based surrogates. A) Compounds BL1-
BL5 differ in chemistry of the linker, as described in the text, which presents different 
orientations of the two mannose 6-phosphonate functional groups.  B) Compounds BL6-
BL10 vary in tether lengths of 4 to 12 repeating unit of PEG to determine the distance 











conformation through an intramolecular hydrogen bond, such as between the hydrogen 
from the amine and an oxygen as seen in BL2, there is a reduction in binding affinity 
most likely due to the inflexibility of this ligand as locked into an unfavorable trajectory.  
Nonetheless, all of these ligands achieved binding similar to M6P, indicating that we 







a, µM (n) RBAb 
M6P 11.6 ± 1.7 (6) 1 
G6P >10 mM (n) N.A. 
BL1 2.7 ± 1.4 (3) 2.1 ± 1.1 
BL2 18.0 ± 3.3 (3) 0.67 ± 0.12 
BL3 5.2 ± 3.3 (3) 1.3 ± 0.84 
BL4 1.7 ± 1.3 (3) 3.9 ± 2.9 
BL5 6.3 ± 4.2 (3) 2.4 ± 1.6 
hGUS 0.02 (1) 640 
 
Table 4.1: Binding Properties of phosphatase-resistant M6P-surrogates BL1-BL5 
for M6P/IGF2R.   
a.  IC50 values for competitive displacement of radiolabeled PMP-BSA from the receptor 
(n = # of trials).  










Figure 4.3: Competitive binding analysis of phosphatase-resistant M6P-surrogates 
BL1-5 in displacement of PMP-BSA from M6P/IGF2R-Sepharose.  A) and B) All five 
compounds bound to the M6P/IGF2R with monovalent binding, similar to M6P.  Human 
β-glucuronidase (hGUS) was employed as a high-affinity, bivalent control whose 
displacement curve is shifted to the left.  Glucose 6-phosphate (G6P) served as a low-




























































C.3.   Receptor binding properties of the varying PEG-linked mannose 6-
bisphosphonate surrogates 
Five M6P-based surrogates were designed with increasing number of PEG units 
within the tether region as a molecular ruler.  Interestingly, the RBA values improved as 
the tether length increased until a length of 8 PEG units (BL8; compound XF-XV-46) was 
achieved (Figure 4.4 and Table 4.2).  From there, the RBA decreased with addition of 
further PEG units.  Although these ligands are predicted to be long enough to cross-
bridge the dimeric M6P/IGF2R, it is possible that the increased tether lengths may 
render them too flexible and unstable such that they fold back on themselves and are 
unable to produce a conformation favorable to bivalent binding.  Additionally, the 
orientation of the phosphonates may not be positioned correctly to bind both M6P-
binding sites simultaneously.  Even though there is mild improvement in the RBAs of 
these ligands, they are still similar to M6P’s binding affinity, indicating that these ligands 




a, µM (n) RBAb 
M6P 11.6 ± 1.7 (6) 1 
G6P >10 mM (n) N.A. 
BL6 5.7 ± 2.4 (5) 1.6 ± 0.69 
BL7 3.2 ± 1.5 (4) 2.1 ± 0.94 
BL8 1.4 ± 1.1 (4) 3.8 ± 3.0 
BL9 4.1 ± 1.2 (6) 1.3 ± 0.37 
BL10 5.7 ± 2.9 (4) 1.2 ± 0.59 
hGUS 0.02 (1) 640 
 
Table 4.2: Binding Properties of phosphatase-resistant M6P-surrogates BL1-BL5 
for M6P/IGF2R.   
a.  IC50 values for competitive displacement of radiolabeled PMP-BSA from the receptor 
(n = # of trials).  




Figure 4.4: Competitive binding analysis of phosphatase-resistant M6P-surrogates 
BL6-10 in displacement of PMP-BSA from M6P/IGF2R-Sepharose.  A) and B) All five 
compounds bound to the M6P/IGF2R with monovalent binding, similar to M6P.  β-
glucuronidase (hGUS) and glucose 6-phosphate were run as high-affinity and low-affinity 
controls, respectively.  BL5 was used as a comparison between the two sets of 





























































D.  Discussion 
Although the compounds with increased tether length were unable to achieve 
high-affinity binding consistent with bi- or multivalent binding, we have expanded our set 
of compounds that function as “molecular rulers” to measure the distance between two 
M6P-binding sites that would clarify intra- vs intermolecular bivalent binding to the 
M6P/IGF2R.  These ligands were synthesized to display diverse linkers to determine if 
linker orientation influenced the binding affinity, which it did.  Some conformations are 
clearly detrimental to binding to the M6P/IGF2R.  Additionally, the tether length was 
increased to measure the distance between the M6P-binding sites.  As the length 
increased, the RBA increased until 8 PEG units were incorporated.  Anything larger than 
this may be too flexible and have too high of an entropic cost.  The amount of enthalpy 
gained from the interaction with the second binding site is insufficient to compensate for 
the loss of degrees of freedom of the tether; thus these ligands are unable to produce 
bivalent binding.  In order to complete these studies, we need to address the design 
concerns that may be affecting our ligand binding affinities.  The increased tether length 
may be long enough, but we would need to stabilize the tether or linker so that these 
longer compounds do not flex so much or fold back on themselves, rendering them too 
short to bind in a bivalent manner.  Additionally, the trajectory of the ligand matters.  
Once the first phosphonate binds to one M6P-biniding site, the second phosphonate 
needs to be either locked into the correct orientation and trajectory (cisoid) or flexible 
enough that it may rotate to find optimal binding.  It is possible that these ligands are not 
able to rotate to allow both phosphnates to bind two M6P-binding sites at the same time.  
Once these issues have been addressed and we have achieved high-affinity, bivalent 
binding, will we need to validate that these synthetic M6P-based ligands are able to 
decrease the IGF-II-dependent growth of cancer cells.  These ligands need to be able to 
cross-bridge the dimeric M6P/IGF2R and accelerate their internalization, and need to 
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bind in such a way that leaves domain 11 of the receptor available for binding any 
bioavailable EC IGF-II.  These ligands must promote internalization and subsequent 
degradation of IGF-II in order to function as a potential therapeutic agent against cancer. 
Our latest panel of M6P-based surrogates was designed to fit the known minimal 
requirements needed to produce high-affinity, bivalent binding to the M6P-binding 
domains of the M6P/IGF2R.  Two M6P groups on separate oligosaccharides or a single 
oligosaccharide containing at least two M6P caps can bind to the M6P/IGF2R’s M6P-
binding sites with high affinity, representing a 100-1000-fold increase in binding affinity 
than the monovalent binding of M6P (93).  Our bidentate synthetic M6P-based 
surrogates have two mannose 6-phosphonate groups per molecule of ligand that are 
capable of binding the M6P/IGF2R.  Furthermore, the high-affinity binding of M6P-based 
ligands is attributed to the negatively charged phosphate groups, as a 25-100-fold 
decrease in affinity occurs when the phosphates are removed or replaced with sulfate, 
as seen in unpublished data in our laboratory (Dr. Christopher Connelly, unpublished 
data).  The crystal structure for the bovine M6P/IGF2R domains 1-3 determined that 
Ser386 within domain 3 interacts with the phosphate oxygens and a water molecule 
(63), and substitution of Ser386 with Ala decreased the recognition of M6P by 100-fold 
(103).  Therefore, conservation of these negative charges were necessary to produce 
appropriate recognition and binding within the M6P-binding pocket.  Lastly, it is 
estimated that the M6P-binding sites within a single M6P/IGF2R monomer are about 45 
Å apart yet the maximum distance between phosphates on oligosaccharides is 
approximately 30 Å (343).  Since increased internalization results from cross-bridging 
the receptor, the distance between the M6P-binding sites on the different monomers 
must be about 30 Å apart.  Therefore, our M6P-based surrogates should be long enough 
to span the dimeric receptor.   
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Despite our failure of achieve bivalent interactions with this panel of new ligands, 
this work has promise.  The resistance to hydrolysis and phosphatase cleavage is 
advantageous as an anti-cancer agent.  We need to address the issues with the 
flexibility of the tether lengths and the trajectory of the linkers in order to achieve high-
affinity binding ligands.  Even though our ligands are long enough to span the dimeric 
structure of the M6P/IGF2R, these studies indicate how important the precise orientation 
































A Putative MP6 Receptor Identififed in Dictyostelium discoideum: 
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The M6P/IGF2R binds many types of M6P-capped glycosylated and non-
glycosylated ligands and traffics them to the lysosome.  This receptor is mostly involved 
in lysosomal biogenesis; its role is to bind newly synthesized acid hydrolases in the TGN 
and transport them to the early endosome. However, the M6P/IGF2R can also bind and 
internalize IGF-II and other non-glycosylated proteins from the extracellular (EC) milieu.  
The vast array of ligands that bind the M6P/IGF2R can be attributed to the receptor’s 15 
EC homologous repeating domains that have high sequence identity to each other and 
to the one EC domain of CD-MPR.  Additionally, each repeating domain has a similar 
tertiary fold, the MRH domain.  The MPRs share overlapping yet distinct roles of 
transporting ligands and are evolutionarily conserved. However, it is thought that the 
MPRs may have arisen from a common ancestor and that the M6P/IGF2R (containing 
15 EC repeats) may have evolved from multiple gene duplications.  However, the most 
primitive form of the MPRs capable of binding M6P to date has been discovered in the 
bivalve mollusk, of the genus unio, while MPR-like proteins have been identified in 
Drosophila melanogaster.  Identification of the earliest forms of the MPRs can provide 
insights into the origin of the receptors and their functions.  Dictyostelium discoideum, a 
social amoeba, has a lysosomal system in which its lysosomal enzymes have been 
shown to bind the mammalian M6P/IGF2R.  However, a MPR has yet to be identified in 
this organism.  We have identified a putative D. discoideum MPR (DDMPR), through 
sequence alignment and bioinformatics studies using multiple mammalian M6P/IGF2Rs 
as references.  The putative DDMPR possesses 5 potential MRH domains with 
conserved key amino acid residues and cysteines involved in disulfide bonds to form a 
functional M6P-binding pocket.  Additionally, we have analyzed the M6P-binding activity 
of this putative receptor through PMP-resin affinity chromatography using recombinant 
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MRH domain mini-receptors that we expressed and purified.  In summary, our data 
demonstrate that D. discoideum has a putative MPR, which would be the most primitive 
MPR known to date, and this finding may have implications on our understanding of the 
MPRs and lysosomal biogenesis. 
 
B. Rationale 
The M6P/IGF2R (300 kDa) and the CD-MPR (46 kDa) are the only two members 
of the P-type lectin family that function to transport newly synthesized lysosomal 
enzymes by recognizing M6P monoester or M6P diester moieties found on the 
glycoproteins (46).  Upon recognition and binding of these glycoproteins to the MPRs in 
the TGN, the complex is transported to the early endosome.  Additionally, any M6P-
containing glycoprotein that is mis-sorted to the plasma membrane and secreted or any 
additional EC M6P-capped protein can bind the M6P/IGF2R, but not the CD-MPR, and it 
is internalized through clathrin-coated pits and shuttled in vesicles to the endosomal-
lysosomal system.  In the late endosome, the MPRs release their cargo once the acidic 
pH of below 6 is encountered.  Late endosomes containing the cargo fuse with the 
lysosome while the MPRs are recycled back to the TGN or plasma membrane for 
another round of trafficking (46, 160-162, 347). 
As type I integral membrane glycoproteins, the MPRs have an N-terminal signal 
sequence, an EC domain that contains ligand-binding sites, a transmembrane domain, 
and a C-terminal cytoplasmic tail.  The M6P/IGF2R has 15 EC repeating domains that 
have high homology (~147) to one another and to the single EC domain of CD-MPR 
(154 residues) (348).  It has been shown that the CD-MPR folds into a carbohydrate 
recognition domain that can bind ligands with high affinity (62, 349, 350).  The 
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M6P/IGF2R, with each EC domain having 14-28% identity (20), has a conserved pattern 
of cysteine residues between each domain and also the EC of the CD-MPR.  This allows 
for each domain to fold into its own MRH domain, allowing for 15 potential binding sites 
in M6P/IGF2R and 1 in CD-MPR.  The CD-MPR, in fact, does bind a single mole of M6P 
per mole of monomeric receptor even though it exists as a dimer or tetramer in the 
membrane (94), but equilibrium dialysis studies have shown that the M6P/IGF2R binds 
only 2 moles of M6P with high affinity per mole of receptor (93).  The high-affinity M6P-
binding sites of the M6P/IGF2R have been localized to domains 3 and 9 (106, 107), with 
a low-affinity M6P-binding site in domain 5, which interestingly has a preference for M6P 
diester modifications (105, 351).  Recently, another low-affinity M6P-binding site has 
been identified in domain 15 (101).  The high-affinity M6P-binding sites are not 
functionally equivalent, as determined by studies using mutant full-length receptors with 
only one functional M6P-binding site (352).  Additionally, a glycan microarray analysis of 
N-glycan isoforms that had zero to two M6P-GlcNAc phosphodiesters or M6P 
monoesters was used to determine specificity of the CD-MPR and M6P/IGF2R; the latter 
receptor is able to recognize a larger repertoire of glycosylated ligands than CD-MPR, 
due to the different ligand-binding domains within the EC domain (353).  Furthermore, 
when either MPR is knocked out in mice or cells, the results indicate that the 
M6P/IGF2R is more efficient at targeting lysosomal enzymes than the CD-MPR (354, 
355).  The M6P/IGF2R has a higher binding affinity and recognizes a broader array of 
lysosomal enzymes than the CD-MPR (356, 357).  However, one receptor cannot fully 
compensate for the loss of the other, indicating that, even though there are 
redundancies, they are both important for proper lysosome biogenesis (88, 89).   
Nonetheless, the M6P/IGF2R has enhanced lysosomal enzyme trafficking over the CD-
MPR in addition to the CD-MPR’s inability to bind ligands at the cell surface as this 
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environment is not at the pH optiumum for ligand binding. These functions of the 
M6P/IGF2R may have evolved from an earlier form of the receptor. 
Dictyostelium discoideum, a social amoeba or slime mold, in the vernacular, has 
a lysosomal system, and its lysosomal enzymes have been well characterized in axenic 
cells (358).  These lysosomal enzymes have N-linked oligosaccharides possessing M6P 
residues in methyldiester linkages or mannose 6-sulfate (M6S) moieties (41, 43, 99, 
359).  D. discoideum lysosomal enzymes, such as α-mannosidase and β-glucosidase, 
can bind the mammalian M6P/IGF2R in domains 3 and 5 with high affinity (105, 108, 
360).  The ability of the mammalian M6P/IGF2R to recognize M6P moieties in diesters 
and M6S may be due to broader binding pockets of domains 3 and 5 that would 
accommodate these larger modifications, which is expected to exist in the MPR of D. 
discoideum (63, 104, 351).  Furthermore, the sulfate and phosphate monoester both 
have one negative charge rather than the two charges that phosphate possesses, which 
may attribute to differences in binding preference.  The precursors for α-mannosidase 
and β-glucosidase are membrane-bound, and following proteolytic cleavage, become 
soluble and are transported to the lysosome, yet to date, there has not been an MPR 
identified in D. discoideum (40, 361).   
Recently, our laboratory in collaboration with David Berkowitz’s laboratory at the 
University of Nebraska-Lincoln has identified a putative MPR in D. discoideum 
(DDMPR).  Thus, the goal of this study was to characterize the structure and ligand-
binding properties of this putative receptor in comparison to the mammalian M6P/IGF2R.  
To do this, initial studies performed multiple sequence alignments and homology 
modeling that compared the M6P-binding domains of the CD-MPR and domains 3, 5, 
and 9 of the M6P/IGF2R, revealing 5 potential MRH domains within the putative DDMPR 








Figure 5.1: Schematic of the DDMPR gene with 5 MRH domains.  The five MRH 
domains (R1-R5) are shown in red with R3 having the highest identity to domain 3 of the 
mammalian M6P/IGF2R.  The G1 and G2 regions may encode possible 
glycotransferase domains just N-terminal to the transmembrane domain (TM).  The 











DDMPR have the cysteine patterning and conserved amino acid residues that are 
involved in M6P-binding comparable to the MPRs.  A recombinant mini-receptor of 
DDMPR R1-3 was expressed in the mammalian expression system and ligand binding 
studies were performed by pulling down the mini-receptors (DDMPR or human mini-
receptors) with PMP-Sepharose resin and competitively displaced with M6P to 
determine relative binding affinities.  Additionally, repeat 3 of the MRH domains in the 
DDMPR was expressed in the bacterial expression system and subsequently purified 
and characterized in vitro.  From these preliminary studies, we have identified a putative 
MPR in D. discoideum that binds M6P, suggesting that the M6P binding function of the 
MPRs arose at an earlier stage in evolution than previously thought, and may serve as a 




C.1. Identification of a putative MPR in D. discoideum via bioinformatics and 
previous binding studies 
There are several proteins that have MRH domains, but these domains within the 
MPRs have been the only ones found to bind M6P (25, 46).  Since D. discoideum 
lysosomal enzymes have been shown to bind to the mammalian M6P/IGF2R (108), it 
was hypothesized that this slime mold species may have a similar protein containing 
MRH domains.  Therefore, several bioinformatics-based searches were conducted 
previously by David Nelson in our collaborator David Berkowitz’s lab at the University of 
Nebraska-Lincoln, to identify any genes/open reading frames within the D. discoideum 
genome that might encode MRH domains and could serve as orthologs of the 
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mammalian M6P/IGF2R.  First, the putative D. discoideum M6P-like receptor (DDMPR) 
needed to have at least one MRH domain, as well as retain key cysteine residues 
forming disulfide bonds and essential binding residues within the MRH domain that have 
been identified in the CD-MPR and M6P/IGF2R.  Lastly, the MRH domain needed to 
retain the canonical anti-parallel flattened β-barrel found in the known receptors’ M6P-
binding domains.  If the putative DDMPR fit the above criteria, it may serve as the most 
evolutionarily primitive form of the MPRs known to date. 
Using a basic local alignment search tool (BLAST) and InterProScan analyses 
that allows searches within various genomes for similar sequences and motifs, 
respectively, two nucleotide sequences that encode hypothetical protein sequences that 
have significant homology with the bovine M6P/IGF2R domain 3 sequence were 
identified in chromosome 5 of D. discoideum AX-3 strain (Hit 1 nucleotide accession: 
XM_630458.1; Hit 1 protein accession: XP_63550.1; Hit 2 nucleotide accession: 
XM_630374.1; Hit 2 protein accession: XP_635466).  These proteins met the 
aforementioned criteria and had five contiguous MRH domains.  Further analysis of 
these two hypothetical proteins yield 1526 amino acid residues for Hit 1 and 2441 amino 
acid residues for Hit 2.  The two sequences are very similar with minor differences, yet 
further study indicates that Hit 1 appears to be an incomplete version of Hit 2; therefore, 
we believe that Hit 1 may not encode an actual protein.  Based on the sequence 
alignment and conservation of cysteines, it was hypothesized that the third MRH domain 
(repeat 3, or R3) of the putative DDMPR would have a similar overall tertiary structure 
with domain 3 of the bovine M6P/IGF2R.  Indeed, through a series of bioinformatic 
analyses (Jmol and Spartan 04) to study the 3-dimensional structure of the DDMPR 
MRH domains compared to the crystal structure of the bovine M6P/IGF2R domain 3 
(Protein Data Bank I.D.: 1ISZO) revealed that the DDMPR R3 retains the anti-parallel 
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flattened β-barrel sandwich (Figure 5.2) needed for a MRH domain.  Additionally, 
DDMPR domains 2-4 were similar to the structure and fold of the bovine M6P/IGF2R 
domains 1-3 with slight differences in amino acid side-chain positioning.  Further studies 
determined the likelihood of M6P interacting with DDMPR R3 in a dynamic simulation 
(AutoDock 4 software; The Scripps Research Institute), which revealed that M6P does 
indeed dock within the potential binding site of DDMPR R1-R3, but it eventually 
dissociates, unlike docking of the bovine M6P/IGF2R domains 1-3.  This dissociation 
most likely occurs because the DDMPR R1-R3 domain forms a larger binding pocket 
that may accommodate a molecule that is larger than M6P; this possibility has not yet 
been explored, but is consistent with the M6P-methylester modifications found on D. 
discoideum lysosomal enzymes.  The DDMPR is unique from the other known MPRs in 
that there are two motifs corresponding to glycosyltransferase domains, which are not 
present in the higher order MPRs.  It has yet to be determined if these domains are part 
of a catalytic activity of the receptor.  A hydrophobic region was detected using Kyte and 
Doolittle analysis (362), indicating that this protein has an N-terminal transmembrane 
domain.  In Dr. Chris Connelly’s doctoral work, Vector NTI® Align X program (Invitrogen, 
Carlsbad, CA) was used to do a multiple species sequence alignment of the DDMPR R3 
against the M6P/IGF2R domain 3.  It predicted that DDMPR R3 was the best candidate, 
sharing 17% identity with all mammalian receptor species used in this alignment and 
21.4% identity with the human M6P/IGF2R.  Furthermore, DDMPR R3 has high identity 
of conserved residues involved in disulfide bonds and M6P-binding in the mammalian 
proteins, with this domain containing 6 cysteines that resemble the pattern of cysteins in 
domain 3 of the bovine M6P/IGF2R.  The MRH domains of the M6P/IGF2R and CD-
MPR are about 150 amino acid residues in length having a pattern of cysteine residues.  
Ten MRH domains of the M6P/IGF2R have 8 cysteines, one domain (domain 13) has 12 
cysteines with 4 of those cysteines residing in the fibronectin type II domain, one domain 
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has 9 cysteines, and three domains of the M6P/IGF2R as well as the single MRH 
domain of the CD-MPR all have 6 cysteines (20).  One final similarity of the DDMPR 
MRH domain to that of CD-MPR is the conservation of His105 that allows formation of a 
hydrogen bond with the phosphate group of the incoming M6P moiety upon binding (98).  
Following the bioinformatics analysis of the conserved sequence alignment and amino 
acid residues and maintaining the tertiary fold similar to the MRH domains of the 
M6P/IGF2R, a DDMPR C-terminally FLAG-tagged construct encompassing R1-R3 was 
designed and synthesized by Dr. Chris Connelly in his doctoral work (unpublished). 
Using a similar cloning strategy that was done previously in our laboratory by Chad Byrd 
during his doctoral work to make the human mini-receptors of the M6P/IGF2R followed 
by a C-terminal FLAG-tag (1-3F, 1-8F, 7-9F, 1-15F) (144), DDMPR R1-R3 was 
synthesized by GenScript Corporation (Piscataway, NJ) and engineered using human 
codon usage tables to be expressed in mammalian cells (HEK 293 and HEK 293T cells).  
The DDMPR FLAG-tagged cDNA was cloned into pCMV5RIX/1-3F vector (the pCMV5 
vector with a mutated EcoRI restriction endonuclease site in the multiple cloning 
sequence) using EcoRI at the 5’-end and XbaI at the 5’-end, thereby dropping out the 3’-
half of the sequences encoding the human M6P/IGF2R domain 1 and the full domains 2 
and 3.  Therefore, the new DDMPR-containing vector would have the human 
M6P/IGF2R leader sequence expressed at the N-terminal end for proper localization and 
expression (Figure 5.3).  Dr. Connelly validated the DDMPR construct to be about 76 
kDa according to SDS-PAGE analysis and αFLAG immunoblots and was expressed in 
both the lysate and conditioned medium (data not shown).  Additionally, Dr. Connelly 
tested the ability of the DDMPR to bind PMP-Sepharose resin, in which the M6P-groups 





Figure 5.2: Ribbon structure of MRH regions 1-3 of the putative DDMPR.  The 
sequence coding the first three MRH domains were aligned with the crystal structure of 
the bovine M6P/IGF2R (PDB: 1ISZO) to create a PDB file using SWISS-MODEL (Swiss 
Institute of Bioinformatics, Lausanne, Switzerland), and docked with M6P (blue mannose 
ring with red oxygens) using SwissDoc (Swiss Institute of Bioinformatics).  The overall 
structure is predicted to fold into flattened β-barrels similar to the MRH domains of the 
M6P/IGF2R.  This docking structure was visualized using the PDB docking file in USCF 









Figure 5.3: Schematic of the DDMPR and human M6P/IGF2R mini-receptor 
constructs.  The pCMV5RIX vector constructs were expression in HEK 293 and 293T 
cells.  DDMPR R1-3 has the first half of the human domain 1 as a leader sequence for 
proper protein expression.  The pCOLD-GST vector constructs were expressed in E. 
coli.  Constructs 13-F, 7-9F, and 11-13F represent the human M6P/IGF2R mini-
receptors encompassing those domains, while DDMPR R1-3 encompasses the first 3 
MRH domains of the putative DDMPR.  All 4 constructs have an N-terminal His- and 
GST-tag.  The pET-22b(+) vector construct was expressed in BL21 cells and has an N-





immobilized PMP should bind the potential M6P-binding pocket of the DDMPR.  
Interestingly, he found that DDMPR R1-3 is pulled down by the PMP-Sepharose resin, 
but the addition of 10 mM M6P appeared to enhance paradoxically the binding rather 
than competitively displace the DDMPR R1-3, and the addition of NaCl slightly increased 
binding compared to his DDMPR R1-3 alone group.  Another interesting observation 
from the pull-down experiment done by Dr. Chris Connelly is that he was unable to pull 
down the human 7-9F mini-receptor in lysates or conditioned medium.  However, since 
the human 1-15F mini-receptor was readily pulled down (possibly through the binding of 
domain 3), this supported these assays as a valid way to determine DDMPR R1-3 
binding.  Nevertheless, these preliminary studies supported the hypothesis that DDMPR 
R1-3 does bind M6P but needed further investigation. 
C.2. DDMPR secreted into conditioned medium by transfected 293 cells binds 
M6P but differs from mammalian M6P/IGF2R 
In order to characterize the binding of DDMPR, we expressed DDMPR domains 
1-3F and human mini-receptors in HEK 293 and HEK 293T cells using a standard 
calcium phosphate protocol as previously described (305).  All constructs expressed well 
in the lysates and conditioned medium (Figure 5.4A).  Previous experiments by Dr. 
Connelly showed that DDMPR R1-3 and human 1-15F mini-receptors bind PMP-
Sepharose resin, indicating that the DDMPR R1-3 mini-receptor’s MRH domain can bind 
M6P moieties.  To determine the extent of M6P-based binding to DDMPR R1-3, we used 
a series of pull-downs and immuno- or ligand blotting studies with increasing 
concentrations of M6P or the negative control glucose 6-phosphate (G6P).  In the first 
sets of experiments, DDMPR R1-3 was pulled down using PMP-Sepharose resin, 
electrophoresed on 10% SDS-PAGE gels, and probed with αFLAG antibody in an 
immunoblot and compared to the positive control human 1-3F to determine that we have 
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proper folding of the mini-receptors (Figure 5.4B).  In a set of samples from each 
receptor, 20 mM M6P was co-incubated during the pull-down phase to competitively 
displace the mini-receptors. Interestingly, DDMPR R1-3 can be pulled down only from 
the conditioned medium pool and not from lysates.  This may indicate that the receptor 
harbored within the cells does not have the proper conformation to acquire ligand-
binding function, whereas the properly folded receptor that is capable of being secreted 
has attained its native conformation and thus, biological function.  Additionally, there 
could also be such high translational rates of the receptor (especially in 293T cells) that 
it escapes proper folding and becomes trapped within the intracellular compartments 
instead of achieving proper folding in the TGN necessary for secretion into the 
conditioned medium.  Nonetheless, DDMPR R1-3 bound well to the PMP-resin, but 
interestingly was not displaced by 20 mM M6P.  The positive control 1-3F mini-receptor 
from cell lysate bound to the PMP-resin and was displaced by M6P as expected, while 
the negative control empty vector pCMV5 lysate did not bind at all as expected 
considering that it does not express a mini-receptor. 
We next tried displacing the DDMPR from the resin using a broader range of 
M6P concentrations to determine which levels of M6P interfere with receptor binding to 
the PMP-Sepharose resin.  In theory, as the concentration of M6P increases, it will 
compete for the M6P-binding sites on the receptors that, after washes of the resin, will 
result in full dissociation of the receptor from the resin.  In this experiment, M6P did not 
interrupt binding of the DDMPR R1-3 to the PMP-resin even at concentrations as high as 
50 mM, but rather appeared to enhance binding slightly (Figure 5.4C).  Conversely, even 
the lowest concentration of M6P (1 mM) that we tested with the human 1-3F disrupted 
binding and released the protein from the resin.  However, the negative control G6P also 
inhibited binding of the human 1-3F, which was not expected.  We next used smaller 
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increments of ligand concentrations to determine if different amounts of M6P could 
modulate DDMPR R1-3 binding.  It appeared as if low concentrations of M6P (0.1-1 mM) 
progressively increased the DDMPR R1-3 binding to the PMP-Sepharose (Figure 5.4D).  
However, 0.5 mM M6P significantly decreased the binding of human 1-3F to PMP-
Sepharose and no binding was detected at 5 mM M6P and higher.  Again, G6P was also 
affecting human 1-3F binding.  To explain this, we may have had an unfortunate M6P 
contamination in our G6P stock, which would explain why DDMPR R1-3 has an 
increased binding with 5 mM G6P but human 1-3F was competitively displaced.  
Confusingly, an additional experiment revealed that 0.01 and 0.05 mM M6P decreased 
the DDMPR R1-3 binding to the PMP-resin, but 0.1-0.5 mM enhanced binding.  The 
addition of 1, 5, and 10 mM significantly decreased the binding of DDMPR R1-3 while 
0.01-10 mM G6P did not have much effect, and DDMPR R1-3 bound well under these 
conditions (Figure 5.4D).  
To account for the possibility that the human 1-3F mini-receptor may be more 
sensitive to improper folding or more readily displaced, we conducted PMP-Sepharose 
pull-down experiments with soluble bovine M6P/IGF2R (125I-sM6P/IGF2R) that contains 
the first 14 EC domains and part of domain 15.  DDMPR R1-3 conditioned medium or 
125I-sM6P/IGF2R was incubated end-over-end at 4°C overnight with the resin in the 
presence or absence of increasing concentrations of M6P or G6P.  Following the pull-
down assay and subsequent washes of the resin, the samples were electrophoresed 
and the 125I-sM6P/IGF2R gel dried down before exposure to radiographic film.  The 
DDMPR R1-3 gel underwent transfer and immunoblotting, probing with αFLAG antibody.  
The 125I-sM6P/IGF2R bound to the PMP-resin and appeared to tolerate the addition of 
M6P until 0.03 mM, which greatly disrupted binding of the receptor for the resin (Figure 








Figure 5.4: Mammalian expression and analysis of DDMPR R1-3F in lysates and 
conditioned medium of HEK 293 cells.  A) Transfected cells expressed the DDMPR 
mini-receptor and all human mini-receptors in lysates and the conditioned medium, as 
detected by α-FLAG immunoblot analysis.  B) DDMPR R1-3F from CM, but not lysates, 
pulled down with PMP-Sepharose resin, which binds to the mini-receptor’s M6P-binding 
domain. M6P (10 mM) was able to partially disrupt the binding of DDMPR R1-3 with the 
resin.  C) M6P partially displaced DDMPR R1-3F from the PMP-Sepharose by 
competitively disrupting M6P-based binding, although M6P was far more effective at 
displacing human 1-3F. Note that DDMPR R1-3F in the CM has a lower contaminating 
band for an unknown reason.  D) Quantification of the M6P displacement in C) 
confirmed that increasing concentrations of M6P improves DDMPR binding to the 
receptor-resin until maximal binding is reached at which point binding drops, while M6P 




























electrophoresis.  In this blot, G6P up to a concentration of 20 mM had no effect on 
receptor binding to the resin, indicating that the binding is specific for M6P.  With the 
DDMPR R1-3 immunoblot following this pull-down, we saw an interesting pattern of 
receptor binding to the PMP-resin, where 1 mM and 10 mM M6P or G6P improved 
binding, while there was a steady decrease in binding with the lower ligand 
concentrations (Figure 5.5).  It is possible that the precise concentration of M6P can 
either aid or hinder the M6P-binding of DDMPR R1-3.  Another possibility is the amount 
of endogenous M6P/IGF2R in the cell lysates from the HEK 293 cells may interfere with 
binding of DDMPR R1-3 to PMP-Sepharose; as M6P increases, it can displace the 
endogenous receptor and free up available binding sites for DDMPR R1-3 to bind.  
Together, these data suggest that the DDMPR binds M6P but not as tightly as the 
mammalian M6P/IGF2R, indicating that the DDMPR may have other ligands it prefers, 
such as M6S or M6P methyl ester. 
At that point in the project, we had lost expression of our DDMPR R1-3 in lysates 
and conditioned medium.  We attempted transfections using different reagents, 
concentrations of reagent and cDNA, different cell lines, and different techniques, all of 
which did not express the DDMPR R1-3 in the conditioned medium.  However, these 
binding assays suggest that DDMPR is able to bind M6P-modified glycoproteins, but this 
receptor may prefer additional or structurally analogous but slightly different ligands, as 
M6P is unable to completely disrupt the binding of the receptor with PMP-Sepharose.  
Additional ligands that may be more suitable for DDMPR’s binding pocket need to be 










Figure 5.5: Differential Affinity of DDMPR R-3F versus sM6P/IGF2R to pull-down by 
PMP-Sepharose and to displacement with M6P.  DDMPR R1-3F from the CM and 
125I-sM6P/IGF2R were pulled down with PMP-Sepharose resin with increasing 
concentrations of M6P and G6P.  The DDMPR R1-3F had a different displacement 









C.3. Purification of endogenous DDMPR from Ax3 conditioned medium using D. 
discoideum lysosomal enzymes 
Due to our inability to express large amounts of properly folded DDMPR R1-3 in 
the conditioned medium, we attempted to purify the endogenous receptor from D. 
discoideum Ax3 and Ax4 cultured cells.  The endogenous DDMPR would be significantly 
larger (~270 kDa according to ExPASy ProtPram analysis using the protein sequence) 
than our mini-receptor.  Since D. discoideum lysosomal enzymes are known to bind the 
mammalian M6P/IGF2R (108), we attempted to purify these enzymes using the soluble 
bovine M6P/IGF2R (sM6P/IGF2R) bound to Sepharose resin.  Our goal was to use D. 
discoideum purified lysosomal enzymes to bind the endogenous DDMPR through affinity 
chromatography.  Following sIGF2R-Sepharose resin pull-down of the conditioned 
medium and 125I-sM6P/IGF2R ligand blotting, M6P-capped proteins were pulled down in 
both Ax3 and Ax4 cell lines (Figure 5.6A).  To improve separation of these M6P-capped 
proteins, we performed DEAE-Sepharose ion-exchange chromatography of the D. 
discoideum Ax3 conditioned medium in sodium phosphate buffer and eluted with a NaCl 
concentration gradient.  After dialysis and lyophilization of the column fractions, the 
samples were electrophoresed and ligand-blotted with 125I-sM6P/IGF2R as probe.  The 
ligand blot showed improved separation of the M6P-capped proteins (Figure 5.6B).  
However, these ligands are not yet purified based on their M6P-content, as additional 
proteins at similar molecular weights and charges but that are not necessarily M6P-
containing proteins could have migrated through the column.  We then tried to purify 
these ligands using a sM6P/IGF2R-Sepharose affinity chromatography eluted with 
increasing concentrations of M6P.  125I-sM6P/IGF2R ligand blot analysis revealed that 
some M6P-modified proteins eluted in the later M6P elution stages, but recovery of 






Figure 5.6: Purification of endogenous D. discoideum lysosomal enzymes.  A) 
Whole cell lysates from D. discoideum Ax3 and Ax4 strains were electrophoresed under 
native conditions and probed with 125I-sM6P/IGF2R to determine if these cells expressed 
M6P-capped glycoproteins.  B)   Ax3 cell lysates were fractionated with ion-exhange 
chromatography eluted with a NaCl gradient and the fractions (1-8) were 
electrophoresed on 8-16% SDS-PAGE. The gel was transblotted to nitrocellulose probed 
with 125I-sM6P/IGF2R under ligand blotting conditions, which revealed that there were 
multiple proteins eluting that bind to the bovine M6P/IGF2R  C) sM6P/IGF2R-Sepharose 
purification of Ax3 cell lysates using M6P as the eluent demonstrated that this method 






discoideum ligands are not eluting off of the column, either because of increased affinity 
for the sM6P/IGF2R-resin or by non-specific binding to the resin that was lost due to 
incomplete column conditioning (i.e. incomplete blocking of the non-specific binding on 
the resin with BSA).  Despite our efforts, we were unable to purify the endogenous D. 
discoideum M6P-containing ligands and immobilize them on a resin bed to capture the 
endogenous DDMPR.  Perhaps a more specific receptor-specific antibody immobilized 
to resin would better serve our purposes of purifying the endogenous receptor, but this 
will have to await further experiments. 
 
C.4. Cloning, expression, purification and folding of pCOLD-GST/DDMPR in a 
bacterial expression system 
Several labs have purified, refolded, and performed structural studies, such as x-
ray crystallography, on bovine M6P/IGF2R mini-receptors in ligand-bound and ligand-
free states (domains 1-3, 5, 11, and 11-13) to characterize the receptor (61, 63, 64, 101, 
343, 363).  Since our laboratory, in collaboration with the Berkowitz laboratory, has 
discovered the putative M6PR in D. discoideum, we decided to express truncated forms 
of the putative receptor in a bacterial expression system.  We engineered FLAG-tagged 
domain 3 of the DDMPR and tri-repeat mini-receptors of the human M6P/IGF2R 
(domains 1-3, 7-9, and 11-13) into a pCOLD-GST vector.  This vector has N-terminal 
His- and GST-tags upstream of the constructs followed by a FLAG-tag to the carboxyl 
terminal end (Figure 5.3).  A human rhinovirus 3 C protease site (Leu-Glu-Val-Leu-Phe-
Gln|Gly-Pro) lies between the GST-tag sequence and upstream of the protein sequence, 
that can be cleaved with proteases such as HRV 3 C or Turbo 3 C.  Additionally, there is 
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a Factor Xa site (Ile-Glu-Gly-Arg) following the His-tag sequence, adding to the 
versatility of this plasmid. 
Using a similar cloning strategy to our previous DDMPR 1-3F construct, we PCR-
amplified our DDMPR 1-3F fragment insert from the pUC57 vector and ligated it into the 
pCOLD-GST vector using an EcoRI site at the 5’ end and an XbaI site at the 3’ end.  
Additionally, human M6P/IGF2R fragments were sub-cloned from our previous 
expression vector pCMV5RIX (pCMV5 vector with an EcoRI site mutated out of the 
multiple cloning sequence) into the pCOLD-GST vector.  We realized that our inserts 
were all engineered to be read in a mammalian expression system instead of a bacterial 
expression system.  To account for this, we used three Rosetta 2 cell line derivatives 
that express several tRNA species capable of aiding in expression of proteins from 
human mRNAs: C41, JRC1, and JRC3.  All of these E. coli BL21(DE3) lines are used for 
expression of toxic proteins or proteins with rare codons, i.e. mammalian codon usage.  
The C41(DE3) cells have at least one mutation that prevents cell death that is 
associated with expression of recombinant, toxic proteins (i.e., membrane proteins and 
some cytoplasmic proteins).  JRC1 cells are C41(DE3) competent cells expressing the 
pRARE2 plasmid and are used for toxic proteins with rare codons (i.e., mammalian 
codons).  JRC3 cells are C43(DE3) competent cells, which have a different set of 
mutations than C41(DE3) that prevents cell death upon expression of toxic proteins, 
expressing the pRARE2 plasmid and are used for toxic proteins with rare codons.  In 
short, Jennifer L. Kopanic from Dr. Paul Sorgen’s laboratory engineered the JRC1 and 
JRC3 cell lines during her doctoral dissertation work by combining the pLysS plasmid 




Using diagnostic restriction endonuclease digestion, we confirmed that the 
banding pattern of the DNA fragments on a 1% agarose gel correlated with the expected 
sizes.  Once we made all clones, we followed the protocol illustrated in Figure 5.7 and 
transformed our constructs into the above three cell lines to determine which cell line 
would express our receptor fragments.  This vector has a unique way of expressing 
inserts and therefore has a specific growth protocol that needed to be optimized.  A 
growth culture was inoculated with starter culture following transformation and growth at 
37°C, 250 rpm, until an O.D.600 of 0.4 was reached.  Cells were then induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG), which is an allolactose mimetic that binds 
the lac repressor to initiate transcription, and expression was allowed to continue for 16 
h at 18°C, 180 rpm.  Aliquots of whole cells taken pre-induction and after the overnight 
induction period were lysed with heat and SDS-PAGE loading buffer and 
electrophoresed on a 10% gel to measure expression.  Coomassie staining revealed 
more intense bands at the correct molecular weights post-induction in all three cell lines, 
indicative of successful expression following IPTG induction, but an αFLAG immunoblot 
revealed that JRC1 and JRC3 had a greater expression of 1-3F than C41 (Figure 5.8). 
Once bacterial expression was achieved, the cells were lysed using a French 
Press and then the lysates were centrifuged at 16,500 rpm for 1 h to separate the two 
fractions: soluble supernatant and the insoluble pellet.  Aliquots of the soluble and 
insoluble fractions were electrophoresed on a 10% SDS-PAGE gel and stained using 
Coomassie blue.  The stained gels revealed that the most constructs (1-3F, 7-9F, 11-
13F, and DDMPR 1-3F) were expressed in the insoluble fraction (Figure 5.9).  The 
insoluble fractions were then extracted with 6 M urea (ÄKTA Buffer A) to resolubilize the 
precipitated protein.  Following an additional spin to discard insoluble cellular debris, the 




Figure 5.7: Purification of DDMPR and human mini-receptor constructs using the 
bacterial expression system.  The mini-receptors were cloned into expression vectors 
and transformed into E. coli.  Cultures were grown according to Table 2.2.  Cells were 
collected through centrifugation, resuspended in lysis buffer, and lysed with French 
Press.  The lysates were centrifuged to separate the insoluble pellet from the soluble 
fraction.  The insoluble pellet was resolublized in urea.  Both fractions, during different 
column runs, were purified on an Ni2+-NTA resin column.  The soluble fraction was 










Figure 5.8: Expression of mini-receptors from E. coli using pCOLD-GST vector.  A) 
DDMPR and human M6P/IGF2R mini-receptors cDNA were transformed into E. coli 
strains C41, JRC1, and JRC3.  Whole-cell samples were electrophoresed and 
Coomassie stained.  All constructs expressed in all cell lines following 1 mM IPTG 
induction.  B) Immunoblot analysis probing with α-FLAG of 1-3F whole-cell samples 
revealed that JRC1 and JRC3 had higher expression of the FLAG-tagged mini-receptor 





Figure 5.9: Solubility of the FLAG-tag mini-receptor proteins expressed in 
bacterial cells.  A) Soluble and insoluble fractions were electrophoresed and 
Coomassie-stained to reveal that all strains expressed the majority of the FLAG-tagged 
proteins in the insoluble fraction.  B)  Immunoblot analysis probing for the FLAG-tag of 








resin) column, which binds the His-tag on the target protein with high affinity.  An elution 
gradient of increasing imidazole concentration (ÄKTA Buffer B) determined that all 
proteins eluted in earlier fractions (near fraction 4-10) (Figure 5.10A).  Aliquots of these 
fractions confirmed the presence or absence of protein on Coomassie blue-stained 10% 
acrylamide electrophoresed gels (Figure 5.10B).  Fractions containing protein were 
pooled. 
We selected the 1-3F mini-receptor for development of the folding methods.  
Refolding proved to be difficult as each mini-receptor contains 3-4 disulfide bonds that, if 
paired in a non-native manner, would result in a misfolded receptor that was defunct in 
binding ability.  Refolding buffer was composed of a mixture of buffer and components to 
allow optimal oxidation/reduction (cystamine/cysteamine 2-mercaptoethylamine) 
reactions to allow the right cysteine pairs to bind and amino acid (L-arginine) to prevent 
protein aggregation. (See Materials and Methods for details.)  With the first few attempts 
to refold the 1-3F mini-receptor, ratios using direct dilutions (1:0 unfolded control, 1:1, 
1:5, and 1:10 in the first attempt and 1:0, 1:10, and 1:20 in the second attempt) of 
protein:refolding buffer were used, where the protein was subjected to ÄKTA Buffer A 
urea to completely unfold any protein that may have incidentally folded before refolding 
buffer was added.  Either half of the refolding buffer was added at time 0 and time 24 h 
and the protein was allowed to fold for 48 h, or the entire amount of refolding buffer was 
added immediately at time 0 and the protein allowed to fold for 48 h.  The GST-tag and  
His-tags were then cleaved from the target protein by using Turbo 3C (T3C) protease 
and the GST bound to glutathione resin and was pulled down, thereby leaving the folded 
protein in the supernatant (Figure 5.10C).  The refolded protein was then analyzed using 
a 125I-PMP-BSA ligand blot, in which the PMP on the radioligand should bind to the 
binding pocket of the properly folded 1-3F mini-receptor with high affinity.  Unfortunately, 
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there was not any detectable properly folded protein in our samples when compared to 
the properly folded 1-3F expressed from HEK 293 lysates (data not shown).  
Additionally, the spectra from the circular dichroism data indicated that we did not 
achieve any folding (absence of detectable secondary structure) (data not shown).  The 
protein was then concentrated using Amicon Ultra centrifuge filters and subsequently 
electrophoresed and stained with Coomassie blue to determine if the GST-tag was 
properly cleaved from the protein.  Interestingly, increased exposure to T3C cleaved 
additional amounts of the GST-tag from the proteins, but the concentration of uncleaved 
protein remained high even after 72 h with the protease (Figure 5.10C).  According to 
the manufacturer’s product datasheet, small traces of urea can inhibit the activity of T3C, 
so we next dialyzed away the urea after refolding prior to the cleavage of the GST-tag.  
Unfortunately, the majority of the GST-tag remained intact with our protein.  This may be 
due to misfolding of the protein that results in the HRV 3 C site being trapped inside the 
protein and is unavailable for cleavage by the protease.  T3C is able to cleave some of 
the protein, which suggests that our protein was a heterogeneous population of different 
folding endpoints, i.e., folded differently but none correctly.  A 125I-PMP-BSA ligand blot 
confirmed that we did not have functional protein regardless of the GST-tag present 
(data not shown). 
We attempted to refold the 1-3F mini-receptor using the refolding buffer as 
previously mentioned except substituting various the buffers (Tris, MES, MOPS, HEPES, 
glycine, or PBS) to determine if the base buffer made a difference in the outcome.   
Again, 125I-PMP-BSA ligand blot revealed that there was no functional mini-receptor 
present (data not shown).  All of the previous folding steps were performed in direct 
dilutions, where a volume of the refolding buffer was added at one time and the protein 
solution sits undisturbed for a given amount of time while it refolds.  It is possible that our 
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mini-receptors need to refold in a timed concentration gradient as opposed to immediate 
folding.  Therefore, we did a urea step-down dialysis in which the refolding buffer was 
replaced with fresh refolding buffer containing a lower concentration of urea (4 M, 2 M, 1 
M, 0 M urea) every 24 h.  Unfortunantely, we were unable to achieve a functional protein 
using these approaches. 
We expressed 1-3F in JRC3 cells using reduced concentrations of IPTG for 
induction in order to improve solubility of the protein.  IPTG at 100, 250, 500, or 800 µM 
was used to induce the JRC3 cells transformed with pCOLD-GST/1-3F. SDS-PAGE 
separation and Coomassie blue staining of the electrophoresed whole cell samples 
lysed under heat in SDS-PAGE loading buffer indicated that these lower concentrations 
of IPTG induced expression of our mini-receptor (Figure 5.9B).  Additionally, lysing the 
cells on the French Press followed by SDS-PAGE analysis of the electrophoresed 
fractions showed that the majority of the 1-3F receptor resided in the insoluble fraction in 
all four samples.  However, αFLAG immunobloting of these fractions determined that 
there is some expression of 1-3F in the soluble fractions (Figure 5.9B).  These soluble 
fractions were purified on the ÄKTA using the aforementioned protocol, and fractions 
containing the protein were pooled and incubated with T3C protease to remove the 
GST-tag.  We were again unable to cleave the GST-tag, indicating that the pCOLD-GST 














Figure 5.10: Purification of His/GST/FLAG-tagged mini-receptors using Ni2+-NTA 
affinity chromotography.  A) Elution profile of mini-receptor from the ÄKTA purification 
system, which showed an absorbance reflecting protein eluting in fractions 2-9.  B)  
Coomassie staining of electrophoresed fractions from chromotagraphy validated the 
fractions containing protein.  C) Cleavage of GST-tag from mini-receptor using T3C 







C.5. Cloning, expression, purification and folding of pET-22b(+)/DDMPR3F in a 
bacterial expression system 
Since we were unable to purify and refold our mini-receptor constructs using the 
pCOLD-GST vector, we chose to clone DDMPR3F into a different bacterial expression 
vector, pET-22b(+), that was the same vector that Brown et al. used to clone 
M6P/IGF2R domain 11 (61).  This unique vector has an N-terminal pelB signal for 
periplasmic localization, which increases solubility of the protein (310), and the signal 
peptidase cleavage sequence allows for cleavage just upstream of the insert.  
Additionally, there is a C-terminal His-tag sequence that allows for purification using a 
Ni2+-NTA resin column.  However, we decided to follow the protocol as done by Brown et 
al. (61), and therefore transformed our pET-22b/DDMPR3F vector into E. coli 
BL21(DE3) cells, which are unable to read mammalian codons.  Therefore, we had to 
convert our codons to preferred bacterial codon usage, so we had a gBlock synthesized 
from Integrated DNA Technologies.  We subcloned the DDMPR3F gBlock into the pET-
22b(+) vector using NcoI and XhoI.  We engineered our insert to have a SpeI restriction 
site, allowing for validation using a single restriction endonuclease digestion (data not 
shown).  Additionally, sequencing revealed that our DDMPR3F receptor was correctly 
cloned into our vector.  ExPasy Protein Parameters tool calculated the estimated 
molecular weight of our protein to be 18,332 with a theoretical pI of 7.64 and a molar 
extinction coefficient of 25,705 M-1cm-1. 
We transformed our pET-22b/DDMPR3F vector into BL21(DE3) cells, and 
following inoculation of our growth culture with our starter culture, we monitored O.D.600 
until 0.6-0.8 at 37°C, 250 rpm.  The cells were then induced with increasing 
concentrations of IPTG and maintained under the growth conditions for 3-4 more hours.  
SDS-PAGE analysis of the samples pre-induction and post-incubation indicated that the 
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DDMPR3F was expressed in these cells (Figure 5.11A).  Cells were lysed on the French 
Press and aliquots of the two fractions were electrophoresed on a 15% SDS-PAGE gel 
and stained with Coomassie blue, which showed that the the vast majority of the protein 
was in the insoluble fraction as it had been in the pCOLD-GST mini-receptor 
experiments (Figure 5.11B).  The insoluble fraction was resolubilized in 6 M urea and 
purified on the ÄKTA using a Ni2+-NTA resin column as previously mentioned (Figure 
5.11C).  The eluted fractions indicated that the protein eluted in the first half of the 
gradient elution.   
The expressed, resolubilized DDMPR3F was then refolded in the refolding 
buffers mentioned previously.  Ratios (1:0 control, 1:1, 1:5, 1:10, and 1:20) of 
protein:refolding buffer were used in Tris, MES, MOPS, and HEPES refolding buffers for 
48 h after a 1 h incubation with urea to unfold any potential contacts within the receptor.  
125I-PMP-BSA ligand blots revealed that the radioligand was unable to bind functional 
protein.  However, our positive control 1-3F from HEK 293 lystate also did not bind the 
radioligand (data not shown).  We next performed a circular dichroism (CD) analysis to 
determine if there was any folding that occurred within the DDMPR3F.  The CD spectra 
observed that the refolding buffers absorbed near 200 nm, and subtracting the buffer 
spectra from the protein spectra revealed no protein folding (data not shown).  This may 
be due to a component in the refolding buffer (L-arginine, cystamine, or cysteamine 2-
mercapoethylamine) causing absorption that interferes with the spectra. Thus, CD 
analysis cannot be performed when these buffers are present.  Therefore, a two-step 
Tris-buffer dialysis was performed to determine if the refolding buffer components could 
be eliminated.  After two rounds of dialysis, residual refolding buffer components remain 
in the sample (data not shown), indicating that additional rounds of dialysis would be 





Figure 5.11: Purification of His/FLAG-tagged DDMPR R3 using Ni2+-NTA affinity 
chromatography.  A) DDMPR R3 was expressed in E. coli BL21 cells.  Coomassie 
staining revealed that increasing concentrations of IPTG all effectively stimulated 
expression of the protein.  B) Coomassie staining of the soluble and insoluble fractions 
revealed that most of the protein expressed was in the insoluble fraction and could be 
re-solubilized in urea.  C) Coomassie staining of the Ni2+-NTA affinity chromatography 
fractions showed that the DDMPR R3 protein eluted in fractions 1-10, with fraction 5 





We attempted to refold the DDMPR3F before purification following protocols 
used by Gao et al. and Brown et al. (61, 364).  The insoluble fraction, following 
expression and lysing the cells, was subjected to 6 or 8 M urea denaturing buffer, and 
the resolubilized fraction was diluted 10-fold in denaturing buffer before incubation with 
folding buffer in 12-h increments.  Following refolding, the sample was Tris dialyzed to 
remove the urea, in which some proteins precipitated out of solution.  The supernatant 
fractions of the collected samples were then concentrated by lyophilization.  
Interestingly, a 125I-PMP-BSA ligand blot of the different fractions (soluble, folded, 
insoluble pellet following folding, and unfolded) showed that the only fraction that bound 
the radioligand was the soluble fraction (Figure 5.12).  The soluble fraction was then 
subjected to 125I-PMP-BSA ligand blots with or without 5 mM M6P, which competitively 
binds with M6P-containing ligands for M6P-binding sites.  The half of the ligand blot with 
the presence of M6P during the introduction of 125I-PMP-BSA resulted in a weaker signal 
than the other half of the ligand blot without M6P, indicating that M6P was able to 
displace some but not all of the radioligand (Figure 5.12).  This is consistent with 
previous data in that M6P is able to only partially displace M6P-based ligands (PMP-
ligands), which may be explained by the lack of preference for M6P, as DDMPR’s 
binding domain may prefer ligands having diester structures or containing sulfur residues 
(i.e. M6S).  Immunoblots of the His-tag on the DDMPR3F following a pull-down using 
PMP-Sepharose 4B resin resulted in either not enough protein concentration for 
detection or the lack of affinity of the receptor for the resin (data not shown).  Dialysis 
and purification of the soluble fraction was unable to yield improved results of properly 
folded DDMPR3F.  Thus, the most effective method to determine ligand binding 
preferences for the DDMPR in the bacterial expression system is to use the soluble 










Figure 5.12: PMP-Sepharose pull-down of DDMPR R3 and displacement with M6P.  
The soluble fraction of the DDMPR R3 expressed in BL21 cells following Ni2+-NTA 
affinity chromatography was electrophoresed under non-reducing conditions and probed 
with 125I-PMP-BSA with or without 10 mM M6P.  M6P partially displaced the radioligand 












Dictyostellium discoideum is a social amoeba with a lysosomal system that is 
similar to the mammalian lysosomal system (365).  The lysosomal enzymes in D. 
discoideum often bear M6S and M6P methyldiester modifications, and it has been 
suggested that these acid hydrolases are transported by an unidentified receptor (41, 
43, 108, 359, 361, 366, 367).  It has also been observed that D. discoideum lysosomal 
enzymes, when trafficked within the cells of this organism, are membrane-associated 
despite the lack of a TM domain until they reach the lysosome, suggesting that a 
receptor is involved in this process.  Additionally, lysosomal enzymes in this organism, 
namely α-mannosidase and β-glucosidase, can bind the mammalian M6P/IGF2R and 
are internalized by cultured human fibroblasts (360).  Despite the evidence that suggests 
a receptor related to the MPRs may be involved in lysosomal biogenesis of this social 
amoeba, one has not yet been found.  Identifying and characterizing a putative MPR in 
D. discoideum can help reveal the ancestral origins of the receptor as well as aid in our 
understanding of trafficking and lysosomal biogenesis.  The simplicity of this organism 
may provide an uncomplicated model system to study diseases associated with 
insufficient sorting or missorting of these enzymes.  Furthermore, the larger MPR in 
higher eukaryotes has 15 EC domains, which may have arisen from gene duplications 
(25), yet we still do not completely understand the function of all of these domains and 
defined their roles in normal and disease-associated biology. 
The multiple-species sequence alignment in earlier work suggested that the 
putative DDMPR R3 retained all of the important amino acid residues that are necessary 
for M6P binding by the mammalian receptor.  Additionally, the cysteine pattern predicts 
disulfide bonding that contributes to the tertiary architecture to fold into an MRH domain.  
Expression of recombinant DDMPR R1-3, which is similar in sequence and folds to 
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human M6P/IGF2R 1-3, can be pulled down using PMP-Sepharose resin in which the 
M6P residues on the PMP interact with the M6P-binding site of the receptor.  This same 
resin is used to purify the M6P/IGF2R from bovine liver extracts and FBS, which allows 
for specific purification of the receptor as there are no other proteins known to bind M6P 
residues at neutral pH (303).  Thus, given such strong similarities between the DDMPR 
and the mammalian M6P/IGF2R, our laboratory may have found the putative MPR in D. 
discoideum.  Nevertheless, much work needs to be done to fully characterize the 
structure and function of this receptor.  Interesting to note in our binding assays of the 
DDMPR R1-3 construct, M6P does not competitively displace the receptor from the 
PMP-Sepharose resin as mammalian M6P/IGF2R full-length and mini-receptors are 
displaced.  Conversely, the DDMPR3R construct expressed from BCL21 cells was 
partially displaced as opposed to having enhanced binding.  These contradictory pieces 
of data may be explained by the different expression systems and methods used.  The 
DDMPR3R was expressed in a bacterial system that does not express an endogenous 
MPR, and our construct was purified through affinity chromatography before doing the 
binding analysis.  Thus, our receptor was pure and the only protein present to bind the 
125I-PMP-BSA.  However, our DDMPR R1-3 construct was expressed in HEK 293 that 
express endogenous M6P/IGF2R and CD-MPR, and crude conditioned medium was 
used in the pull-down procedure, which may have had soluble M6P/IGF2R present.  In 
these experiments, some endogenous receptor may have initially bound to the PMP-
resin, but as M6P concentration increased, its ability to displace the sM6P/IGF2R from 
the resin was also increased; thus, more functional groups may have become available 
on the resin for DDMPR R1-3 to bind.  Furthermore, the inconsistencies in the ability of 
M6P to enhance or displace the DDMPR R1-3 from the PMP-Sepharose resin can also 
be attributed to the amount of endogenous sM6P/IGF2R present in the conditioned 
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medium that is released by protease activity that cleave the M6P/IGF2R in domain 15 
(287, 368)  
We have seen that M6P has a weaker affinity for the DDMPR than for the 
mammalian M6P/IGF2R, which may be attributed to the slightly larger binding pocket of 
DDMPR.  NMR studies showed that the six cysteines in the structure of domain 5 of the 
bovine M6P/IGF2R allow for a broader binding pocket that may accommodate M6P-
GlcNAc-phosphodiesters (104).  DDMPR R3 also has six cysteines but lacks the critical 
tryptophan and tyrosine residues found in the ligand-binding pocket of M6P/IGF2R 
domain 5.  On the other hand, DDMPR R3 has a histidine residue positioned at nearly 
the same position as His105 found in the CD-MPR’s EC domain that coordinates 
hydrogen bonding with an incoming phosphate group on a M6P molecule.  Alternatively, 
the imidazole ring in this histidine in DDMPR R3 could cause steric constraints that 
result in broadening the binding pocket as seen with other bulky amino acid residues 
within domain 5 of the M6P/IGF2R (104).  The molecular modeling study of M6P docking 
with the DDMPR R1-3 that Dr. Connelly had simulated gave credence to the idea that 
DDMPR folds into a broader pocket.  In his simulation, the rate of dissociation of M6P 
was increased as well as increased solvation compared to the binding pocket of the 
bovine M6P/IGF2R domains 1-3, indicating a larger binding pocket in DDMPR. The 
presence of additional water molecules within the binding pocket suggests that there is 
enough space to accommodate larger functional groups, such as M6P-methyldiester.  
Our binding studies support this, as 10 mM M6P, an amount that competitively displaces 
binding of PMP-Sepharose to the sM6P/IGF2R, does not completely disrupt binding of 
the DDMPR to PMP-resin.  However, if we were to use a different type of ligand that 
may be better suited for the M6P-binding pocket (i.e. M6S or M6P-methyldiester) in 
DDMPR, we expect to see tighter binding of that ligand for DDMPR and thereby disrupt 
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the interaction with PMP-resin at much lower concentrations.  This needs to be 
addressed to determine what ligands DDMPR prefers, which may help in understanding 
the evolutionary origin of the MPRs. 
Another unique feature of the DDMPR that was discovered during the 
bioinformatics analysis was that this putative receptor has two glycosyltransferase motifs 
just upstream of the potential TM domain.  These domains need further investigation to 
determine if they have, in fact, functional activity.  If so, it is interesting to think that the 
ancestral MPR may have had dual roles in lysosomal biogenesis: transport of acid 
hydrolases and post-translational processing of M6P-based oligosaccharides.  
Additionally, it is interesting that the MPR in higher-order organisms evolved into the 
receptors we know today (i.e., acquired duplications of the MRH domains and IGF-II 
binding in the M6P/IGF2R) while the putative MPR of D. discoideum acquired 
glycosyltransferase motifs. 
Nonetheless, we have found, for the first time, a putative MPR in D. discoideum, 
which would make this the most primitive MPR known to date.  Studies need to be done 
to fully understand the binding preferences of this putative receptor compared to the 
M6P/IGF2R, and to identify the roles of the glycosyltransferase motifs.  These studies 
may have an impact on the biomedical field, as understanding the evolution of the 





































A.  Overview 
The M6P/IGF2R is involved in lysosomal biogenesis and internalization of EC 
M6P-glycosylated and non-glycosylated ligands for transport to the lysosome.  The 
M6P/IGF2R is thought of as a tumor suppressor by regulating the excess of ligands in 
the cell milieu, such as IGF-II.  Additionally, the inability of M6P/IGF2R to transport newly 
synthesized acid hydrolases to the lysosome, such as defects in the glycosylation 
pathway limiting their ability to bind to the MPRs, can result in one of over 35 lysosomal 
storage diseases.  Thus, this receptor is vital in multiple different functions of the cell.  
However, one of the most well studied features of this receptor is its role of M6P-based 
binding.  High-affinity, bivalent M6P-based ligands, such as lysosomal enzymes, bind 
and stabilize the dimeric M6P/IGF2R at the cell surface, leading to its internalization at a 
faster rate than when there is no M6P-based ligand bound (131).  Moreover, this 
accelerated internalization of the receptor allows for IGF-II to bind in a different binding 
domain and it is taken up by the receptor and trafficked to the lysosome at faster rate as 
a passenger along with a multivalent M6P-based ligand.  Furthermore, a decrease in 
IGF-II concentration in the cell milieu as a result of rapid internalization by CREG led to 
cell cycle arrest and inhibited growth of several different cell types (228, 229, 311).  
Therefore, we were interested in producing a panel of M6P-based ligands capable of bi- 
or multivalent binding to the M6P/IGF2R that could suppress IGF-II-dependent growth of 
cancer cells.  Additionally, the MPRs are well conserved through evolution, with the 
earliest form of “true” MPR known to date in the invertebrates such as mollusk.  
However, the social amoeba, D. discoideum, was found to produce lysosomal enzymes 
that bind to the M6P/IGF2R, a discovery that predated identification of a receptor 
capable of transporting these acid hydrolases within this organism.  We provide 
evidence of a putative MPR protein that retains all the necessary components of an 
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MRH domain that also binds M6P.  The studies presented in this dissertation further our 
understanding of the origin of the M6P/IGFR as well as increase our potential for 
exploiting this receptor as a potential target against IGF-II-dependent cancer. 
 
B.  PMP-ligands 
B.1.  Conclusions 
Our bi- and multidentate panel of PMP-pseudoglycan ligands bind to the 
M6P/IGF2R with bivalent, high affinity about 100-1000-fold higher than M6P alone.  
Upon binding to the receptor in vitro, cell viability is decreased presumably through 
depletion of bioavailable IGF-II in the conditioned medium.  Add-back of either 10 mM 
M6P or 10 nM IGF-II to the PMP-ligand-treated cells rescues the inhibition on cell 
viability effect, suggesting that our ligands operate in both a M6P- and IGF-II-dependent 
manner.  Different cell lines had different levels of responsiveness to our ligands.  As 
such, these cell lines exhibited varying levels of IGF-II dependency.  This variation may 
be explained by differences in receptor density on the cell surface, resistance or 
sensitivity within the intracellular signaling pathways, cell-to-cell contact density, genetic 
mutations in oncogenes or tumor suppressors that are not related to the IGF axis yet 
contribute to cell growth, or slight batch-to-batch differences in our PMP-ligand 
preparations.  Additionally, it was difficult to find an established cell line that has 
complete IGF-II-dependency, as all cell lines we tested had only a certain level of 
dependency.  IGF-II over-expression has been shown in many tumors, yet if our cell 
lines are just partially IGF-II-dependent, our PMP-ligands would be able to operate only 
to the level of dependency.  Patient samples resected from IGF-II-dependent tumors 
through the Rapid Autopsy Program at UNMC may provide a more responsive model for 
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our PMP-ligands.  Nonetheless, some of our cell lines were responsive, which appeared 
to be established cell lines that were obtained from tumors classified as moderate-to-well 
differentiated.  The poorly differentiated cell lines that we tested were not responsive to 
our PMP-ligands and had minimal or no response to IGF-II, indicating that these cancer 
cells are not IGF-II-dependent and would not be good candidates for therapy using our 
novel therapeutic agents.  At best, it would seem that the PMP-ligands may be most 
efficacious in combination chemotherapy approaches. 
We hypothesized that our PMP-ligands were functioning by stimulating 
internalization of IGF-II from the medium and causing degradation of the growth factor in 
the lysosome, thereby leaving the receptor tyrosine kinases such as the IGF1R less 
activated.  Our 125I-IGF-II internalization assay provided support for our hypothesis by 
showing an increase in TCA-soluble radioactive material (125I-IGF-II degradation 
products) when our PMP-ligand is present.  Conversely, the addition of unlabeled IGF-II 
or M6P abrogated the effect by protecting the 125I-IGF-II in the conditioned medium, 
which resulted in more radioactive counts present in the TCA-insoluble pellet (intact 125I-
IGF-II). 
As IGF-II is internalized at an accelerated rate when PMP-ligands are present, 
we expect to see the reduction of cell viability that is caused by reversal/blockade of the 
IGF-II signaling pathway.  That is, we would expect to see cell cycle arrest as seen with 
CREG (228, 229, 311) or an increase in apoptosis/decrease in survival.  We were 
unable to determine the exact mechanism of action that is a result from our PMP-
ligands.  We saw a slight increase in cell death in some experiments, but this finding was 
not entirely supported by the caspase 3/7 activity assay or caspase 3 cleavage 
immunoblot, nor did our annexin V staining support the increase in cell death.  The 
annexin V staining may have had technical issues when doing these assays and would 
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need to be repeated.  Also, the JEG-3 cells appeared to have a unique biology in that 
they may have a hyperactive flippase that flips the PS to the outer membrane of the 
plasma membrane even when apoptosis is not occurring.  We also may not necessarily 
detect an increase in activation of the executioner caspases if caspase-independent cell 
death was occurring in our studies.  We need to delve deeper into these apoptotic 
studies to determine if our PMP-ligands are inducing cell death, either through 
decreasing IGF-II activation or by off-target effects. 
Our migration assays proved interesting and yielded unexpected results.  In 
scratch assays, it appeared as if different ligand preparations caused different outcomes.  
The first sets of scratch assays were performed using PMP-OVA from one batch and the 
second sets of scratch assays with another.  As such, the first set did not show a 
significant decrease in wound closure rates, but the ligand caused a slight reduction in 
closure compared to control.  Interestingly, the IGF-II-treated groups did not close faster 
than the control.  The second sets had the opposite outcome, wherein the PMP-OVA 
accelerated the wound closure rate.  Upon closer examination, there may have been a 
chemotactic response occurring at the high concentration (200 nM) of PMP-ligand.  In 
the earlier batch, the stock concentration was lower and it was slightly lower molecular 
weight than the second batch, indicating the possibility that there were fewer PMP 
groups per unit protein.  This slight difference in molecular weight may have caused a 
ligand that is more potent at lower concentrations but causes an odd chemotactic 
response at higher concentrations.  We would need to repeat these experiments with 
increasing concentrations of PMP-ligand in order to determine if there is a particular 
concentration that decreases migration.  The preliminary data on the transwell assays 
suggest that our PMP-ligand may decrease migration, but more thorough analyses need 
to be done. 
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There is also the potential that our PMP-ligands alone are not potent enough to 
initiate cell death or cell cycle arrest.  For example, the initiation of apoptosis is 
reversible until a certain point when the executioner caspases are activated (341, 369).  
It is possible that once apoptosis is initiated, our PMP-ligands may be enough to 
overcome the protection against apoptosis and drive the cell toward cell death.  If so, 
this would greatly reduce the toxicity effects of chemotherapeutic drugs by allowing a 
smaller dose of the pro-apoptosis drug in combination with our PMP-ligands to cause 
cell death of the tumor.  Further studies into the mechanism of PMP-ligand action as well 
as combination studies will contribute to novel treatments against IGF-II-dependent 
growth of cancer cells. 
 
B.2.  Future Directions 
Our PMP-ligands reduce cell viability in an M6P- and IGF-II-dependent manner.  
However, we need to understand the mechanism of the inhibition of cell growth.  
Additional studies focusing on the apoptosis cascade can determine the cause of cell 
death.  As of now, we do not know if this is a caspase-dependent or –independent 
apoptosis.  There is a growing body of evidence that suggests many factors can 
interplay to initiate caspase-independent cell death, such as cathepsins (namely 
cathepsin B and D), calpains, and AIF-mediated cell death (370). We would need to 
investigate the activities of these caspase-independent apoptotic proteins to tease out 
which may play a role in mediating the cell death that we see with our PMP-ligand 
treatment. 
We have seen in vitro that our PMP-ligands can reduce cell viability of IGF-II-
dependent cancer cells, but in order for our ligands to function as potential 
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chemotherapeutic agents, we need to test the efficacy in vivo.  One valid concern is that 
our PMP-ligands are capped with a number of M6P moieties (approximately 2 to 24), 
which have the potential to be cleavage by phosphates and proteases in the animal 
model.   Our PMP-ligands are effective in conditioned medium up to 72 hours, as seen in 
125I-IGF-II internalization assays and PMP-ligands degradation assays.  We would need 
to determine if our PMP-ligands are efficient at targeting the tumor and at what dosage 
and frequency we need to administer our agents.  These are important questions that 
need to be answered in order to use our PMP-ligands against IGF-II-dependent cancer. 
When we treated the cells with PMP-ligands, we were disappointed that the 
response from the cells was not always consistent.  We would see a slight increase in 
cell death and possibly a slight delay in cell cycle progression.  However, we did not see 
a robust enough response that would account for the reduction on cell viability.  There is 
a possibility that our PMP-ligands are not potent enough to induce cell cycle arrest or 
apoptosis alone, but they may work synergistically with a chemotherapeutic agent.  For 
example, we may see an increase in apoptosis following PMP-ligand treatment because 
the cells underwent a pro-apoptotic signal that they otherwise would recover from, but 
our agent was able to drive them to cell death.  Decreasing IGF-II from the conditioned 
medium may be just enough to commit the cell to apoptosis.  If so, the standard of 
therapy may call for less toxicity by allowing decreased concentrations of global 
cytotoxic drug in conjunction with our very specific agent.  We need to test this first in 
vitro and then in vivo by providing a pro-apoptotic signal (such as staurosporine, TRAIL, 
or paclitaxel) in the presence of our specific PMP-ligand to measure the synergistic 
effects.  If the two agents are synergistic, then we should see enhanced sensitivity to the 
cytotoxic agent in the presence of the PMP-ligand.  This approach would have the 
potential to improve the therapeutic window for the cytotoxic drug. 
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M6P/IGF2R trafficking is continuous with constitutive internalization regardless of 
bound ligand (46).  Furthermore, the presence of EC ligands can influence receptor 
localization to the plasma membrane to take up the additional ligands and transport 
them to the lysosome (67, 219, 221).  It is not known if receptor localization and 
trafficking are affected upon PMP-ligand binding.  We would hypothesize that as PMP-
ligand binds to the M6P-binding sites within the EC domain of the M6P/IGF2R, the 
dimeric structure is stabilized and allows for rapid internalization of the receptor and all 
bound passenger ligands, such as IGF-II.  From there, the complex would be trafficked 
to the early endosome for sorting to the lysosome for destined cargo, while the receptor 
is recycled.  However, we need to verify that our PMP-ligands drive the receptor through 
the classical internalization pathway and do not promote internalization into a vesicle 
and mis-sorting or prevention of lysosome/endosome fusion.  Additionally, it is presumed 
that our PMP-ligands bind with high affinity yet the low pH of the late endosome would 
cause the complex to dissociate so that the receptor may be recycled.  We need to 
monitor the intracellular trafficking to demonstrate that the M6P/IGF2R is not becoming 
degraded along with the complex, which would limit the efficacy of our agents if the 
receptor cannot return to the cell surface to undergo another round of rapid 
internalization.  Lastly, we need to validate that our PMP-ligands are, in fact, functioning 
through the M6P/IGF2R.  We have concluded that our ligands are binding very 
specifically to the M6P-binding sites located within the receptor because the addition of 
M6P or IGF-II rescues the effect caused by our ligands.  But we need to perform 
M6P/IGF2R knockout studies to validate the specificity of our ligands; that way, we 
would be able to identify any potential off-target effects employed by out agents.  
Targeting the M6P/IGF2R to enhance its tumor suppressor functions shows promise in 
treating IGF-II-dependent cancer and understanding the mechanism caused by the 
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ligand-receptor interaction can aid in the development of novel therapeutic agents 
against these types of cancer. 
 
C.  A Panel of Phosphatase-inert M6P-based Surrogates as “Molecular Rulers” 
for the M6P/IGF2R 
C.1.  Conclusions 
The synthetic M6P-based, phosphatase-resistant surrogates bound to the 
M6P/IGF2R.  These bidentate molecules were designed to determine the binding 
preferences of the linker and to measure the distance that spans the dimeric receptor.  It 
is important to determine the exact chemical preferences of the M6P-binding sites of the 
M6P/IGF2R in order to better design therapeutic agents that can target this receptor in 
IGF-II-dependent cancers.  Several studies from different labs have contributed to our 
understanding of the M6P-based binding to this receptor, including the amino acids 
involved in recognition of the incoming M6P (46), preferred glycosidic linkages between 
mannose residues (95), and distance spanning the M6P-binding domains (343).  Studies 
on the M6P recognition by the M6P/IGF2R has led to the design of M6P-based binding 
ligands in different labs. 
In earlier studies in our lab, the phosphonate has been shown to be a suitable 
replacement for phosphate at the sixth carbon of the mannose ring (312).  Another set of 
M6P-surrogates used various tether lengths to determine the distance needed to span 
the dimeric M6P/IGF2R.  However, these ligands were unable to produce bivalent 
binding.  Work presented in this dissertation investigated the binding of two new panels 
of synthetic M6P-based surrogates to determine if the linker chemistry affected the 
binding affinity and increased tether length would allow for cross-bridging the receptor.  
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Much to our disappointment, we were unable to achieve bi- or multivalent binding with 
these bidentate molecules.  However, we were able to determine that the orientation of 
the linker impacts the binding affinity of these ligands for the M6P/IGF2R.  A molecule in 
the cisoid orientation may offer a better presentation of the phosphonate ends to the 
M6P-binding sites, producing higher affinity binding.  Additionally, increasing the tether 
length correlates with binding until the tether reaches a certain number of atoms.  When 
the tether length exceeds 8 repeating units of PEG, we suspect that the tether is too 
flexible and folds back on itself instead of remaining outstretched and long enough to 
span the distance.  Additionally, there may be too much flexibility and lack of stability of 
the orientation of the phosphonates so that after one phosphonate end binds to a 
M6P/IGF2R monomer, the other end is unable to achieve the correct orientation for 
productive binding.  When the two ends are so conformationally independent, the first 
binding event would not reduce the entropic cost of the second event very much. 
 
C.2.  Future Directions 
Synthetic M6P-based ligands for the M6P/IGF2R that resist hydrolysis as well as 
phosphatase and protease cleavage would be valuable for treating IGF-II-dependent 
cancer.  High-affinity, bivalent binding to the receptor leads to accelerated internalization 
of the receptor and any bound passenger ligand, such as IGF-II.  By targeting this 
receptor to internalize at a faster rate, we can deplete the bioavailable IGF-II from the 
cell milieu that would subsequently lead to decreased IGF1R and IGF1R/IR-A activation.  
Work in our lab using our PMP-ligands supports this idea as our ligands decrease cell 
viability.  Our collaborators in Lincoln were able to synthesize M6P-based ligands that 
are not cleavable by phosphatases and would have a longer half-life in in vitro and in 
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vivo studies.  Since these ligands were unable to produce bivalent binding, we will need 
to design new panels of ligands that would be able to achieve bivalent binding.  The 
linker affects binding, so we will need to keep the linker in mind when designing these 
new sets.  The linker should support a cisoid configuration as opposed to transoid and 
should not be too bulky, as demonstrated with the loss of binding attributed to the 
triphenylphosphine linker in the BL2 compound.  The tether length is important, as it 
needs to be able to span the dimeric receptor.  However, we will need to introduce some 
stability into the flexible linker in order to prevent potential folding of the compound. 
Once we are able to achieve high-affinity, bivalent binding to the M6P/IGF2R, we 
will need to validate these ligands in vitro to determine if they are able to decrease cell 
viability similar to the PMP-ligands.  If successful, these ligands may be administered in 
vivo to decrease tumor burden in IGF-II-dependent cancers.  Our mannose 6-
phosphonate ligands would be advantageous as chemotherapeutic agents in these 
types of cancers, so further studies are necessary to develop them into a novel anti-
cancer therapy. 
 
D.  A Putative MP6 Receptor Identififed in Dictyostelium discoideum: 
Chacterization of the M6P-based Binding of the MRH Domains 
D.1.  Conclusions 
Previous work done by David Nelson and Dr. Chris Connelly identified a 
hypothetical protein in the D. discoideum genome that possesses MRH domains and 
appears to be a homolog to the MPRs.  Further bioinformatics analysis revealed that the 
third MRH domain (DDMPR R3) retains the cysteine pattern observed in the mammalian 
M6P/IGF2R domain 3.  A recombinant DDMPR R3 protein was shown to bind PMP-
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Sepharose resin.  M6P resulted in a different displacement pattern from this resin than 
for either human M6P/IGF2R 1-3F or 125I-sM6P/IGF2R.  The difference in the 
displacement pattern may be due to the preferences of ligands that each receptor 
prefers, where M6P and M6S have differet overall charges that affect binding  We 
predict that M6P is a preferred ligand for the M6P/IGF2R but not for the DDMPR, which 
may explain why the addition of M6P can increase the binding of DDMPR to the PMP-
resin.  As M6P increases, it competitively displaces the endogenous M6P/IGF2R 
allowing more binding sites on the resin available for DDMPR.  The DDMPR R3 that was 
purified from BL21 cells further supports that M6P is not the preferred ligand of this 
putative receptor, as 10 mM M6P only partially displaced the 125I-PMP-BSA from the 
ligand blot at the bands corresponding to the molecular weight of DDMPR R3.  This was 
purified, recombinant protein, so other proteins would not be interfering with the results.   
 
D.2.  Future Directions 
We have seen that the putative DDMPR binds M6P-based ligands and can be 
partially displaced with M6P.  We suspect that DDMPR may prefer sulfated ligands or 
those larger than M6P such as M6P-methyldisester modifications.  The overlay of the 
DDMPR R3 modeled structure with the crystal structure of the bovine M6P/IGF2R 
domain 3 shows that these receptors have similar folding.  However, minute changes 
within the DDMPR binding pocket allow for a slightly larger pocket similar to domain 5 of 
the mammalian receptor.  Domain 5 of the M6P/IGF2R has been shown to bind 
phosphodiesters with high affinity and has lower affinity for M6P (105).  We hypothesize 
that the DDMPR is similar in that it binds M6P but it prefers M6S and M6P-methylester.  
Additionally, lysosomal enzymes purified from D. discoideum have been shown to have 
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sulfated caps and M6P-methylesters (99, 100).  Furthermore, the charges on the ligands 
differ, so  the receptor transporting these types of ligands must have a binding pocket 
that can accommodate the size and charge of the ligand. 
We are interested in knowing the binding preferences of this putative receptor for 
ligands.  To determine this, we must express purified DDMPR R3 or expansions of the 
binding pocket (R1-5) and perform displacement assays using 125I-PMP-BSA as a tracer.  
Increasing concentrations of different ligands that the receptor may prefer (M6S, M6P-
methylester, mannose 6-sulfonate, mannose 6-sulfenate, mannose 6-phosphamine) 
should displace the DDMPR R3 from PMP-Sepharose resin or displace the radioligand 
from the ligand blot.  Thus, IC50 and RBA values can be calculated and compared to 
those of M6P.  We expect that M6S an M6P-methylester will bind with highest affinity for 
the DDMPR.  Additionally, there are two potential glycosyltransferase domains within the 
C-terminal domain of this putative receptor.  Investigation of this region will determine if 
these domains are enzymatically active; if so, it is interesting that this organism may 
have one multifunctional protein involved in lysosome biogenesis.  Characterization of 
the ligand binding properties and structural features of the DDMPR may further our 
understanding in the origins of the MPRs and aid in lysosomal storage disease research. 
 
E.  Summary 
Our data support further investigation into exploiting the M6P/IGF2R as a 
potential therapeutic strategy for IGF-II-dependent cancers.  High-affinity M6P-based 
ligands can bind the receptor and decrease cell viability in a M6P- and IGF-II-dependent 
manner.  If we can design high-affinity ligands that are resistant to degradation in vitro, 
we can create a more stable anti-cancer agent that would function in IGF-II-dependent 
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cancer in combination chemotherapy that can lower the toxic effects seen in patients.  
Our M6P-based ligands would operate most efficiently in tumors or tumor 
microenvironments that express the IGF axis: IGF1R and/or IR-A, M6P/IGF2R and IGF-
II.  By limiting the concentration of IGF-II in the tumor microenvironment, we can inhibit 
IGF-II-dependent growth of the cancer cells and allow for a more specific approach to 
treating the tumor in a subset of patients.  Further investigations will allow us to 
understand the biochemical mechanism in which our M6P-based ligands operate to 
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